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Abstract
Like many viruses, papillomaviruses ai'e totally dependent upon host biosynthetic 
machinery for replicating their genomes and establishing infection. These 
processes are associated with the production o f antigenic proteins that make the 
virus vulnerable to immune surveillance which ultimately results in elimination of 
viral infection. However, papillomaviruses have developed mechanisms to escape 
the cellular immune recognition o f the virally-infected cells by encoding proteins 
that interfere with antigen presentation to immune cells.
Papillomavirus E5 are small oncoproteins o f 42 to 83 amino acids in BPV-4 and 
HPV-16 respectively, expressed at low levels mainly in the deep layers o f infected 
epithelia and down-regulate the expression and transport to the cell surface of the 
major histocompatibility complex class I (MHC I). The BPV-4 E5 protein inhibits 
transcription of heavy chain, retains MHC class I in the Golgi apparatus and 
prevents its transport to the cell surface. In this study, we investigated expression 
of MHC class I in natural infection by BPV-4. We determined that MHC I is not 
expressed in cells expressing BPV-4E5. We also determined that expression of 
BPV-4E5 is accompanied by expression of the proliferation marker (Ki67) also in 
the differentiated cells o f upper layers o f papillomas. Down-regulation of MHC 
class I in papilloma cells expressing E5 would allow escaping recognition by 
cytotoxic T lymphocytes (CTL). Cells lacking MHC I are subjected to NK cells 
attack, which recognise and destroy cells lacking surface expression o f MHC I 
imless non classical MHC class I molecules are presented on the cell surface. 
Because of the impossibility to investigate expression of non classical MHC class I 
in cells expressing classical MHC class I due to the absence o f appropriate 
antibodies, we investigated the effect o f BPV-4E5 on expression of bovine
classical (N*01301) or non classical (N*50001) MHC class I in transfected mouse 
mastocytoma cells. We determined that E5 does not retain N* 50001 MHC class I 
complex in the Golgi, and does not inhibit the transport o f the complex to the cell 
surface. We also determined that E5 induces degradation of N *01301 heavy chain 
but does not affect the stability o f N *50001 heavy chain. We also determined that 
retention of MHC class I in the Golgi and thus prevention o f its transport to the cell 
surface requires the C-terminus domain of E5. We also investigated the 
relationship between HPV-16E5 and HLA class I. HPV-16E5 down-regulates 
surface expression of HLA-A, but not o f HLA-C/E. Because o f a lack o f antibodies 
capable of distinguishing C and E, we introduced either HLA-A2 or HLA-E cDNA
:
in mouse mastocytoma cells expressing HPV-16E5. We confirmed that HPV-16E5
down-regulates HLA-A2 by retaining it in the Golgi and inliibits its transport to the
■
cell surface but it does not affect HLA-E. We extended our observations to
,investigate the effect o f HPV-16E5 on expression of MHC class I in cervical 
intraepithélial neoplasia grade I (CIN I). We determined that in some CIN cells, 
expression of E5 and HLA class I was incompatible, while in other cases E5 and 
HLA class I were co-expressed. Expression of E5 in some cells was accompanied 
by expression of Ki67. We also determined that down-regulation o f HLA class I by 
E5 is independent of expression of HPV-16E7 in raft cultures of HaCaT cells 
expressing HPV-16E5 only. E5 does not affect expression of HLA-E. Therefore 
down-regulation of classical MHC class I by PVE5 proteins on the surface of 
infected cells would allow escaping recognition by CTL while, undisturbed 
expression of non-classical MHC I on the cell surface would escape destruction by 
NK cells. It remains to be determined if  E5 expressing cells do avoid being killed 
by both CTL and NK cells.
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Chapter 1 ; Introduction
1 Introduction
1.1 Cancer
Cancer is a family of diseases characterized by uncontrolled cell proliferation. The 
development of cancer is a multistage process in which cells gradually become 
malignant through a progressive series of alterations. The process of 
carcinogenesis may be divided into at least three stages: initiation, promotion, and 
progression based on evidence from experimental models (Dragan et al 1993). The 
first step of the process, initiation, generally results from an irreversible genetic 
alteration, one or more simple mutations and or small deletions in cellular DNA 
within a single cell, leading to cell proliferation. The cells at this stage, although 
altered at the DNA level, are phenotypically normal. The second stage, promotion, 
is reversible and does not involve changes in the structure of DNA. The initiated 
cells undergo selective clonal expansion to form primary tumour (premalignant 
lesions) characterized by sustained cellular proliferation. During irreversible 
progression, further genetic and epigenetic changes take place such as DNA 
méthylation which inhibits the transcription o f tumour suppressor genes. DNA 
méthylation occurs in the promoter region of tumour suppressor genes, blocking 
transcription by preventing transcriptions factors from binding to these genes 
(Jones and Laird 1999). The epigenetic changes affect gene expression, and 
contribute to irreversible phenotypic changes with highly invasive growth and 
tendency to metastasize (Sugimura 1992; Vogelstein and Kinzler 1993). Induction 
of DNA damage and genetic instability has been considered in some cancers to be 
promoted by environmental exposure to extrinsic agents such as chemicals, 
radiation and viruses. Extrinsic agents may act in several ways, including the
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direct promotion of cell proliferation or interference with apoptosis (e.g, through 
oncogenic viruses),(Sieber et al 2005).
1.1.1 Oncogenes and tumour suppressor genes
Cancer generally develops after a prolonged latent period which suggests that more 
than one event must occur within a single cell before manifestation of malignant 
transformation. Genetic disturbances of two broad classes o f genes are required for 
cancer development and progression.
1.1.1.1 Oncogenes
One class is the proto-oncogenes; these are normal cellular genes. The products 
thereof act as elements o f the signaling pathways that regulate cell proliferation 
and survival in response to growth factor stimulation. Proto-oncogenes were 
identified experimentally by the homology o f their nucleotide sequences to 
retroviral oncogenes. The viral and cellular oncogenes have defined a large group 
of genes (about 100 in total) that can contribute to the abnormal behavior of 
malignant cells. Proto-oncogenes have been classified according to the functions of 
their proteins. They include polypeptide growth factors, growth factor receptors, 
elements of intracellular signaling pathways, and transcription factors. Viral 
oncogenes were first defined in Rous Sarcoma virus and tumour* cell filtrate was 
able to induce cancer within two weeks after inoculation in healthy chicken (Rous 
1979b). The RSV oncogene, termed v-src oncogene, was first postulated by 
Huebner and Todaro (1969) as a determinant o f cancer. Later it was discovered 
(Stehelin et al 1976) that a cellular homologue of v~src is present in normal DNA, 
which is called o.-src proto-oncogene. The c-src is the prototype of a family of at
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least 8 closely related genes encoding protein tyrosine kinases that form a 
cytoplasmic signal transducer group, one o f five groups in which protooncogenes 
are classified according to the function of their gene products. The signal 
transducer protein c-src is expressed at a low level in many cell types, also 
expressed at a high level in certain cells that are specialized for regulated secretion, 
including neurons, endocrine cells (Brugge et al 1986). The src protein is an 
essential mediator of the transmission of signals between cell surface and 
cytoplasm. Src activity initiates a signal transduction cascade, which culminates in 
the transcriptional activation of the transcription factor Myc and consequently 
regulates proliferation, adhesion and migration (Brown 1997). In transformed cells, 
v-src suppresses expression o f the cyclin-dependent kinase inliibitor p27, leading 
to rapid transit of the G1 phase o f the cell cycle and failure to enter the quiescent 
state (Johnson et al 1998). Strongly transforming Src proteins lead to loss of actin 
organisation and disruption o f cellular adhesions resulting in cell detachment 
(Fincham et al 1999)
C-myc is a nuclear phosphoprotein. The myc oncogene was originally isolated 
fi*om the avian myelocytomatosis virus. Protooncogene c-myc has been detected in 
high copy number in lymphomas in humans and mice. Amplification of c~myc is 
due to translocation of an active cellular promoter from the immunoglobulin gene 
to another chromosome that contains c-myc. Elevated levels of amplification o f c- 
myc maintained the tumorigenic phenotype in SW 613-S cells established from a 
human breast carcinoma (Lavialle et al 1988). Myc contributes to oncogenicity by 
binding to and inactivating growth arrest and down regulation of DNA repair 
inducible (GADD45a and GADDI53) genes transcription (Barsyte-Lovejoy et al
Chapter 1 : Introduction
2004). Deregulation of the c-myc expression has been demonstrated to inhibit 
differentiation of murine erythroleukemia cells (Bar-Ner et al 1992).
The ras family of oncogenes has three primary members ()L-ras, Yi-ras and N- 
ras). They were first discovered as proteins encoded by retroviral oncogenes that 
had been picked up from the host genome by the Kirsten and Harvey rat sarcoma 
viruses. In normal cells, the activity o f ras proteins is controlled by the ratio of
abound GTP to GDP; GTP-bound ras is active and becomes able to engage 
downstream targets (Campbell et al 1998). In cancer, the majority o f ras mutations 
involve codon 12 of the gene, with a smaller number involving other regions such 
as codons 13 or 61. Substitution of a single base-pair converts glycine into valine 
at amino acid number 12 o f the Ras protein (Oudejans et al 1991). The mutational 
damage compromises the GTPase activity of ras and prevents GAPs from 
promoting hydrolysis o f GTP on Ras; this leads to accumulation of an active form 
of GTP-bound Ras which acts as a molecular switch connecting extracellular 
signals with nuclear transcription factors (Valencia et al 1991). It has been found 
that Ha-ras 1 gene is activated in alimentary canal carcinomas of cattle (Campo et 
al 1990; McCaffery et al 1989). In human colon cancer cells, the expression of 
p21-ras has been found to be reduced by the inhibitory action o f quercetin 
(Ranelletti et al 2000)
1.1.1.2 Tumour suppressor genes
The second class of genes are functionally antagonistic to oncogenes, and so they 
are called tumour suppressor genes. They are important normal constituents of the 
genome that regulate normal proliferation and growth. Tumour suppressor genes,
I
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unlike oncogenes, are defined by their inactivation in the malignant phenotype and 
both alleles o f the gene must be disrupted or deleted in order to remove normal 
constraints on cell proliferation. Two of the best studied tumour suppressor genes 
are the Rb gene, involved in human retinoblastoma, and the p53  gene, which is 
universal in its distribution and activity.
1.1.1.2,1 Retinoblastoma
The existence of tumour suppressor genes was first suggested by cell hybridization 
experiments through the observation o f a benign hybrid that resulted from fusion 
of normal cells with malignant cells (Sasabe and Inana 1991). Further support for 
the existence of tumour suppressor genes were obtained from cytogenic studies of 
families at risk for retinoblastoma. The study demonstrated that a chromosome 
deletion leads to loss of genes important in preventing tumour development 
(Brown 1997).
The retinoblastoma is a typical tumour suppressor gene and the major negative 
regulator of the cell cycle progression through its controlling of the expression of 
cyclin E. Cyclin E promotes transit from G1 to S phase (Geng et al 2001). It was 
initially identified by its association with the development of a malignant tumour 
which arises in the eyes of children. This ocular cancer is hereditary and results 
from losing both copies of Rb gene in embryonic retinoblasts (Friend et al 1986). 
The Rb gene comprises 180 kb of DNA on chromosome 13q 14, and encodes a 105 
kD nuclear phosphoprotein Rb. The unphosphorylated form o f Rb protein inlhbits
I
cell growth and represses genes required for DNA synthesis through its interaction
with the E2F family of transcription factors (Nevins 2001). In addition, Rb/E2F 
interaction prevents formation of the cylin E/cdk2 complex that is required for S
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phase entry and stimulation of replication machinery (Bartek et al 1997). The 
activity of Rb is regulated by cyclin D/cdk4, 6  at late G l, and phosphorylation of 
Rb leads to release o f the E2F transcription factors. In DNA tumour viruses, 
human adenovirus E l A, SV40 T antigene and human papillomavirus E7 can form 
complexes with the unphosphorylated form o f Rb of the host cell. Formation o f the 
complex with viral protein leads to releasing of E2F from Rb/E2F complex, and 
free E2F promotes DNA synthesis in growth-arrested cells (Johnson et al 1993). In 
addition to its function as negative regulator of cell cycle, Rb can also contribute to 
cell death programme stimuli by its degredation by proteases and release of E2F 
which activates P53 (Tan and Wang 1998).
1.1.1.2.2 P53
P53 gene is a 20kb fragment o f chromosome 17 p i3.1 which encodes a nuclear 
phosphoprotein that has been associated with a variety of human cancers in its 
mutated forms. It was discovered through the ability of its encoded protein to 
complex with SV40 large T antigen in virus -transformed cells. P53 is normally in 
inactive form due to the nature o f C-terminus and inhibition of its DNA binding 
domain. The activity of p53 is required during the cell cycle at G1 to maintain the 
replication checkpoint, and in the case of DNA damage, p53 arrests the cell cycle 
to allow repair o f the damage by stimulating growth arrest. One o f the p53- 
inducible genes, p53R2, encodes a ribonucleotide reductase that is directly 
involved in the p53 checkpoint for repair of damaged DNA (Tanaka et al 2000). If 
repairs fail, p53 intiates cell death programme (apoptosis) by stimulating pro- 
apoptotic gene such as (BAX) expression and inhibiting antiapoptotic gene (bcl-2); 
also p53 may induce apoptosis directly by changing mitochondrial membrane
Chapter 1 : Introduction
potential through reactive oxygen (Li et al 1999). The activity of p53 is controlled 
by its negative regulator MDM2, which binds to p53 and enhances its degradation 
by ubiquitin ligase (Brady et al 2005),
Loss o f p53 functions, whether by mutation or by degradation by DNA tumour 
virus oncoproteins, contributes to tumorigenesis. Uncontrolled cell cycle and 
failure of apoptosis are required for induction o f primary tumour. The vascular 
endothelial growth factor (VEGF) is upregulated in the presence of mutated p53 
(Kieser et al 1994a), and is downregulated in cells expressing wild-type p53 
(Bouvet et al 1998). Upregulation of the positive regulator of angiogenesis (VEGF) 
(Kieser et al 1994b) allows metastasis by stimulation of secretion and activation of 
enzymes involved in degradation o f the extracellular matrix (Lamoreaux et al 
1998; Unemori et al 1992).
1.1.2 Virus and Cancer
Viruses have long been recognized as agents o f neoplasia. In the first decade o f the 
twentieth century, two oncogenic viral infections, avian leukosis virus and Rous 
sarcoma virus were identified in poultry (Rous 1979a). Later more viruses were 
identified as causing cancer. Viruses have been considered as contributing factors 
in at least 15% of human cancer worldwide. As tumour progression is a multistep 
process, viruses may be an essential step but alone they might not cause cancer. 
Certain co-factors are implicated in PVs associated tumor progression such as 
bracken fern, cigarette smoking and sexually transmitted diseases. Cigarette 
smoking, alcohol drinking and aflatoxins are risk factors for hepatocellular
carcinoma. There are two classes of tumour viruses: generally the DNA tumour 
viruses inhibit the tumour suppressor genes whereas the RNA tumour viruses
___
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contribute to cancer by activating oncogenes. All RNA tumour viruses belong to 
the retrovirus family and are classified in Class I and Class II (Coffin 1992). Class 
I RNA tumour viruses carry cellular oncogenes that were picked up by accidental 
recombination between viral and cellular DNA. Class II RNA viruses do not carry 
cell-derived oncogenes but they act by insertion of proviral DNA into the host cell 
genome close to cellular oncogenes. Unlike DNA tumour viruses, RNA tumour 
viruses can induce cancer within days after infection. This may be attributed to 
alteration of host genes during transduction and elevated level of their transcription 
as a result of association with powerful transcriptional promoter sequences of 
retrovirus LTRs, and this leads to unrestricted cellular proliferation (Ruddell
1995).
DNA tumour viruses are members of five distinct families that are capable of 
directly causing cancer in either experimental animals or humans. DNA viruses 
induce cellular proliferation, interfere with cellulai* differentiation and block 
apoptosis in postmitotic cells in order to meet their requirements for cellular 
enzymes for their genomes replication. Occasionally these processes lead to 
permanent cell transformation. The mechanism by which these viruses can induce 
unrestrained cellular proliferation is protein-protein interaction. This interaction is 
mediated by binding of viral oncoproteins to specific cellular proteins such as Rb 
and P53 proteins. In addition, DNA tumour viruses can also activate some cellular’ 
proto-oncogenes such as ras gene to accelerate cellular proliferation in order to 
meet their requirements for enzymes needed for replication. DNA viruses that 
cause cancer include hepatitis B viruses, SV40 and Polyomavirus, Adenoviruses, 
Kaposi's sarcoma-associated herpesvirus, Epstein-Barr virus, and papillomaviruses.
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1.1.2.1 Human T-cell Leukemia virus Type 1 (HTLV-1)
After its discoveries in the US in 1980, the oncovirus HTLV-1 was aetiologically 
associated with both adult T cell leukamia (ATL) and a degenerative neurologic 
disorder known as tropical spastic paraparesis or human T-cell lymphotropic virus 
type I-associated myelopathy (HAM/TSP). It is currently estimated that HTLV-1 
affects about 2 0  million people in the world and the majority o f infected 
individuals remain healthy lifelong asymptomatic carriers. Approximately 5-10% 
HTLV-1 infected individuals develop either ATL or HTLV-1-associated 
myelopathy (HAM/TSP) an inflammatory disease of the central nervous system 
caused by increased viral replication which activates immune cells that 
subsequently enter the nervous system and cause injury by immunopathological 
mechanisms (Maroushek et al 1995). ATL is an aggressive malignancy of CD4 + T 
lymphocytes which presents 20-25 years after infection and develops in fewer than 
5% of infected individuals (Mui'phy et al 1989). HTLV-1 displays an in vivo 
cellular tropism for various cell populations within the peripheral blood, suggesting 
that its receptor is ubiquitously expressed and its presence in these cells is thought 
to be a risk for ATL (Goon et al 2004). The pathogenesis of ATL has been linked 
to the effects of the viral protein Tax (Gatza et al 2005; Marriott and Semmes
2005). Tax is a 40-kDa phosphoprotein essential for both viral replication and 
cellular transformation. Tax protein can set infected T-cells into a continuous 
uncontrolled replication increasing the number of HTLV-I-infected cells by 
promoting proliferation and inhibiting apoptosis.
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1.1.2.2 Kaposi’s sarcoma-associated herpesvirus (KSHV)
KSHV was first discovered in 1994 as a member of the gammaherpesviruses 
subfamily {Rhadinovirus genus) based on similarities at the levels of nucleotide 
sequence, gene content, and genomic structure with the Rhadinovirus prototype, 
Herpesvirus saimiri (HVS) of the South American squirrel monkey (Moore et al 
1996). They are double-stranded DNA viruses approximately 165kbp in size. Like 
other gammaherpesviruses, KSHV has numerous genes with homology to cellular 
host genes which have been captured during virus evolution. KSHV is associated 
with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's 
disease. The lesions that characterize Kaposi's sarcoma are not a result of 
neoplastic transformation of cells but arise from an excessive proliferation of 
spindle cells mixed with endothelial cells, fibroblasts, and inflammatory cells, 
accompanied by new blood vessel formation (Safai et al 1985). Lesions expand 
throught the dermis and these spindle cells form vascular channels which contain 
red blood cells and finally form an aggressive nodular growth with cutaneous and 
visceral spread. KSHV infection is characterized by a long latency period in B- 
cells and endothelial cell. While the vast majority of tumor cells from these 
malignancies contain virus in latent form, only a small subset of viral genes are 
actually expressed. One o f these genes, the latency-associated nuclear antigen 
LANA-I, is a multifunctional protein encoded by the viral gene orf 73. LANA-1 is 
essential for the replication and maintenance of latent episomes; it acts as 
molecular bridge between the viral episome and cellular chromosome thereby 
ensuring equal segregation of virus into daughter cells (Ballestas et al 1999; Cotter 
II 1999). LANA-1 binds to p53, repressing its transcriptional activity and its ability 
to induce apoptosis (Friborg et al 1999). It is also able to abrogate the induction of
11
Chapter 1 : Introduction
cell cycle arrest through its association with the phosphorylated form of pRb 
(Radkov et al 2000).
1.1.2.3 Epstein-Barr virus (EBV)
EBV is a member of the gammaherpesvirus family, lymphocryptovirus genera and 
is present in more than 90% of the human population. It preferentially infects B- 
lymphocytes and epithelial cells (Cohen 2000). Primary EBV infection is usually 
asymptomatic but can cause infectious mononucleosis. EBV is strongly associated 
with the development o f several cancers, in particular with Burkitt's lymphoma 
(BE), Hodgkin's disease, and lymphoproliferative disorders which complicate 
immune suppression conditions. Latent EBV infection is an early event in the 
development of nasopharyngeal carcinoma (NFC) (Pathmanathan et al 1995). NPC 
is a tumour of poorly differentiated epithelial cells, highly prevalent in southern 
China, South-East Asia and North Africa. EBV was first identified by Epstein, 
Achong and Barr in 1964 in Burkitt lymphoma biopsies and its association with 
BL was demonstrated by the observation that sera from Burkitt lymphoma patients 
had higher titres to EBV antigens than controls. EBV genome is composed of 
linear double-stranded DNA, approximately 172 kbp in length. Only nine of the 80 
genes encoded by EBV are expressed during latency. Among these genes, EBNAl 
and LM Pl have been shown to be essential for infection and immortalization, 
EBNAl is a DNA binding nuclear phosphoprotein, which is required for the 
replication and maintenance of the episomal EBV genome. EBNAl protein 
contributes to latency via its glycine-alanine (Gly-Ala) repeat domain which acts as 
an inhibitor of MHC class I presentation by inhibiting antigen processing via the 
ubiquitin/proteosome pathway (Levitskaya et al 1995). LM Pl is the major
12
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transforming protein of EBV, induces upregulation of antiapoptotic proteins 
(Henderson et al 1991) and has been shown to be essential for EBV-induced B-cell 
transformation in vitro (Wang et al 1985). LM Pl is prevalent in NPC in high risk 
areas, which would allow the virus to resist immune recognition and may in pait 
contribute to prevalence of NPC in these populations. EBV associates with gastric 
carcinoma in approximately 10% of cases throughout the world (Takada 2000). 
Analysis o f carcinoma biopsies has indicated that 100% of carcinoma cells in each 
case are EBV-infected and derived from proliferation of a single EBV infected cell 
suggesting that EBV plays an important role in the development o f cancer.
1.1.2.4 Hepatitis
The hepatitis B virus (HBV), discovered in 1966, infects more than 350 million 
people worldwide. HBV belongs to the family hepadnaviruses and the HBV 
genome is a relaxed circular, partially double stranded DNA of approximately 3.2 
kbp. Hepatitis B is a leading cause of chronic hepatitis, cirrhosis, and 
hepatocellular carcinoma (HCC) accounting for 1 million deaths annually. HCC is 
the fifth most common cancer worldwide and the third most common cause of 
cancer death. Chronic infection with hepatitis B virus (HBV) is one of the major 
risk factors for liver cancer. Most HCCs (80%) arise in a cirrhotic liver and rates 
of progression to cirrhosis and hepatocellular carcinoma vary according to the state 
of the immune system, the age o f the patient, the serologic stage o f infection, and 
geographic and genetic factors (Brechot 2004). Hepatitis B is spread 
predominantly parenterally, tlirough intimate personal contact, and perinatally. At 
greater risk of infection are intravenous drug users and children o f mothers with 
HBV. Approximately 5% o f the world’s populations are carriers of HBV. Most
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tumours arise in persons over 50 years o f age, suggesting carcinogenesis is a 
protracted and (possibly) multi-step process and the integration of HBV-DNA into 
the hepatic genome is a significant event in hepatocarcinogenesis (Brechot 2004; 
Shafritz and Kew 1981), Aflatoxin B1 uptake, chronic alcohol consumption and 
cirrhosis are cofactors that increase the development of HCC in patients with 
chronic viral infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) 
(Dominguez-Malagon and Gaytan-Graham 2001).
1.2 Papillomavirus
Papillomaviruses contain a small molecular weight DNA genome, which is circular 
and approximately 8 kbp in length. The genome is contained in an icosahedral 
capsid, creating an extremely stable structure that is very resistant to environmental 
factors and thereby enabling effective transmission. In virions, the PV DNA is 
found associated with cellular histones to form chromatin-like complexes. The 
genome of PV is divided into three regions; a long control region and regions 
containing open reading frames corresponding to early and late genes. The viral 
genomes carry on average eight major open reading frames (ORPs), and these are 
expressed from a single strand o f the double-stranded genome. Infection by 
papillomavirus is thought to occur through microwounds of the epithelium that 
expose cells in the basal layer to viral entry. The viral genome is normally 
maintained stably as autonomously replicating plasmids present at a low copy 
number, where it replicates in synchrony with the cell cycle (Gilbert and Cohen 
1987). The replication of the viral genome and production o f new infectious 
viruses is tightly aligned to the stratification and differentiation state of the 
epithelial cells. The viruses infect many species, including humans, rabbits, cows,
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and dogs (Campo 2002). PV infection normally results in hyperproliferative 
lesions or benign tumors of epithelial cells o f the skin or mucosa (warts) that 
usually persist for several months to one year and regress by activation of host 
immune system against viral antigen. However, occasionally, some lesions can 
persist and transform to carcinoma in the presence of genetic or environmental 
contributory factors. PV-associated neoplasias comprise anogenital carcinoma and 
skin squamous cell carcinoma in humans, skin cancer in rabbits and upper 
gastrointestinal cancer and urinary bladder cancer in cattle.
1.2.1 Papillomavirus life cycle
The life cycle of papillomavirus is intimately tied to the differentiation status of the 
host epithelium and has two distinct stages: the non-proliferative and proliferative 
stages. In the non-proliferative stage of the life cycle, initial infection requires 
access of infectious particles to the basal layer via the epithelium. This is thought 
to require a break in the stratified epithelium. Following infection, the virus 
maintains its genome as low copy number episome in the basal cells of the 
epithelium (Egawa 2003; Schmitt et al 1996). The pattern of viral gene expression 
in these cells is not well defined, but it is generally thought that the viral 
replication E l and E2 proteins are expressed in order to maintain the viral DNA as 
an episome (Wilson et al 2002) and to facilitate the correct segregation o f genomes 
during cell division (You et al 2004). Studies been carried out on HPV31 showed 
that failure to express full length E l protein prevents episomal maintenance, and in 
cultured epithelial cells leads to the integration of viral genome into the host cell 
chromosome (Frattini et al 1996). It has been suggested that the viral genome is 
maintained extracliromosomally in the basal cells at around 50-100 copies per cell
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and the viral early proteins (E l, E2, E6  and E7) are expressed at low level (De 
Geest et al 1993). In uninfected epithelium, basal cells exit the cell cycle after 
migrating into the suprabasal cell layers and undergo a process o f terminal 
differentiation. Changes include the physical cross-linking of keratin intermediate 
filaments, the formation of cornifled envelopes and secretion of lipids, which 
together allow the epithelial surface to form a physical barrier against the 
enviromnent (Madison 2003). In virally-infected epithelium, as the host cells 
differentiate, the proliferative stage of viral life cycle occurs in the suprabasal layer 
of the epithelium. Amplification of viral genome requires expression o f all viral 
early gene products. The E6  and E7 expression contributes to viral DNA 
amplification via their action to delay the terminal differentiation of the cells. E4 
expression in this stage is thought to interfere with keratin network in order to 
facilitate virus particles assembly (Peh et al 2004). The expression o f E5 in the 
proliferative stage contributes to viral DNA amplification by increasing the 
percentage of the infected suprabasal cells undergoing DNA synthesis (Genther et 
al 2003), it also activates late viral functions upon epithelial differentiation 
(Fehrmann et al 2003). Once viral genome amplification has been completed, 
transcription from the late promoter is activated. The virus encodes two structural 
proteins LI and L2, which are organized into a 72 capsomere icosohedral shell at 
the sites of viral DNA replication, which is thought to facilitate packaging of the 
infectious virions (Becker et al 2004). Infectious virions are released into the 
enviromnent as the upper layer o f the epithelium is shed to infect new individuals 
or new sites in the same host.
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Figure 1. The life cycle organization during productive infection by HPV types
Virus detection
Figure 1. Life cycle organization during productive infection by HPV 
types.Diagram represents infected skin showing patterns of HPV-16 gene 
expression. Red arrow represents early genes expression (E1-E7) from the early 
promoter P97 at low levels in deep layers (basal and suprabasal) and elevated 
levels in intermediate layers (spinous). Green arrow represents an increase in 
abundance of early genes E l, E2, E4, and E5 expression in granular layers during 
viral DNA replication (Blue arrow). Yellow arrow represents expression o f capsid 
proteins (LI, L2) from the late promoter P670. Viral DNA assembly in capsid and 
new infectious viral particles are released during shedding of dead cells. Picture 
f r o m Doorbar /  Journal o f  clinical virology 32S (2005) S7-SJ5.
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1.2.2 Human papillomavirus
Human papillomaviruses (HPV) infection o f epidermal or mucosal epithelial cells 
causes different types of warts such as laryngeal warts in young children (Cook et 
al 1973) and genital condylomas (Kumar et al 1990). Certain types o f HPVs are 
detected frequently in anogenital cancers, particularly cancer of the cervix (Klaes et 
al 1999), head and neck squamous cell carcinomas (Ringstrom et al 2002). To date, 
over 1 0 0  different types of human papillomavirus have been identified, some of 
which are frequently associated with cancers and are considered high risk HPV 
(type 16, 18, 31 and 45), whereas infection by others causes warts and benign 
lesions and are considered low risk (types 6  and 11) (Munoz et al 2003). High risk 
HPVs are common in many epithelial derived cancers and are found in more than 
99 % of all cervical carcinomas (Walboomers et al 1999). Infection by high-risk 
HPVs is not limited to the genital tract, since approximately 20% of oral cavity and 
oropharynx cancers contain HPV-16 DNA, the most common HPV type in genital 
cancers (Herrero et al 2003).
1.2.2.1 HPV-16
HPV-16 is clinically the most prevalent virus among the approximately 30 HPV 
types that infect the genital tract and is the virus most often associated with 
cervical cancer (Zur Hausen 1996). It is also associated with oral and laryngeal 
malignancies (Baez et al 2004). All HPVs have an overall similarity in the 
genomic organization which can be divided into two parts; the early genes and late 
genes regions. The early genes encode viral nonstructural proteins (E l, E2, E4, E5, 
E6 , and E7 proteins) that are expressed early in infection in the basal and 
suprabasal layers. The late genes encode two capsid proteins (LI and L2 proteins),
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which are expressed later in the granular layer. The early and late regions are 
separated by a 850 bp long non-coding region rich in transcription factors sites 
called long control region (LCR) located between the LI and E6  genes. The 3’ end 
of LCR contains the origin of replication (ori) and binding sites for the 
transcription factor SP-1, YYl and the 4 binding sites for viral E2. Gene 
expression of HPV-16 and other HPV types is epithelial specific and is controlled 
by cellular transcription factors binding to the LCR and by the virally encoded E2 
(Steger and Corbach 1997); (Bouvard et al 1994b). Transcription initiates at 
several promoters, and the P97 promoter is the main early promoter (Tan et al 
1994). Most of the early genes are transcribed from the P97 promoter, localized 
upstream of the coding region o f the genome and regulated by transcription factors 
such as SPl (Apt et al 1996). The late P670 promoter is differentiation-dependent 
and is only activated in the upper part of the epithelium, where transcription 
initiates in the middle of the coding region of E7 (Grassmann et al 1996), the late 
promoter encodes the capsid proteins (LI, L2) and E4.
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Figui'e 2. Map o f human papillomavirus type 16 genome
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Figure 2. Map of human papillomavirus type 16 genome. The genome is marked 
in kilobase pairs (Kbp), and is shown linearized in the noncoding region (NCR). 
The NCR contains the origin o f replication and enhancer and promoter sequences. 
All early (E l-7) and late (L1,L2) open reading frames are shown on the same 
strand of viral DNA. The highlighted box represents E5 ORF, the minor 
transforming gene in HPV while E6  and E7 are the major transforming genes. E l 
and E2 are involved in viral gene transcription and replication. LI and L2 express 
capsid proteins.
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1.2.2.2 HPV and cervical cancer
The cervix is the narrow lower portion of the female uterus that extends into the 
vagina. Cancer of the cervix is a very common malignant disease in women 
worldwide. In many developing countries, and among female cancer deaths, 
cervical cancer is second only to the breast cancer. Although it is still a common 
disease, it has declined dramatically in incidence over the last several decades. For 
the most part, this is due to the widespread use of the Papanicolaou ("Pap") test. 
Various types of the human papillomavirus (HPV), a sexually transmitted 
infection, are responsible for the majority of cervical cancer cases and infection 
with high risk human papillomavirus (HPV) types, most frequently HPV 16, is the 
most significant risk factor in its aetiology (Bosch et al 1995).
Cervical intraepithélial neoplasia (GIN) is essentially a precursor to invasive 
cervical cancer, and is a condition characterized by new growth (dysplasia) in the 
normal epithelium of the cervix. The lesion arises from the transformation zone (T- 
zone) located between the mature epithelium of the exocervix and the columnar 
epithelium of the endocervical canal. Under physiological conditions, the columnar 
epithelium undergoes metaplasia to a stratified epithelium, during this process, it is 
vulnerable to external insults such as oncogenic HPV, resulting in the development 
of premalignant and possibly malignant cells rather than a normal epithelium 
(Arends et al 1998). The level of cellular changes is determined by histopathology 
and microscopy of Pap smears. GIN is recognised by disturbances of cellular 
maturation and stratification, and by the presence of cytological atypia. Infection of 
the genital tract by low-risk HPV (non-oncogenic) such as HPV - 6  and 11 is 
associated with cervical condylomas, which can be distinguished from GIN by the 
absence of nucleai- atypia in the basal layers o f the epithelium. The high-risk HPV-
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16 and 18 aie found in 50-80 % of GIN II and GIN III lesions and up to 90% of 
invasive cervical cancer (Arends et al 1990). Infrequent detection o f intermediate 
risk types such as HPV-31, 33 and 35 is associated with all grades of GIN and 
occasionally with cancer. GIN is classified histologically into three classes (mild 
(GIN I), moderate (GIN II) and severe intraepithélial neoplasia (GIN III), based on 
the proportion of the epithelium occupied by dysplastic cells. Initial infection with 
the high risk types (HPV-16 &18) causes low grade squamous intraepithélial 
lesions (GIN I), which is manifested by inhibition of the normal differentiation in 
the lower third of the epithelium, while differentiation occurs in the superficial two 
thirds of the epithelium. In GIN II, lesions move up to engage the middle third of 
the epithelium. The lesions may remain low grade or progress to severe dysplasia 
(GIN III), but the vast majority of GIN I and II lesions are cleared by the immune 
system. In GIN III, differentiation, which is minimal or even absent, occurs only in 
the most superficial third o f the epithelium. GIN III therefore morphologically 
describes severe dysplasia and carcinoma in situ, which may persist or may start to 
invade below the basement membrane leading to invasive cancer. Although a 
certain correlation exists between the degree of severity of dysplasia and 
progression to a higher grade o f GIN or cervical cancer, invasive cancer of the 
cervix can also develop from GIN I, while GIN II and GIN III cases do not always 
progress (Syrjanen 1996). Abnormalities usually attributed to the presence of HPV 
infection such as koilocytosis and epithelial multi-nucleation, are often present and 
are most conspicuous in GIN I and II, and minimal or absent in GIN III.
22
Chapter 1 : Introduction
HPV and Vaccine development
Infection by certain high risk human papillomaviruses (HPVs) is the most 
significant risk factor in the development of malignant tumours o f the anogenital 
tract. HPV infections are associated with the vast majority of cervical cancer cases 
of more than 95% of cases and the other 5% of cervical cancer cases may be 
unrelated to HPV infection (Zur 1991). The recognition that HPV infection plays 
the central etiologic role in cervical cancer has encouraged efforts to develop 
vaccines against HPV. HPV-16 is most commonly linked with cancer since it is 
present in 50% of cervical cancer and high-grade CINs and in association with 
HPV-18, 33, and 45 in 80% of cases worldwide. An effective HPV vaccine that 
targets HPV-16 and possibly other known oncogenic HPV types is therefore 
required to decrease the incidence o f cervical cancer and its associated precursor 
lesions. Two main types of vaccine have been developed: prophylactic vaccines to 
prevent HPV infection and its cervical neoplasia, and therapeutic vaccines to 
induce viral clearance and regression of precancerous lesions. The clinical trials to 
develop prophylactic papillomavirus vaccine are composed o f the viral LI capsid 
protein which is expressed in eukaryotic or in prokaryotic systems and purified in 
the form of virus-like particles (VLPs) (Lowy and Schiller 1999). The LI protein 
when is expressed in the absence of other papillomavirus genes can self-assemble 
into VLP that is morphologically and immunologically similar to infectious 
papillomavirus. Since the VLPs do not contain the papillomavirus DNA genome, 
they are not infectious and can not cause neoplastic changes in cells. VLP vaccines 
have been highly successful in the prevention and treatment of papillomavirus 
infection in animal models o f cottontail rabbit virus, bovine virus and canine oral 
papillomavirus (Breitburd et al 1995; Kirnbauer et al 1996). Although,
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prophylactic vaccine is mainly developed to generate neutralizing antibodies 
against HPV infection, it is also induces LI-specific T cell responses detectable by 
proliferation of both CD4+ and CD8 + T cells and in vitro production o f both T hl- 
and Th2-type cytokines (Pinto et al 2003). Cell-mediated immune response 
participates in the generation and maintenance o f protective B cell response and 
therefore may have an important role in the achievement of high neutralizing 
antibody titres. Furthermore, cytotoxic T cell responses to LI may also be 
important for maximization of prophylactic efficacy by eliminating the number of 
HPV-infected cells that have escaped antibody neutralization (Zinkernagel et al
1996). Therapeutic vaccines are also being developed to protect HPV-positive 
patients against tumour development. Most efforts have been directed toward use 
of the E6  and E7 proteins, or peptides derived from them largely because these are 
the viral proteins that are retained and expressed in cervical cancer (Ling et al 
2000). Papillomavirus genes can be introduced into cells as naked DNA, which is a 
relatively inefficient process, or as part of a viral vector such as vaccinia virus 
which usually more efficient. Therapeutic vaccines can also be developed against 
E l and E2, which are required for the viral DNA to be maintained as an 
extrachi'omosomal element that is unintegrated in the host DNA, represent 
potential interesting targets for benign lesions ((Brandsma et al 2004). It has been 
indicated that tumour formation was prevented in mice after vaccination with 
HPV-16 L1/E7 fusion protein (Tian et al 2006). This kind of vaccination induces 
LI-specific antibodies and also LI- and E7-specifîc CTL responses (Kuck et al
2006). Recently, several studies have tested a quadrivalent recombinant vaccine 
referred to as Gardasil that consists o f recombinant viral-like particles (VLPs) o f 
HPV 6 , 11, 16, 18 mixed with an aluminum-containing adjuvant. Gardasil prevents
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HPV infection but does not treat it, so it has been approved for use in girls and 
women 9 to 26 years of age. Although, the vaccine is highly immunogenic and
I
3
I
induces elevated antibodies titres, using this vaccine is a controversial and making 
concern for parents that the sexual activity o f their children might be promoted if  
they got vaccinated. There is another HPV vaccine, Cervarix, which is currently 
under development. These vaccines constitute the most significant development in
cervical cancer prevention so far, having the potential to reduce the incidence of :3:
cervical cancer by up to 70% (Widdice and Kahn 2006).
1.2.3 Bovine papillomavirus
Bovine papillomaviruses (BPV) predominantly infect cutaneous epithelium 
although some show specificity for the mucosal epithelium (e.g.BPV-4). The six
3
well-characterised BPVs were originally classified into two groups based on their 
genome size, structure, tissue tropism, and the histology o f the lesions: subgroup A 
and subgroup B. Subgroup A is comprised o f BPV-1, BPV-2 and BPV-5. The y;
feature that characterses these BPVs among all papillomaviruses is the ability to 
infect both epithelium and underlying fibroblasts, giving rise to fibropapillomas 
and may also induce papillomas in the less keratinized epithelium of the rumen.
Subgroup B comprises BPV-3, BPV-4 and BPV-6 , which infect only the 
epithelium and induce true papillomas. Papillomaviruses have recently been 
reclassified following the Greek letter nomenclature used for other vims families 
(de Villiers et al 2004). The epitheliotropic BPVs types 3, 4 and 6  are defined as 
Xi-papillomaviruses and BPV-1 and BPV-2 as Delta-papillomaviruses. It has been
V.found that the genome of BPV-5 share homology with Xi-PVs in E l ORF 
sequences and closely related to Delta-PVs in the genome size and structure (Bloch
25
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et al 1994). These observations have led to the reclassification of BPV-5 in an 
intermediary subgroup o f Epsilon-PV genus (de Villiers et al 2004). Like other 
PVs, BPV virions have constant structure and morphology of non-enveloped 
icosahadral structure, 55-60 nm in diameter. It contains the double stranded closed 
circular DNA com pleted with cellular histones. The virion is composed of the 
major LI and L2 capsid proteins. The BPV virion is characterised by exposing the 
C-terminus o f LI on the surface o f virion, which probably has a role in infection 
and immunogenicity (Modis et al 2002). The genome differs in size and structure 
among BPVs; Delta-PV genome is 8  kbp whereas Xi-PV genome is approximately
7.3 kbp. The genome is divided into three regions: a long control region, the region 
containing early genes and region containing the late genes. The genome of Delta- 
PV is similar to most PVs, whereas Xi-PV lack the E 6  gene which has been 
replaced by the E5 gene (Jackson et al 1991). In addition to the differences 
between Delta and Xi-PV, the LCR of Delta-PV contains 12 E2 binding sites (BS), 
whereas Xi-PV LCR contains only 4 E2 binding sites and shows similar 
arrangement patterns to the LCR of Alpha-PV (genital HPVs). Delta-PVs encode 
three oncoproteins, E5, E6  and E7, whereas Xi-PVs encode E5 and E7. E5 is the 
major transforming protein of BPV-1, followed by E6  with a modest role played 
by E7. In BPV-4, E5 and E7 are the transforming proteins and unlike BPV-1 E7 
whose expression is restricted to the cytoplasm and nucleus of the basal and 
suprabasal layers, BPV-4 E7 is major transforming protein expressed in all layers 
and stages o f papillomas. Both BPV type 1 and 2 predominantly induce 
fibropapillomas on the skin of cattle and experimentaly are capable of transforming 
primary bovine fibroblast or epithelial cells to complete oncogenicity, both as virus 
and as DNA (Campo 1992), but BPV type 4 DNA alone is not sufficient to induce
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transformation o f primary bovine cells and needs the cooperation o f an activated 
ras oncogene. BPV infection is readily transmitted in herd animals through direct 
contact of abraded skin. Natural infection of horses with BPV-1 often occurs after 
placing the horses in stalls previously housing infected cattle. Sexual transmission 
of venereal warts in cattle apparently occurs since these warts are rare when using 
artificial insemination. PVs virions have also been detected in milk suggesting that 
mammary epithelium may also be susceptible to infection and may represent a 
potential route for vertical infection.
Table 1: Bovine Papillomaviruses (BPVs) and the tumours they cause 
Genus type Tumour caused
Delta (ô)“PV BPV-1 Fibropapillomas o f paragenital areas
BPV-2 Fibropapillomas of skin; Fibropapillomas
of alimentary canal 
Epsilon (e)-PV BPV-5 Fibropapillomas o f teats and udders
Xi-PV (^) BPV-3 Papillomas of skin
BPV-4 Papillomas of alimentary canal
BPV - 6  Papillomas of teats and udders
From de Villiers et ah, 2004
Although, the majority of cases (warts) caused by different types o f BPVs are 
usually eradicated by a cell-mediated immune response directed against viral 
antigens, few cases have been associated with progression to squamous cell 
carcinoma. BPV-1 and BPV-2 which cause skin warts, also cause cancer of the 
urinar y bladder, BPV-4 has been found as the causative factor o f upper alimentary
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canal cancer (Cainpo 1997), BPV-1 also induces penile papillomas that can 
progress to cancer (Jarrett 1985). As cancer is a multi-factorial disease and several 
steps aie required before fully transformation is achieved, both urinary bladder 
cancer and upper alimentary canal cancer develop as a result of the interaction 
between the virus, environmental factors (bracken fern) and host cell factors 
activation. BPV-3, BPV-5 and BPV - 6  can cause significant economic 
consequences particularly infection by BPV-6 , where papillomas spread around the 
primary tumour to form large infected area, which interfere with milking and 
suckling. These lesions can get ulcerated, become infected with bacteria with 
susceptibility to cause mastitis.
1.2.3.1 BPV-4 genome
BPV type 4 is a tissue-specific virus that infects only the mucosa of upper 
alimentary tract. All sites from the tongue to the rumen can be affected (Campo et 
al 1980). BPV-4-associated papillomas are widespread in nature, they have been 
observed in different geographical areas. These benign tumours can become a 
focus for transformation to squamous cell carcinomas in animals feeding on 
bracken fern (Campo et al 1994). The contribution of viral, immunological and 
chemical factors in neoplastic progression of BPV-4 papillomas was first 
established in the field, and the high cancer incidence overlaps with grazing areas 
in which there is severe infestation of bracken fern (Jarrett et al 1978). The 
specificity of the virus for mucosal epithelium could be due to cellular receptors 
used by the virus to enter the cells or possibly to cellular factors restricted to the 
alimentary tract that are needed for viral replication (Jarrett 1985). The BPV-4 
genome consists of a single molecule o f double-stranded, circular DNA containing
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approximately 7261 base pairs. The entire BPV-4 genome is required for the 
induction of papillomas (Moar et al 1986), but the presence of the BPV-4 DNA is 
not necessary for the progression to, or the maintenance of, the transformed state 
(Campo et al 1985). The BPV-4 genome is functionally divided into tln-ee regions, 
at the end of each coding region there are poiyadenylation sites: the regions 
encoding the early and late gene products are separated by a noncoding region of 
500 to 1,000 bp (about 12% of the viral genome), called the long control region 
(LCR). The LCR regulates transcription and replication of the viral DNA and 
contains a number of binding sites for transcription factors including virus-encoded 
E2. The BPV-4 long control region (LCR), and those of human papillomaviruses 
(Desaintes and Demeret 1996), have similar organizations: an enhancer region, a 
promoter region, and a highly conserved distribution of E2 DNA binding sites 
(BS). The BPV-4 enhancer shares similarity both in size and position to that of 
HPV-16 and HPV-18 (Morgan et al 1999). The enhancer of these papillomaviruses 
is epithelial cell specific, as it fails to activate transcription from hetrologous 
promoter in non epithelial cell types. The promoter region of BPV-4 is 127 bp and 
contains the origin of replication, three binding sites for viral E2, a TATA box and 
an initiator element. BPV-4 promoter region does not contain binding sites for the 
cellular factors SPI (a positive regulator), YYl (negative regulator) and CDP/Cut, 
the repressor of HPV-16 transcription and replication. It has been found that the 
family of C/EBP transcription factors are implicated as both positive and negative 
regulators of transcription from HPV and BPV-4 LCR (McCaffery and Jackson 
1994). It has also been shown that BPV-4 LCR contains a 21bp cis element 
designated QRE-1, which is located immediately downstream of the TATA box. 
QRE-1 up-regulates transcription from LCR and thus an increased expression of
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viral oncoprotein in response to quercetin exposure (Connolly et al 1998). In the 
LCR of mucosal PV, including human papillomavirus type 16 (HPV-16), there are 
four E2 binding sites (B Sl-4), (Desaintes and Demeret 1996). Binding sites (BSl, 
2) are located immediately upstream from the TATA box and separated from each 
other and from the TATA box by 3 or 4 base pairs (bp). Binding site (BS3) is 
beside the E l DNA-binding site which involved in the regulation o f viral DNA 
replication, and (BS4) is a further 3 0 0 ^ 0 0  bp upstream. Mutational analysis of an 
individual E2 shows that E2 binding to sites 1 and 2 results in transcriptional 
repression, while E2 binding to sites 3 and 4 leads to transcriptional activation 
(Demeret et al 1997).
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Figure 3. Map of bovine papillomavirus type 4 genome
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Figure 3. Map of bovine papillomavirus type 4 genome. The genome is marked in 
kilobase pairs (Kbp). The boxes represent open reading frames (ORFs) which 
encode for early genes (E l-7) and late genes (LI, L2). All the ORFs are on the 
same strand of viral DNA. The highlighted box represents E5 ORF that occupies 
the position o f the missing E6 ORF in Xi PV genus. E5 ORF was orginally named 
E8 and because of similarities with BPV-1E5, it was renamed E5.
1.2.3.2 BPV-4 and squamous cell carcinoma of upper gastrointestinal tract 
(GIT)
Papillomaviruses are necessary, but often not sufficient factors in the induction of 
squamous cell carcinomas of cutaneous and mucosal epithelia (Jackson et al 1993). 
BPV-4 infects the mucous epithelium of the upper alimentary tract of cattle and 
induces benign proliferative lesions (papillomas). In healthy cattle, the papillomas 
develop and persist for approximately 1 year and are then rejected by a cell 
mediated immune response (Knowles et al 1996). However, in cattle grazing on
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braken fern the papillomas can transform and progress to squamous cell cancer 
(Campo and Jarrett 1986). Braken fern contains immunosuppressants and 
mutagens. Bracken-eating cattle become chronically immunosuppresed and 
incapable o f mounting an appropriate immune response against the virus or virus 
infected cells (Campo 1997). An incidence o f upper and lower GI tract cancers has 
been found to occur at high frequency in very restricted geographical areas such as 
Nasampolai valley of Kenya and the western highlands of Scotland where cattle 
graze on bracken-infested land (Jarrett et al 1978; Plowright et al 1971). The 
bracken mutagens are probably implicated for the observed activated ras in 
alimentary and urinary bladder carcinomas (Campo et al 1990), mutation of p53 
(Scobie 1996) and increase in epidermal growth factor receptors. Quercetin is a 
powerful flavonoid mutagen widespread in natuie, is found in high levels in 
bracken fern (Bjeldanes and Chang 1977; Nakayasu et al 1986). It binds DNA 
causing single DNA breaks (Fazal et al 1990), DNA rearrangements (Suzuki et al 
1991) and chromosomal damage. Moreover, quercetin arrests normal proliferating 
cells in the G l phase of the cell cycle (Connolly et al 1998). It has been shown that 
exposure to a single dose of quercetin can cause anchorage-independent growth of 
partially transformed PalF cells by E7, achieve oncogenic transformation and the 
cells can induce tumours in nude mice (Cairney and Campo 1995; Pennie and 
Campo 1992). Therefore, quercetin substitutes for E5 in inducing independence 
from substarte (see 1.2.6), for E 6  in conferring immortality and for mutant p53 in 
inducing oncogenicity (see 1.2.5.3.1). The synergy between quercetin and BPV-4 
E7 has been supported by induction of trans-activation of the transcriptional 
promoter/enhancer (LCR) via QRE-1 bound by quercetin (Connolly et al 1998). 
Up-regulation of the LCR increases the expression of viral transforming proteins,
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most likely E7. In the normal cells, exposure to quercetin induces cell cycle arrest 
in G l but in kératinocytes transformed by HPV-18 E6  and E7, which is a similar 
situation to that of PalF cells transformed by BPV-4 E7, quercetin upregulates 
LCR and increases E7 expression. E7 inhibits the cell cycle regulator p27 '^*’\  
preventing the quercetin-induced cell cycle arrest in G l, propelling the cell tlirough 
the cell cycle (Beniston and Campo 2005).
1.2.4 Papillomavirus viral proteins
1.2.4.1 Viral DNA replication proteins
Viral DNA replication occurs in the infected cell using the cellular DNA 
replication machinery. Viral infection of the basal cells leads to activation of viral 
gene expression which results in production of approximately 50 
extrachromosomal copies o f the viral DNA per cell. Among the first viral proteins 
to be expressed are the replication factors E l and E2. These proteins form a 
complex that binds to sequences at the viral origin of replication and also acts to 
recruit cellular polymerase and accessory proteins to mediate replication (Conger 
et al 1999; Frattini and Laimins 1994; Mohr et al 1990).
1.2.4.1.1 E l protein
The E l ORF encodes a 6 8  kDa protein essential for viral DNA replication. The 
full-length E l product is a phosphorylated nuclear protein that binds to the origin 
of replication positioned at the 3Terminus in the LCR of papillomaviruses. The E l 
protein carries multiple activities required for the initiation o f DNA replication. It 
contains blocks o f homology in the C-terminal amino acids with the SV40 
replication protein large T antigen and other polyomaviruses. E l protein of
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papillomavirus has ATPase dependent helicase activity that functions to allow the 
separation of viral DNA strands ahead o f the replication complex (Hughes and 
Romanos 1993). By itself, E l weakly binds the origin of replication, but complex 
formation with E2 facilitates loading E l onto the origin. E l proteins also bind 
DNA polymerase and help to recruit cellular' replication complex to the viral origin 
of replication (Masterson et al 1998). E l may also promote replication initiation 
and elongation by alteration of viral chromatin structure and disruption of 
nucleosomes at the replication fork (Swindle and Engler 1998). As E l transcription 
results from activation of early promoter in the basal cells, it is not fully 
understood yet how the E l activity is regulated in differentiating cells, but studies 
with HPV-11 have shown that expression of E l transcripts shifts from the early to 
late promoters, resulting in increased E l expression (Deng et al 2003).
1.2.4.1.2 E2 protein
The products of the papillomavims E2 open reading frame play a key role in the 
regulation of the viral cycle. E2 proteins can activate or repress viral promoters by 
several distinct mechanisms. E2 proteins are approximately 50 KDa in size and 
function as dimers. The C terminus contains a DNA binding domain which 
interacts with E l (Chen and Stenlund 2000). E2 dimers bind to consensus 
sequences (ACC6 GGT) called E2 binding sites located in LCR. On infection, early 
gene transcription is activated primarily by cellular transcription factors binding 
these sequences in LCR. At low concentrations E2 activates eai'ly gene expression, 
while at high concentration, it functions directly as an active repressor and inhibits 
HPV transcription at srages after TATA box recognition by TBP or TFIID (Hou et 
al 2000). This regulation o f viral expression by E2 contributes to control of copy
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number in undifferentiated cells. When the late promoter is switched on at the 
differentiation stage, at which its activation is differentiation dependent and is not 
repressed by E2, this results in transcription shifting from the early to the late 
promoter leading to increased levels o f E l and E2 expression, and an increase in 
viral DNA amplification (Klumpp and Laimins 1999). E2 may also form 
complexes with C/EBP transcription factors which regulate many promoters of 
genes involved in differentiation (Hadaschik et al 2003). Apart from its role in the 
regulation of transcription, overexpression of E2 protein can induce apoptosis by a 
p53 independent mechanism (Dowhanick et al 1995). In addition, introduction of 
heterologous expression vectors for E2 in cervical carcinoma cell lines (HeLa 
cells) containing HPV-18 results in a suppression of endogenous E6 and E7 gene 
transcription, leading to senescence of these cells (Goodwin and DiMaio 2000; 
Hwang et al 1993). This indicates that the continued expression o f E6 and E7 is 
required to maintain the transformed phenotype.
1.2.4.1.3 E4 protein
The E4 gene product is found primarily in the cytoplasm of kératinocytes, where it 
is extremely abundant, but certainly detected in the nucleus and at perinuclear sites 
in some infections. The E4 ORF is translated from spliced transcripts as a fusion 
with the first five amino acids of E l to generate E1^^E4 fusion protein. The E4 
ORF lacks an initiator AUG codon and uses the E l sequence for translation 
initiation (Howley 1996). All papillomaviruses express EU E4 proteins in the late 
phase of viral life cycle. E U E4 proteins from the high-risk types associate with 
keratin networks in the cells, suggesting that the five N-terminal E l amino acids 
play a major role in the interaction o f E4 proteins with intermediate filaments
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(Rogel-Gailiard et al 1993). In transient-transfection assays, overexpression of 
E U E4 proteins induce collapse of keratin (Doorbar et al 1991), but in natural 
infection only limited amount of collapse has been observed. It has been indicated 
that E4 proteins play a significant role in promoting viral genome amplification, 
maintenance of S phase during differentiation and expression of capsid proteins, 
these observations were correlated with initiation of E4 expression in suprabasal 
epithelial cells (Peh et al 2004; Wilson et al 2005).
1.2.4.2 Capsid proteins
Papilloma virions contain two virally encoded proteins, LI and L2, which are 
synthesized late in the infectious cycle. These two proteins encapsidate a histone- 
associated closed circular, double-stranded DNA. The LI ORF encodes the 56- 
60kD major capsid protein. The minor capsid protein L2 has a molecular weight of 
76-78kD. The N-terminal domain o f the L2 protein is highly conserved among 
different papillomaviruses. Since LI protein forms into capsomeres in the 
cytoplasm, viral DNA packaging should occur in the nucleus. After translocation 
o f L2 to the nucleus, L2 has been proposed to be responsible for recruiting LI 
capsomeres into nucleus and also recruits the viral genome to assembly sites (Day 
et al 1998). The outer shell of the virion contains 72 pentamers of L I, centered on 
the vertices of a T = 7 icosahedral lattice (Baker et al 1991; Trus et al 1997). L2, a 
largely internal protein, is present at about 1/30 the abundance of Ll(Kirnbauer et 
al 1993). The LI major virion structural proteins have recently been shown to self- 
assemble into vims-like particles when expressed in insect cells. These particles 
are the basis for a prophylactic vaccine to prevent genital HPV infection (Lowy et 
al 1994).
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1.2.4.3 Papillomavirus transforming proteins
1.2.4.3.1 The E6 protein
Analysis sequence of genus Xi (^) of bovine papillomaviruses including BPV-4 
revealed that the virus does not possess an E6 ORF and failure to induce full 
transformation may be due to lack o f this gene. The E6 functions might be 
performed by another viral or host protein. Furthermore, the position that might be 
expected to be occupied by E6, between the long control region and the E7 ORF, 
contains the E5 ORF (Jackson et al 1991). Apart from BPV-4 and other member of 
genus Xi, animal and human papillomaviruses have an E6 gene and its product is 
one of the major transforming proteins in HPV-16. The HPV-16 E6 protein is a 
151 amino acid protein, containing two zinc finger domains. E6 induces several 
important changes in the host cell that affect both the normal viral life cycle and 
the process o f immortalization. E6 can efficiently immortalize human mammary 
epithelial cells and cooperates with E7 to immortalize primary human foreskin 
keratincytes (HFK) (Kiyono et al 1998). An important function o f E6 in 
tumorigenesis is its binding to and inactivation of p53 (Wemess et al 1990). p53 is 
a transcription factor that stimulates the expression o f genes involved in cell cycle 
arrest and apoptosis, such as the cyclin dependent kinase inhibitor, p21 (Ko and 
Prives 1996). E6 induces p53 degradation via a process mediated by an ubiquitin 
ligase called the E6-associated protein (E6-AP) (Huibregtse et al 1991). E6 can 
also indirectly downregulate p53 activity through its association with p300/CBP, 
which is a transcriptional coactivator of p53 that gathers transcription factor and 
the basal transcription machinery at gene promoters (Zimmermann et al 1999). 
Another major function of the HPV-16 E6 is their ability to activate the expression 
of the catalytic subunit of the telomerase, hTERT (Klingelhutz et al 1996).
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Telomerase is a four subunit enzyme that adds hexamer repeats to the telomeric 
ends of chromosomes, following cell division which leads to shortening of 
telomerase. This process is only restricted to embryonic cells and absent in somatic 
cells which undergo senescence after cell division (Liu 1999), Reactivation of 
hTERT expression occurs in most cancer and leads to reconstitution of telomerase 
activity. It has been shown that E6 binds to Myc and its cofactor Max, leading to 
transcriptional activation of the hTERT promoter (Veldman et al 2003). In the 
productive life cycle, the main role of E6 is to facilitate viral replication, as shown 
by the observation that E6 of HPV-31 and HPV-6 is required to maintain stably 
episomal replication (Thomas et al 1999) probably, by a disruption of the 
mechanisms that prevent the maintenance o f extrachromosomal DNA.
1.2.4.3,2 The E7 protein
The E7 is a potent transforming protein which is well conserved among different 
PVs. In BPV-4, E7 has been detected in most papilloma cell layers, in the nucleus 
of the basal and suprabasal cells and in the cytoplasm of the spinous and squamous 
layers (Anderson et al 1997). In HPV, E7 proteins o f both low- and high-risk are 
found predominantly in the nucleus. They aie approximately 100 amino acids in 
size. The protein is divided into domains; CRI at the N terminus; CR2, which 
contains an LXCXE m otif that binds the Rb protein and CR3, which contains two 
zinc finger-like motifs. The CRI and CR2 domains of E7 have sequence homology 
to adenoviral E l A CRI and CR2 domains that also bind to Rb proteins (Phelps et 
al 1988). E7 proteins contribute to cell transformation thiough their binding to and 
abrogation of the function of members of the retinoblastoma family of proteins. 
The ability of E7 to inliibit the transcription repressive functions of the Rb proteins
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leads to stimulation of cell cycle progression, even in the presence of cellular an'est 
signals (McCance 2005). In BPV-4, E7 ORF encodes a polypeptide homologous 
to HPV-16 E7 with recognizable pI05Rb binding domain and two cys-x-x-cys zinc 
binding motif (Dyson et al 1989; Munger et al 1989). Recently, it has been 
demonstrated that Rb binding domain is shared by all E7 proteins with exception 
of E7 proteins of fibropapillomaviruses (Narechania et al 2004) and therefore the 
ability of BPV-4 E7 to transform cell may be due to its binding to Rb protein 
whereas, BPV-1 E7 which does not have Rb binding domain, is not able to 
transform cells unless it cooperates with E6. E7 has also been associated with 
histone deacetylases (HDAC), AP-1 transcription factors, cyclins, cyclin- 
dependent kinases (cdks), and cdk inliibitors. These associations contribute to the 
ability of E7 to induce cellular proliferation, immortalisation and transformation. 
Cyclin E-cdk2 is essential for initiation o f DNA synthesis and can activate cell 
cycle progression in the absence o f cyclin D-cdk4 underlining this complex as a 
potential target by which E7 propels cell cycle re-entry. The expression of E7 
induces dysregulation of cyclin E expression at transcriptional and post 
transcriptional levels, suggesting that E7 may affect cyclin E-cdk2 activity via 
increased synthesis of cyclin E (Zerfass et al 1995). Additionally, E7 inhibits the 
cell cycle regulator p27^^'^\ preventing cell cycle arrest in G l in quercetin-treated 
cells (Beniston and Campo 2005). E7 can also interact with members of the Ap-1 
family o f transcription factors including c-Jun, JunB, JunD and c-Fos. Ap-1 
transcription factors mediate early mitogenic effects and are implicated in 
keratinocyte and myeloid cell differentiation. Mutational analysis revealed that the 
E7 zinc finger motif is involved in c-Jun/ E7 interaction. It has been demonstrated
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that the binding of E7 to c-Jun increases the ability of E7 to transform rat embryo 
fibroblasts (REFs) in the presence of activated ras (Antinore et al 1996).
1.2.5 Papillomavirus E5
The analysis of the DNA sequence o f the papillomavirus genome revealed that the 
E5 ORF commonly is located at the 3’ end of the early region before the L2 ORF 
and overlaps the E2 ORF in the early region. However, in the epitheliotropic Xi- 
papillomavirus BPVs the E5 ORF (originally designed E8) occupies the position of 
the missing E6 ORF at the 5’ end o f the eai’ly region, between the long control 
region and the E7 ORF (Jackson et al 1991). E5 genes of PVs encode small highly 
hydrophobic proteins ranging from 42 amino acids in BPV-4, 44 amino acids in 
BPV-1 to 83 amino acids in HPV-16. The gene is not well conserved at the DNA 
level between HPVs or BPVs, although there is conservation of the physio- 
chemical properties in that the proteins are all highly hydrophobic and membrane 
bound (Conrad et al 1993). The HPV-6 and HPV-11 E5 proteins share structural 
properties with the BPV-1 E5 protein: they contain a Cys-X-Cys sequence near the 
carboxy terminal and glutamine residue within the hydrophobic domain. Both 
these regions have been shown to be critical for the transforming activity o f BPV-1 
E5 (Horwitz et al 1989). The most studied PV E5 proteins in animal and human are 
BPV-1 and HPV-16 respectively. In BPV-1, 95 to 99 % of the in vitro 
transforming activity of BPV-1 DNA is due to the E5 gene and the remaining 
percentage of transforming activity is due to E6 (Neary and DiMaio 1989; Schlegel 
et al 1986). BPV-1 E5 can be divided into two domains: N-terminus and C- 
terminus. The N-terminus, which is a hydrophobic domain, includes 30 amino 
acids and is thought to exist in an a-helical conformation important for membrane
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anchoring and cell transformation. The carboxy-terminal sequence is generally 
hydrophilic and contains two cysteine residues. The Cys-X-cys sequence is 
conserved in E5 protein of bovine and human papillomaviruses oligomeres via 
disulfide bond, contributing to the transforming activity of E5 (Schlegel et al 
1986). The E5 protein is thought to be a type II transmembrane protein that is 
localized largely to the membranes of the endoplasmic reticulum and Golgi 
apparatus o f transformed cells and exists as a dimer of two identical subunits 
linked by disulfide bonds involving cysteine residues in the carboxyl-terminal third 
of the protein which appears to extend into the lumen of these organelles 
(Burkhardt et al 1989; Horwitz et al 1988). In naturally infected bovine cells, E5 is 
expressed in early stages of infection, where it has been found that the majority of 
basal cells within a wart are infected with virus (Burnett et al 1992). However, 
large amounts of E5 has been detected in the differentiated kératinocytes and the 
role of E5 in this stage is thought to alter the normal physiology of the host 
differentiated kératinocytes to promote viral DNA replication and capsid protein 
expression. In HPV-16, E5 gene ecodes a hydrophobic transmembrane protein 
localized mainly in the endosomal membranes and Golgi apparatus. E5 proteins 
encoded by several HPVs which infect the genital region (e.g., types 6, 11, 16, 18, 
33) exhibit a conserved hydrophobic structure, but not a conserved amino acid 
sequence (Bubb et al 1988). The analysis of amino acids sequence of HPV-16 E5 
indicates that the protein is composed of thi’ee distinct hydrophobic domains that 
are capable o f spanning a membrane three times. Unlike BPV-4 and BPV-1 E5, 
HPV-16 E5 protein has a lower oncogenecity compared with the two major 
transforming proteins E6 and E7. E5 can transform rodent fibroblasts, but is unable 
to immortalize kératinocytes, although it extends the in vitro life span of these cells
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(Straight et al 1993). The HPV-16 E5 protein has been shown to cooperate with E7 
protein to induce proliferation o f 3T3 cells in the presence of certain growth factors 
for transformation and stimulation o f DNA synthesis, suggesting that E5 may 
cooperate with the E7 gene to stimulate cell proliferation in vivo (Bouvard et al 
1994a). Detection of E5 mRNA as well as an elevated levels of its gene product in 
low grade of CIN suggests that E5 has a significant role in the viral infection and 
early steps o f cellular transformation (Kell et al 1994; Stoler et al 1992). In well- 
developed carcinomas, E5 has been found to be hequently deleted upon 
incorporation of viral DNA into the host genome, suggesting that E5 is not 
necessary to maintain the malignant state. It has been shown that expression of E5 
gene is regulated by transcriptional factors encoded by the E2 ORF in C l27 cell 
transformation assays. E2 transactivation results in an increase transcription from 
the P2443 promoter whose transcripts encode the E2 transactivator as well as the 
E5 oncoprotein, whereas the P2443 promoter activity could be inhibited by the E2 
trans-repressor (Hermonat et al 1988). E5 gene is required for efficient focus 
formation and elimination of E2 transactivation activity, removal of the LCR, or 
increased of E2 repressor synthesis causes dramatic decreases in the expression of 
the E5 gene and severely inhibits focus formation (Prakash et al 1988). In BPV-4, 
E5 and E7 are the major transforming proteins. The E5 ORF is located at 5’ end of 
the early genes and encodes the smallest PVs E5 proteins; it is only 42 amino acids 
long. BPV-4 E5 protein comprises two distinct domains: the N-terminus is a highly 
hydrophobic, 30 amino acids residues with the capacity to form an a-helix and a 
hydrophilic C-terminal tail o f 12 amino acids residues (Jackson et al 1991). The 
BPV-4 E5 protein is localised in endoplasmic reticulum and Golgi apparatus and it 
is expressed in deep layers of early stages papillomas of the upper alimentary tract
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(Anderson et al 1997). E5 proteins from both animal and human PVs possess 
biological activities with varying degree of efficiency in the transformation of 
mammalian cells. E5 contributes to cell transformation through interaction with 
several cellular proteins, including the epidermal growth factor receptor (EGF-R), 
the human receptor for colony stimulating factors (CSF-1) and the 16 kDa subunit 
of the vacuolar ATPase. In addition, BPV-1, BPV-4 and HPV-E5 interact with 
platelet-derived growth factor receptor PDGF-R.
1.2.5.1 BPV-1 E5 and platelet-derived growth factor receptor
The E5 protein does not have intrinsic enzymatic activity but rather induces 
transformation by modulating the activity o f cellular membrane proteins that 
regulate cell growth. It has been suggested that E5 protein targets the growth factor 
receptors since co-transfection of E5 gene with human epidermal growth factor 
receptors genes in NIH3T3 cells resulted in transformation of cells correlated with 
delayed turnover of activated EGF receptor in co-transfected cells (Martin et al 
1989). Moreover, expression o f E5 induced DNA synthesis in quiescent fibroblasts 
after being treated with E5 and purified growth factors (Settleman et al 1989).
The platelet derived growth factor beta receptor (PDGF-^) activated by the BPV-1 
E5 protein has elevated levels of tyrosine kinase activity with the receptor 
activated PDGF. In addition, PDGF receptors whether activated by E5 or by PDGF 
have been shown to be associated with various SH2 domain containing cellular 
proteins that play crucial roles in response to PDGF (Cohen et al 1993; Petti et al 
1991). It has been shown that cells lacking endogenous PDGF p  receptor are not 
susceptible to E5-induced transformation. However, co-expression of the E5 
causes receptor activation and transformation and provides an anti-apoptotic signal
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in the face o f growth factor deprivation (Nilson and DiMaio 1993). It has been 
reported that certain mutants of E5 are able to transform cells without binding to or 
activating the PDGF y? receptor, suggesting that these mutants utilize alternative 
PDGF P receptor-independent mechanisms to transform cells (Schapiro et al 2000; 
Suprynowicz et al 2000). However, recent data indicated that at least some of these 
mutants interact productively with the PDGF p  receptor (DiMaio et al 2000). The 
E5 protein and the PDGF p  receptor form a stable complex in cells. Unlike PDGF, 
which binds to the extracellualr domain of the receptor, E5 protein interacts with 
transmembrane and juxtamembrane domains o f the PDGF P receptor (Cohen et al 
1993; Staebler et al 1995). It has been proposed that formation of the complex E5/ 
PDGF p  receptor requires an electrostatic bond between juxtamembrane lysine in 
the PDGF p  receptor and aspartic acid 33 of the BPV E5 protein and hydrogen- 
bond between a transmembrane tlireonine in the receptor and glutamine 17 of the 
E5 protein (Horwitz et al 1988; Klein et al 1998). The requirement of the 
glutamine 17 and aspartic acid 33 in E5 and PDGF p  receptor interaction may 
explain the inability of the E5 protein to activate the PDGF alpha receptor, which 
lacks the essential tlireonine and lysine (Staebler et al 1995) Complex formation 
also requires dimerization of E5 protein and glutamine 17 plays a role in stabilizing 
the E5 dimer (Klein et al 1998). It has been demonstrated that PDGF P receptor is 
activated, complexed and colocalized with E5 protein in neoplastic epithelial cells 
from bovine urinary bladder tumours (Borzacchiello et al 2006).
1.2.5.2 HPV-16 E5 and EGF-R
Viruses have evolved mechanisms to modulate cellular signaling pathways to 
reprogram host cells to support their life cycles or modulate host defense responses
44
Chapter 1 : Introduction
(Burgert et al 2002). Alterations in the expression and/or activity of epidermal 
growth factor receptor (EGFR) family members are common in many types of 
cancers, and their activity contributes to tumorigenicity. Epidermal growth factor is 
the ligand for EGF receptor (EGFR), a transmembrane receptor protein present on 
all epithelial cells. The binding of EGF to the extracellular domain of the receptor 
intiates receptor dimerization and stimulates the activity of tyrosine kinase 
localized on the intracellular domain of the receptor resulting in 
autophosphorylation and initiation of downstream cascades leading to the 
stimulation o f DNA synthesis (Chen et al 1987; Moolenaar et al 1988; 
Schlessinger et ai 1988). PV E5 contributes to cell transformation via its ability to 
inhibit down-regulation of the epidermal growth factor (EGF) receptor (EGF-R). It 
has been reported that the cooperation between E5 and high levels of EGF 
receptors is associated with inhibition of receptor degradation and persistence of 
activated receptors on the cell surface (Martin et al 1989). Recent studies have 
demonstrated that HPV-16 E5 has activities to transform rodent fibroblasts and 
stimulates mitogenesis in human epithelial cells and these activities are enhanced 
by stimulation of EGF. Furthermore, these activités may be attributed to the ability 
of HPV-16 E5 in human kératinocytes to increase the number o f EGFRs at the cell 
surface, inhibit degradation of the receptor in endosomal vesicles, increase receptor 
kinase activity and cause the recycling o f the receptor to the cell surface (Straight 
et al 1993). It has been revealed that inhibition of the EGFR down-regulation by 
E5 results from the defective endosomal acidification in E5-expressing cells 
(Straight et al 1995). The lack o f acidification may be due to interference with H^- 
ATPase pump which may be associated with the ability o f E5 to bind to a 16-kDa 
proteolipid, which is a component o f the vacuolar proton-ATPase pump (Conrad et
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al 1993). This binding has been suggested to cause delaying of EGFR degradation 
and an increased recycling of EGFR to the cell surface. It has been suggested that 
HPV E5 proteins contribute to proliferation of kératinocytes by enhancing the 
mitogenic activity of outocrine growth factors such as endothelin-I (ET-1) (Venuti 
et al 1998). ET-1 is a potent vasoconstrictor peptide, secreted by kératinocytes, 
which influence the growth and function of epidermal and dermal cells by binding 
to specific growth factor receptor subtypes that belong to the family of G-protein- 
coupled receptors. Exposure to external stimuli such as UV irridiation leads to 
upregulation of ET-1 expression (Tsuboi et al 1994), which in turn stimulates 
melanocyte proliferation and melanogenesis (Tada et al 1998).
1.2.5.3 E5 and 16 K subunit c/ductin
Several viral oncoproteins such as BPV E5 proteins (Goldstein et al 1991), HPV 
E5 proteins (Conrad et al 1994) and T-cell leukaemia virus type 1 p l2  (Franchini 
et al 1993) bind to 16 KDa. 16 KDa is a highly conserved transmembrane protein 
which is the subunit c component o f the vacuolar H (+)-ATPase (V-ATPase) and a 
component of the comiexon channel o f gap junctions. 16 KDa is very hydrophobic 
and is thought to contain four transmembrane segments arranged as a four alpha 
helix bundle (Finbow et al 1992). The V-ATPase is one of the most fundamental 
enzymes in nature. It functions in almost every eukaryotic cell and energizes and 
acidifies endosomes, Golgi apparatus and other endomembranes compartments 
(Nelson et al 2000). V-ATPases are multisubunit, heteromeric proteins composed 
of two structural domains, a peripheral, catalytic VI domain and a membrane- 
spanning VO domain. 16 KDa provides the pathways for proton translocation in 
the VO sector of the ATPase. The binding of E5 protein to 16 KDa leads to
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impairment of function, inliibition of endosomal acidification in cells transformed 
by BPV-1 and in cells expressing HPV-16 E5 (Straight et al 1993). PV E5 proteins 
are not conserved in their aminoacid sequences; however, the HPV-6 and HPV-11 
E5 proteins share structural properties with BPV-1 E5 protein. They contain a Cys- 
X-Cys sequence which is located near the carboxyl terminus and the position 17 (a 
glutamine residue) within the hydrophobic domain. Both of these regions have 
been shown to be important for the transforming activity of BPV-1-E5 protein 
(Horwitz et al 1989). A part of that, the glutamine residue mediates binding of E5 
to the 16-KDa vacular ATPase component (Goldstein et al 1992). In HPV-6, there 
is a binding domain other than the glutamine residue; a construct o f HPV-6 E5 
lacking the carboxyl terminus and glutamine residue maintains the ability to bind 
to ductin (Conrad et al 1993). Mutational analysis of HPV E5 proteins 
demonstrated that the interaction with the V-ATPase is mediated by the central 
hydrophobic region of the viral proteins, and some E5 mutants able to bind the V- 
ATPase do not impair V-ATPase function (Adam et al 2000). In BPV-4, both the 
hydrophilic C-terminal tail and the residue at position 17 in the hydrophobic 
domain are crucial for E5 functions including binding to ductin and transactivation 
of cyclin A promoter (O'Brien et al 1999). It has been suggested that induction of 
transformation in established murine kératinocytes expressing BPV E5 is due to 
E5-induced malfunction V-ATPase since these cells do not normally express 
PDGF receptor (Leptak et al 1991).
1.2.5.4 E5 and gap junction
Down-regulation of gap junction-mediated cell-cell communication is another 
biological activity of PV E5 and observed in kératinocytes expressing HPV-16 E5
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and PalF cells expressing BPV-4 E5. Gap junctions are clusters of intercellular 
channels between adjacent cells, which allow the transfer of ions, metabolites and 
messenger molecules less than 1 KDa in size between connected cells. The 
structural proteins comprising these channels, collectively called connexins, are 
members of a highly related multigene family consisting of at least 13 members. 
Each connexin has four transmembrane domains and is oriented with the N- and C- 
termini located in the cytoplasm (Bruzzone et al 1996). It has been demonstrated 
that HPV-16 E5 induces a significant reduction of gap junctional cellular 
communication in kératinocytes, which is probably mediated by a 
dephosphorylation of Cx43, the major component of gap junction (Oelze et al 
1995). Recently, it has been reported that BPV-4 E5, the protein analogous to 
HPV-16 E5, is able to inhibit intercellular communication in PalF cells expressing 
E5 compared with control cells. This has been examined by injecting a single 
transformed cell with a fluorescent dye that show no spreading o f dye to 
surrounding cells whereas control cells show spreading of the fluorescent dye to 
neighbours (Faccini et al 1996). Down-regulation of gap junction has been 
attributed to binding of E5 to ductin, which comprises a part o f the gap junctional 
complex (Finbow and Pitts 1993). However, binding to ductin is not sufficient for 
down-regulation of gap junction communication as Ashrafi et al., (2000) have 
shown that same mutant forms of BPV-4 E5 can not inhibit gap junctions 
communication despite their ability to bind ductin in vitro. Therefore, down- 
regulation of gap junction can be dissociated from growth in suspension and is not 
necessary for transformation, although it may help the establishment of a 
transformed clone. Expression of E5 in the deep layers of papillomas would lead to 
temporary closure o f the gap junction charmels and blockage of transduction of
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homeostatic control signals exerted by uninfected neighbour cells onto infected 
cells.
1.2.5.5 E5 and Apoptosis
Papillomavirus depends on the host DNA replication machinery to synthesize its 
own DNA, since the virus does not encode a DNA polymerase. The host DNA 
replication machinery is readily available in the proliferating basal cells, but is 
limited in the postmitotic differentiated cells of the suprabasal compartment. The 
response o f healthy cells to inappropriate DNA replication is apoptosis. Therefore 
it is to the advantage of the virus to promote DNA replication and cell 
proliferation, delay terminal differentiation and suppress apoptosis within the host 
cells (McMurray et al 2001). Apoptosis is the best-charaterized form of 
programmed cell death and is of fundamental importance in tissue homeostasis. 
The morphological features of apoptosis consist of chromatin condensation and 
cell shrinkage whilst the biochemical features include DNA fi'agmentation, protein 
cleavage at specific locations, increased mitochondrial membrane permeability 
(Kerr et al 1972; KeiT et al 1994). In mammalian cells, two major pathways have 
been identified to be involved in the initiation o f apoptosis: the extrinsic death 
receptor (DR) pathway and the intrinsic mitochondrial pathway. In many cell types 
including numerous tumor cells, both extrinsic and intrinsic pathways act in 
coordination, leading to activation o f the executioner caspase cascade. Activation 
of the DR pathway takes place by ligation of members of the tumour necrosis 
factor (TNF) family, such as Fas ligand (FasL; also called A pol) and Apo2 ligand 
(Apo2L; also called TNF-related apoptosis-inducing factor [TRAIL]), to DR on the 
plasma membrane. TRAIL is a member o f the TNF ligand family that rapidly
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induces apoptosis in a variety of transformed cell lines. It cross-links with the 
death receptors DR4 or DR5, while the FAS ligand, which is a type II 
transmembrane protein that belongs to the TNF family, binds to the Fas CD95 
receptor. Binding o f these ligands to their respective receptors, leads to aggregation 
o f the receptors. Trimerization of the activated Fas or TRAIL receptors leads to 
recruitment and binding to the adaptor molecule F ADD (Fas-associated DD), and 
subsequently activation of initiator caspase-8 (Kischkel et al 2000). The complex 
protein which is formed by binding o f Fas and TRAIL to F ADD is called death- 
inducing signalling complex (DISC) which stimulates the activation o f procaspase- 
8. The caspase-8 is member o f the interleukin-1 beta converting enzyme (ICE) 
family of cysteine proteases. The activated caspase-8 is released into the cytoplasm 
and initiates a protease cascade that activates "effector" caspases, such as caspase-3 
and caspase-7. Fas and TRAIL receptors are widly expressed on normal epithelial 
cells. Downregulation of Fas expression is a common abnormality in 
gynaecological cancer whereas TRAIL receptor is not reduced in cervical cancer. 
HPV-16 like many other viruses has evolved mechanism to delay apoptosis in the 
infected cells by preventing intrinsic p53-dependent apoptosis mediated by the 
expression o f E6. Furthermore, it has been reported that HPV-16 E5 impairs 
extrinsic apoptosis mediated by TRAIL and FasL in human kératinocytes. The 
expression of E5 reduces the surface expression of Fas receptors, suggesting that a 
reduction of Fas receptors lowers the probability that ligands reach their respective 
targets causing E5 cells to be less susceptible to FasL-induced apoptosis. It has 
also been observed that DISC formation induced by TRAIL is impaired, although, 
there are no differences in the expression of the death receptors DR4 (TRAIL-Rl) 
and DR5 (TRAIL-R2) between E5 and control cells (Kabsch and Alonso 2002).
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Fas-induced apoptosis can be blocked by activation of EGF via EGF-EGFR 
binding which causes activation of its downstream effector (PI3K)Akt. Akt is 
known as protein kinase B (PKB) and an important molecule in mammalian 
cellular signaling as anti-apoptotic and cell survival signals. PKB has been 
implicated as a major factor in many types o f cancer due to its ability to overcome 
the natural apoptosis signals that the cell receives (Franke et al 1995; Kulik et al 
1997). Since HPV-16 E5 can enhance EGFR activation, human kératinocytes 
expressing HPV-16 E5 were examined for apoptosis following exposure to UVB 
irradiation. Protection o f the cells from UVB-irradiation-induced apoptosis was 
attributed to expression of E5 which in the presence of EGF, acts to keep the cell 
survival Akt and ERK l/2 at high levels in UVB-irradiated human kératinocytes 
(Zhang et al 2002).
1.2.5.6 BPV-4 E5 and cell cycle regulators
The cell cycle in mammalian cells is regulated by the coordinated activity of a 
family of cyclin-dependent kinases (CDKs). These are positively and negatively 
regulated by the cyclin and CDK inhibitor families (Sherr and Roberts 1995). 
Based on the timing of their appearance in the cell cycle, cyclins can be divided 
into two groups: the mitotic cyclins A and B and the G l cyclins of the D and E 
families (Lew et al 1991). There are at least two distinct families of CDK 
inhibitors: the INK4 and the Cip/Kip inhibitors. Both families play regulatory roles 
during the G l/S  cell cycle check point (Hunter and Pines 1994). The inhibitors of 
Cip/Kip family which consists of p21, p27 and p57 control the G2 check point as 
well. The p27 has capacity to arrest cells in G2 (Polyak et al 1994). In response to 
growth promoting signals, cyclin D is synthesized and forms a complex with cyclin
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dependent kinase 4 (CDK4) and CDK6, which provides a mechanistic link 
between extracellular growth signals and the initiation of entry into S phase from 
GO/Gl. Its role in this pathway is to phosphorylate the members of retinoblastoma 
Rb family (Ely et al 2005). The phosphorylation of Rb protein inhibits its 
repressing function, permitting the release and activation of E2F transcription 
factors, which in turn up-regulates the genes required for S phase, such as cyclin A, 
cyclin E, c-myc and DNA polymerase (Dyson 1998). Cyclin A promotes both 
G l/S  and G2/M transitions. It is also required for DNA synthesis and once 
transported into the nucleus, it forms a complex with cdkl, which is required for 
entry into mitosis (Pagano et al 1992). Deregulation of cell cycle is a common 
strategy employed by many DNA and RNA viruses to trap and exploit the host cell 
machinery towards their own benefit. It has been reported that BPV-4 E5 
expression in NIH3T3 cells promotes transcriptional activation o f cyclin A 
promoter and increases endogenous protein levels in cells maintained in 
suspension culture and in low serum, whereas both theses culture conditions 
promotes down-regulation of cyclin A in control cells (O'Brien and Campo 1998). 
In addition, cyclin A associated kinase activity is increased in E5-3T3 cells despite 
elevated levels of CDK inhibitor p27 protein. Continued proliferation o f E5-3T3 
cells in the presence of p27 has been attributed to the fact that the ability of p27 to 
block CDKs activity and cell cycle progression might be disrupted by E5 
expression. Additionally no correlation was observed between elevated levels of 
p27 and cell cycle arrest or inhibition of cyclin A-cdk following serum removal.
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1.3 Host immune system
The immune system is a group of cells, molecules, and organs that act together to 
defend the body against foreign invaders that may cause disease, such as bacteria, 
viruses and parasites. There are two types of immunity: the innate immune 
system and the adaptive immune system, which are crucially important in 
eliminating infections. The innate immunity is characterised by induction o f non­
specific responses and no memory or lasting protective immunity can be achieved. 
The innate immune system forms early barriers to viral infection at epithelial 
borders and is stimulated via several immunomodulatory cytokines and cellular 
effectors including monocytes, macrophages, natural killer (NK) and antigen 
presenting cells (APC). Such cells rapidly differentiate into short-lived effector 
cells whose main role is to get rid of the infection. However, in some cases, the 
innate immune response is not able to eliminate infection and requires the 
induction of the adaptive immune response. Adaptive immune responses are 
activated in peripheral lymphoid organs.They allow for specific recognition and 
elimination of antigens that are abundant in the body fluids or within cells. 
Adaptive immunity provides long-term immunity to reinfection, (immunological 
memory). The major effector cells o f the adaptive immune response are B and T 
lymphocytes. B lymphocytes express and secrete antibodies, which target and 
neutralise humoral antigens for later destruction, whereas cytotoxic T lymphocytes 
recognize and destroy infected or malignant cells. T cells react directly against a 
foreign antigen that is presented to them on the cell-surface of a host. Several 
changes including high levels of cytokines released by antigen presenting cells 
(APC) which leads to an interaction between T cell receptors (TCRs) and peptide- 
MHC class I complex at the interface between the T cell and APC. This binding is
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critical for selection of the T cell in the thymus, as well as the activation of mature 
T cells in the periphery, and complete stimulation and differentiation of T cell into 
cytolytic effectors CD8^ T is induced from interaction between TCR and 
peptide/MHC class I on the surface of target cells, leading to killing the infected 
cells (Gonzalez et al 2005; Kalergis et al 2001; Kalergis 2003)
1.3.1 The major histocompatibility complex
The major histocompatibility complex (MHC) is a multi-gene complex critical to 
vertebrate immunity. It is contained within about 4 Mbp of DNA (1 % of the 
genome) on the short arm of chromosome 6 at 6p21.3 (Campbell and Trowsdale 
1993). The MHC is the most gene-dense and polymorphic region of the 
mammalian genome and is associated with resistance to infectious diseases, 
autoimmunity and transplantation (Kumanovics et al 2003). The MHC genome 
regions of the human, chicken and mouse have been fully sequenced and mapped, 
but information on the MHC genome structmes of other vertebrates is limited. The 
human MHC is divided into three distinct nonoverlapping regions designated from 
the centromere to the telomere as the class II, III and class I regions, respectively. 
Class I is suggested to be the most divergent region between different animal 
species, class II is intermediate and the class III region is conserved in gene 
diversity and organization.
The human MHC is known as human leukocyte antigen (HLA) system, which is 
distinguished from other regions of the human genome by a high gene density with 
about 40 % of the expressed genes (class I and class II), with class I having 
immune system frmctions and large number o f duplicated and polymorphic genes. 
The human MHC (HLA) class I molecules have a critical function in the
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recognition of virally infected cells by the cytotoxic CD8^ T cells. Since CTLs 
cannot access the interior o f the cell for inspection, MHC molecules present 
intracellular antigens on the surface of nucleated cells, where they are recognized 
by cytotoxic T lymphocytes (Wong and Pamer 2003). The MHC molecules are 
extensively polymorphic, which is critically important in antigen recognition by T 
cells. The MHC polymorphisms confer allelic-specific peptide-binding properties 
and broaden the repertoire of peptides that can be presented by different species 
(Adams and Parham 2001; Falk et al 1991). This behaviour of T cells is called 
MHC restriction. The MHC class II molecules are encoded in HLA-D region, 
which has three main subregions: HLA-DR, DQ and DP, each of which contains 
one a  and one |3 gene. An association between HLA a  chain and p chain forms 
heterodimers, with peptide binding grooves on the cell surface of antigen 
presenting cells such as B cells and macrophages. The cell surface glycoproteins of 
class II serve as receptors that present exogenously derived peptides to CD4^ 
helper T cells. The class III genes encode a variety of immune and non-immune 
system molecules; most of them not involved in antigen presentation and include 
cytokines and components of the complement system.
1.3.1.1 Major Histocompatibility Complex class I
The major histocompatibility (MHC) class I molecules are subdivided into two 
families, MHC class la or classical, and MHC class Ib or non-classical.
1.3.1.1.1 Classical MHC class I
The classical MHC I molecules are a family of extremely polymorphic cell surface 
glycoproteins expressed on the cell surface of all nucleated cells. These molecules
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play crucial role in warning the immune system against the virally infected and 
transformed cells by facilitating the immune recognition of the intracellular viral 
peptides and altered self-proteins (Hewitt and Dugan 2004). The MHC molecules 
were first demonstrated in mice and called H-2 (H-2K, D and L) antigens. In 
human MHC are also known as HLA (human-leucocyte-associated antigens) 
because they were first demonstrated on leucocytes. Human MHC class I locus 
contains smaller loci for the classical genes, named A, B and C. In bovine, 
serological analysis of lymphocyte cell provided the first evidence for highly 
polymorphic MHC genes in cattle and other ruminant species. The MHC of cattle 
was thus named the bovine leucocyte antigen (BoLA) system, which function in a 
similar mamrer to those of mice and humans (Amills et al 1998). The bovine MHC 
class I (BoLA)-A locus contains (B oLA )-A ll, A20, BoLA-HDl, -HD6 and 
BoLA-HD. MHC class I molecules are composed of a type 1 membrane anchored 
heavy chain (HC, 44 KDa) and a non-covalently associated soluble protein termed 
P2-microglobulin (P2M) (12 KDa). The heavy chain is composed of thiee 
extracellular' domains called ( a l ,  a 2  and a3) transmembrane and C terminal 
cytoplasmic domain. The a  I and a2  domains form the peptide-binding site where 
is a groove on the distal surface o f the MHC class I molecule and binds antigenic 
peptides of 8-10 amino acids in length (Falk and Rotzschke 2002; York et al 
2002). The maturation of MHC class I proteins within the endoplasmic reticulum 
(ER) is regulated by chaperones calnexin and calreticulin (Sadasivan et al 1996). 
Following cotranslational translocation of MHC class I heavy chain and p2- 
microglobulin into ER via the Sec61 complex, both HC and P2M mature, where 
HCs dissociate from calnexin and associate with P2-microglobuIin. After 
proteasomal degradation of unwanted proteins or defective ribosome products,
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resulting peptides are translocated into the endoplasmic reticulum by the 
transporter associated with antigen processing (TAP) (Hengel et al 1997; 
Koopmann et al 1997). The loading of peptides into MHC class I molecules is 
regulated by a multi-protein complex in the ER termed the loading complex, which 
includes TAP, and is a prerequisite for its efficient transport to the cell surface. 
Misfolded MHC class I molecules or those that are not loaded with peptides and 
are therefore retained in the ER are retrotranslocated to the cytosol for degredation 
(Hughes et al 1997; York et al 1994). Following peptide binding, MHC-peptide 
complex are released from ER and shuttled via the Golgi and vesicular transport to 
the cell surface where they are scanned by CTLs.
1.3.1.1.2 Non-classical MHC class I
These molecules show homology to classical class I molecules but generally have 
limited polymorphism, low cell surface expression, and more restricted tissue 
distribution (Shawar et al 1994). In human, non-classical MHC class I (MHC class 
Ib) includes HLA-E, HLA-F, and HLA-G molecules. The function of the non- 
classical MHC class I molecules remains unclear, but some of them may have more 
specialized antigen presentation activities. HLA-G has been shown to play a role in 
immune tolerance during pregnancy, in tumour escape from immunosurveillance, 
and probably in transplantation (Rabreau et al 2000; Rouas-Freiss et al 2000). 
HLA-E is another non-classical class I molecule and, like classical MHC class I 
loci, the HLA-E gene is transcribed in many tissues, but little is known about its 
localisation within the cell. Recent studies have shown that HLA-E is a major 
ligand for the CD94-NKG2 receptors expressed by natural killer (NK) cells, and is 
thought to be involved mainly in innate immunity (Borrego et al 1998). The
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structure of HLA-E is similar to that o f the MHC class la molecules, but the 
groove that is formed between a l  and a2  domains is occupied by the leader 
peptide derived from amino-acid residues 3-11 o f the polymorphic classical HLA- 
A, HLA-B and HLA-C. The delivery o f class I MHC leader peptides to HLA-E is 
dependent on the presence o f the TAP transporter, where they can interact with 
HLA-E (Brand et al 1998b). This peptide binding is highly specific and stabilizes 
the HLA-E protein, allowing it to migrate to the cell sui'face.
1.3.2 Natural killer Cells
Natural killer cells are important contributors to innate immune defences against 
viral infections. They were first identified by their ability to spontaneously mediate 
lysis of certain tumour cells and by their large granular lymphocyte morphology 
(Trinchieri 1989). NK cells express receptor that respond to stimulation by MHC 
class I on surface of target cells. In human NK cells, there are two types of 
receptors: the killing inhibitory receptors (KIRs) and the lectin-like heterodimer 
CD94/NKG2 receptors. The KIRs recognize and bind to self-MHC class I 
molecules, and alter the balance between the activating and inhibitory signals that 
regulate NK cell function, thus preventing NK cells from being activated by 
healthy target cells. In virus infected cells, dowmegulation of MHC class I lead to 
activation of NK cells via stimulating activating receptor by tyrosine kinase, and 
overriding negative signals (Karre et al 1986). The CD94/NKG2 receptors 
recognize MHC leader sequence peptide presented by the non classical MHC class 
I molecules such as HLA-E (Brand et al 1998a). These molecules are able to 
deliver negative signals to NK cells through immunoreceptor tyrosine-based 
inhibitory motifs (ITIM) in their cytoplasmic domain, which acts to recruit tyrosine
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phosphatases, thereby cutting positive signal pathways (Eissmann et al 2005; 
Lanier 1998; Watzl 2003). The activating receptors provide a mechanism by which 
NK ceil function is stimulated. Thus, NK cells would kill classical MHC I negative 
virus-infected cells, unless non-classical MHC-E molecules are present.
1.3.3 Papillomavirus and immune response
Coexistance of a virus and its immunocompetent host requires a balance between 
the rates of viral replication and viral clearance by the immune system for mutual 
survival. The host’s immune system employs a variety of strategies to eliminate the 
virus, whereas the virus has developed an array o f immune evasion mechanisms to 
escape its elimination by the host’s immune system. Papillomaviruses, like other 
small oncogenic DNA viruses, are intracellular pathogens and their genome 
replication is dependent on the cellular replication machinery. They have evolved 
mechanisms to avoid immune recognition in order to establish their infection. The 
mechanisms for viral immune evasion can broadly be divided into tluee catogories: 
avoid immune recognition by the humoral immune response, interfere with the 
functioning of the cellular immune response, and interfere with immune effector 
functions. Failure of inducing anti-viral immune response during papillomavirus 
infection is suggested to be due in part to the nature of the virus life cycle. The 
early genes products (E l, E2) for viral replication and the viral transforming 
proteins (E5, E6, and E7) are expressed at low levels that may not be detectable by 
the immune surveillance, although these transforming proteins ai'e inununogenic 
when administrated as vaccine preparations and induce rejection of transplantable 
tumour cells in mice (Tindle 1996). Vegetative viral replication and expression o f 
high levels of viral proteins and viral assembly take place in the upper layers of
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epithelium. There is no cytolysis or cytopathic death as consequence o f viral 
replication and viral particle release, because the keratinocyte is a cell destined for 
death far from the sites of the immune response and not accompanied by 
inflammation, so that there is no obvious signal to alert the immune system. 
Hov^ever, even in the absence o f viral-induced cytolysis and cell death, PV- 
infected cells should activate a powerful antiviral defence system, type 1 interferon 
(IFN-a and and IFN-p) secretion that has antiviral, antiproliferative, 
immunostimulatory properties, acts as a bridge between innate and adaptive 
immunity (Le Bon and Tough 2002). IFN -a and IFN-p are secreted by infected 
cells as cellular responses to virus infection, they destroy viral mRNA, thus 
inhibiting viral protein expression, increase the expression of MFIC class I in most 
uninfected cells to enhance their resistance to NK attack and they activate NK cells 
to kill virus infected cells that lack the expression of MHC class I. Most DNA 
viruses including papillomaviruses have evolved mechanisms for inhibiting IFN 
synthesis and signalling. It has been shown that high-risk HPV down regulates 
IFN-a-inducible gene expression and HPV-16 E6 and E7 oneoproteins directly 
interact with components of IFN signalling pathways (Barnard and McMillan 
1999; Ronco et al 1998), and abrogate these pathways. Furthermore, these 
oncoproteins inhibit dendritic cells activation as consequence o f interference with 
IFN and also E6 and E7 inhibit M IP-3a transcription, resulting in suppression of 
the migration of immature Langerhans precui'sor-like cells (Guess and McCance 
2005), the only antigen presenting eells that can activate immature T lymphcytes. 
Viruses also evolved several distinct strategies to avoid killing of infected cells by 
the host, including the production o f caspase inhibitors (Irmler et al 1997). In 
papillomvirus infection, HPV-16 E6 proteins inhibit apoptosis by inducing
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degradation of p53. Apoptosis is a normal event in the maturation of B and T cells, 
as well as in their effector function o f killing infected cells. Engagement of Fas (a 
member of the tumour necrosis factor receptor family) on immature dandritic cells 
(DCs) by Fas ligand (FasL) induces maturation o f primary DCs. Fas-activated DCs 
upregulate the expression of the major histocompatibility complex class II, and 
secrete proinflammatory cytokines (Rescigno et al 2000). Mature DC cells cause 
activation of naive T cells through antigen presentation, which in turn produce 
IFNy. It has been shown that in vitro, both IFN -a and IFNy are able to increase 
the expression of a number of apoptosis-related proteins including Fas thereby 
rendering cells susceptible to Fas-mediated apoptosis (Kamei et al 2003; Ossina et 
al 1997; Ruiz-Ruiz et al 2000).
The clearance of virus infection requires antigen-specific lymphocytes that can 
recognize the virally infected cells via ligation o f their receptors to MHC class I 
molecules. MHC class I present viral peptides on the surface of infected cells for 
recognition and elimination by CTL. The virus has evolved mechanisms to 
interfere with antigen presentation by encoding oncogenic proteins. It been known 
that most cancers including cervical cancers induced by HPV, aie characterized by 
losing the expression of cell surface MHC class I (Bontkes et al 1998; Brady et al 
2000). Losing MHC expression may be a tumour phenotype rather than a direct 
result o f a disruption by viral proteins. However, reduction of MHC class I 
expression is also observed in benign papillomas (Araibi et al 2004; Bonagura et al 
1994; Vambutas et al 2000). Many investigations have been made recently to 
determine the mechanism of interference with MHC class I pathways by which 
papillomavirus avoids immune recognition in PV-associated disease. It has been 
shown that E7 proteins of high risk H PV-16 and 18 are able to repress the MHC
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class I heavy chain promoter (Georgopoulos et al 2000). Moreover, HPV-18 E7 
proteins induce disruption of MHC class I pathway through repressing the 
TAP1/LMP2 promoter that regulates the expression of genes that encode the TAP- 
1 and LMP-2 proteins, which are involved in transport of the peptide/ MHC class I 
complex to the cell surface (Williams et al 1996).
1.3.4 Viral infection and MHCI
Major histocompatibility complex (MHC) class I molecules present antigenic 
peptides to CD8-expressing cytotoxic T lymphocytes (CTLs). This antigen 
recognition system is critically important for immune surveillance against viruses 
and tumors. A more radieal approaeh is utilized by HCMV to interfere with MHC 
class I expression on the cell surface, such as withdrawal of peptides or 
intracellular retention of MHC complex. In HCMV-infected cells expressing US2 
or U S l l ,  the MHC class I molecules are transported from the ER back into the 
cytosol, where they are degraded by proteasomes following their deglycosylation 
(Wiertz et al 1996). Moreover, HCMV US3 protein impairs maturation and 
intracellular transport of MHC class I heavy chain by the formation o f a complex 
with pzM-associated class I heavy chain prior to peptide loading in the HR (Jones 
et al 1996). The murine CMV (MCMV) m4 (a CTL-evasion gene), encodes a 
glycoprotein (gp34), which is expressed at the cell surface in a complex with MHC 
class I molecules, thus inhibiting CTLs recognition of infected cells, without 
blocking MHC class I surface expression (Kavanagh et al 2001). The adenoviral 
E3-19K gene product is synthesised on membrane-bound ribosomes in the host cell 
and subsequently translocated in ER and glycosylated. In ER, the viral protein 
binds to MHC class I heavy chains, inhibiting terminal glycosylation of MHC class
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I complex, thereby preventing its translocation to the cell surface (Andersson et al 
1985). It has been demonstrated that the human immunodeficiency virus (HIV) 
N ef protein down-regulates classical MHC I (Williams et al 2002) but does not 
down-regulate non-classical HLA-E (Cohen et al 1999), which is mostly involved 
in positive selection of inhibitory receptors on NK eells.
1.3.5 PV E5 protein and MHCI
PVs E5 proteins may contribute to virus persistence and disease pathogenesis by 
dowmegulating MHC class I expression. Lack of surface MHC I would have 
profound consequences for presentation of viral peptides to the immune system. 
BPV E5 protein, a major transforming protein, causes a down-regulation o f surface 
MHC class I molecules in transformed cells by redueing transcription of the MHC 
class I heavy chain gene and inducing heavy chain degradation (Ashrafi et al 
2002). It also retains MHC class I in the Golgi apparatus and prevents its 
translocation, resulting in expression of a lower level of the MHC class I molecules 
on the cell surface (Marchetti et al 2002). It has been shown that HPV-16 E5 
protein causes downregulation of MHC class in transformed human kératinocytes 
by retaining MHC class I in the Golgi and INF treatment increases transcription of 
the MHC class I heavy chain gene and releases the Golgi-trapped MHC elass I to 
cells surface (Ashrafi et al 2005).
1.4 Aims of study
Papillomavirus-induced lesions (papillomas) persist for several months to one year 
before clearance by cell mediated immune response. Persistance o f lesions has 
been suggested to be due to the fact that the host immune system is unaware of
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viral infection. It has been reported that E5 proteins of BPV-4 and HPV-16 cause 
down- regulation o f MHC class I, preventing viral peptide presentation on the cell 
surface for CTL scanning.
Down-regulation or lack of MHC class I expression on the cell surface in virally 
infected cells, stimulates the activating receptors of NK cells. Thus, NK cells 
would kill classical MHC I negative virus-infected eells, unless these receptors are 
engaged with non-classical MHC class I molecules, which initiate inhibitory 
signals and block NK cells activity.
The overall aim of this project is the analysis o f the interaction between E5 and 
MHC class I.
The individual objectives are:
- To investigate if  BPV-4 E5 can down-regulate MHC class I in natural infections 
(papillomas) as well as it does in vitro.
-To determine the mechanism whereby BPV-4 E5 causes a reduction of MHC 
class I heavy chain protein.
-To determine whether BPV E5 does down-regulate non-classical MHC I on the 
eell surface.
- To determine whether likewise HPV-16 E5 down-regulates classical but not non- 
classical MHC class I.
- To determine whether HPV-16 E5 reduces surface expression of MHC class I in 
CIN biopsies.
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2 Materials and Methods
2.1 Materials
2.1.1 Histopathology materials
Paraffin embedded blocks of upper GIT papillomas 
Paraffin embedded bloeks of CIN 
Paraffin embedded blocks of raft culture
2.1.2 Antibodies
-Supplied from Dakocytomation
Swine Anti-rabbit IgG 
Rabbit Anti-mouse IgG 
Anti- Ki67 Antigen elone Mb-1 
-Supplied from Sigma
Anti-FLAG M2 mAb
mAb 4A3 raised against the Golgi protein GM130
Anti mouse IgG FITC conjugated antibody
Horse Radish Proxidase
-Supplier from Serotec
mAh W6/32 raised against HLA/A,B and C
mAh DT9 anti human HLA-C/E (for FACS & IF) (A kind gift from Dr. Véronique
Brand, Centre National de la Recherrche Scientifique, Sophia Antipolis, France)
-Supplier from abeam®
mAh MEM-E/02 raised against HLA-E
-Cancer Research UK
mAh HCIO against HLA-A2 heavy chain
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mAh IL-A88 against bovine MHC elass I heavy chain (from Dr Shirley Ellis, 
Institute of Animal Health, Compton.)
Polyclonal rabbit IgG (274, 275) against C-terminal domain of BPV-4 E5 
(available in laboratory)
Polyclonal rabbit IgG (11547, 11823) against a P-galactosidase-BPV-4 E7 fusion 
protein (available in the laboratory)
Polyclonal rabbit IgG against C-terminus and N-terminus domains of HPV-16 E5 
(from Prof Dan DiMaio, Department of Genetics, Yale University School of 
Medicine, New Haven, USA)
-Scottish Antibody Production Unit, UK 
Normal rabbit serum 
Normal swine serum
- CalbioChem- Novabiochem corporation San Diego, USA
Anti-aetin (Ab-1), mouse monoclonal IgM antibody (clone JLA20).
2-1-3) Antibiotics
-Sigma Chemical Co.Ltd (Dorest, U.K.)
Ampieillin 
-Invitrogen 
Geneticin (G-418)
CALBIOCHEM
Blasticidin
2.1.4. Bacteriology
-Institute of Comparative Medicine Central Services
L-broth
LB-agar
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-Becton Dickinson Labware (Oxford, U.K.)
Falcon 1059 polypropylene tubes 
Falcon 2059 polypropylene tubes 
-Bibby Sterilin Ltd (Staffordshire, U.K.)
90mm bacteriological petri dish
-Lisons Scientific Equipment (Leicestershire, U.K.)
Glycerol
-Invitrogen Ltd (Paisley, U.K.)
E. coli D H5-a eompetent cells with SOC medium 
-Nunc (Hereford, U.K.)
Sterile disposable inoculating loops
2.1.5 Cell line
Mouse mastocytoma P815 cells 
Bovine primary fibroblast PalF cells
2.1.6 Cell Culture materials
-Institute of Comparative Medicine Central Services
Sterile phosphate buffered saline (PBS)
-Becton Dickinson Labware (Oxford, U.K.)
90 mm tissue culture dishes 
Falcon 2097 polypropylene tubes 
Falcon 2098 polypropylene tubes 
Serological plastic pipettes 
Sterile Plastipak syringes
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6 well plates
24 well plates
96 well plates
Cover glass 22x22mm
Cover glass 13mm
Sterile plastipak syringes
Sterile syringe needles
-Bibby Sterilin Ltd (Staffordshire, U.K.)
Sterile plastic bijoux
Sterile plastic universal containers
-Invitrogen Ltd (Paisley, U.K.)
Dulbecco’s Modified Eagle Medium (DMEM), high glucose,
without calcium chloride
RPMI 1640 + L-Glutamine medium
2.5% Trypsin-EDTA (IX )
Foetal Calf Serum (FCS)
L-Glutamine (10 OX)
Sodium pyruvate MEM lOOMM 
MEM (lOOX) Non-essential amino acid 
MEM amino acid (5 OX)
-Nunc (Hereford, U.K.)
Cryotubes
T25, T75 and T175 cm^ tissue culture flasks
-Gelman Science, Northampton, England
Sterile 0.2 pm acrodisc filters
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-GREINER
Gel loading tips
2.1.7 Chemicals and Reagents 
-National Diagnostics, USA
Histo-elear
-Cambridge Bioscience
Bodipy® TR Ceramide 
-Novagen
Gene Juice® Transfection Reagent
-Amersham International pic (Buckinghamshire, U.K.)
Enhanced Chemiluminescence (ECL-plus) Western detection agent 
-Invitrogen Ltd (Paisley, U.K.)
Agarose (ultrapure electrophoresis grade)
Phosphate buffered saline (PBS)
20 X MES SDS running buffer
20 X MOPS SDS running buffer
20 X MOPS SDS transfer buffer
NUPAGE® Antioxidant
NUPAGE® Sample Reducing Agent (lOX)
NUPAGE® EDS Sample Buffer (4X)
Tricine Glycin SDS Sample Buffer 
Tricine SDS Runing Buffer (lOX)
Nu PAGE™ 4-12% Bis-Tris gel
Nu PAGE™ 16% Tricine gel
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-Institute of Comparative Medicine
IX  TBE buffer
10 X loading buffer (65% Sucrose, lOmM Tris-HCl, lOmM EDTA, 0.3% BPB, 
Bromophenol Blue up to 10ml dH20)
- Gibco 
HEPES
-Sigma Chemical Co. Ltd (Dorset, U.K.)
Poly-L-Lysin hydrobromide
3,3- Diaminobenzidine (DAB) peroxidase substrate
(3 -mercaptoethanol
Bicinehonoinic Acid (BCA) solution
Bovine Serum Albumen (BSA)
Copper (II) sulphate (pentahydrate 4% (w/v) solution)
Ethidium bromide 
Nonidet P-40 (NP-40)
Phenol:Chloroform:Isoamyl Aleohol (25:24:1 (v/v)
Ponceau S solution
Tween-20 (Polyoxyethylene sorbitan nonolaurate)
Xylene Cyanol
-University of Glasgow (Glasgow, U.K.)
Crude Ethanol 
Glycerol
-VWR International (Dorset, U.K.)
DPX Mountant 
Hydrogen peroxide H 202
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Acetic acid
Di-sodium hydrogen orthophosphate (anhydrous) 
Dimethyl sulfoxide (DMSO)
100% pure ethanol
Ethylene diamine tetraacetate (EDTA) disodium salt
Hydrochloric acid
Magnesium chloride
Methanol
Propan-2-ol
Sodium acetate
Sodium chloride
Sodium dodecyl sulphate (SDS)
Tri-Sodium Citrate 
Tris base
2.1.8 Enzymes and Kits 
-Dakocytomation
Dakocytomation envision kit 
Strept AB Complex/ HRP 
- (AMAXA GMBH)
Mouse T cell Nucleofector kit 
-Applied Biosystems (Warrington, U.K.) 
Amplitaq® DNA polymerase with Geneamp® buffer 
Bigdye v3.1 DNA sequencing kit 
Hi-Di formamide
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TaqMan® EZ RT-PCR® kit 
-Invitrogen Ltd (Paisley, U.K.)
The restriction enzymes Hind III, Xba-I, and their respective reaction buffers. 
Alkaline phosphatase 
T4 DNA ligase 
5X ligase buffer
-Qiagen Ltd (Crawley, U.K.)
QIAquiek PCR purifieation kit 
QIAprep plasmid maxiprep kit 
QIAprep Spin plasmid miniprep kit 
QIAquiek Gel extraction kit 
RNease mini kit 
-Centra Systems, USA 
Generation Capture column kits
2.1.9 Molecular Weight Markers 
-Invitrogen Ltd (Paisley, U.K.)
Ikb ladder 
lOObp ladder
See-Blue 2 protein markers
2.1.10 Plasmids
pcDNA empty vector carrying the universal immediate early (IE) promoter of 
cytomegalovirus (CMV) (Invitrogen, Glasgow, UK).
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PcI-16E5 expresses the wild type HPV16-E5 protein under the control of the CMV 
IE promoter.
pC“4E5 expresses BPV-4 E5 protein under the control of immediate early (IE) 
promoter of cytomegalovirus (CMV) (Invitrogen, Glasgow, UK).
PEGFP-Cl is a eukaryotic expression plasmid for the Green Flourescent Protein 
(GFP). Expression is driven by the CMV promoter (BD Biosciences Clontech). 
pBS/A2 is a plasmid (pBlueScriptll SK(-t-)) carrying HLA-A2 in EcoRV/Spel a 
gift from Barbara Marchetti, Institute of Comparative Medicine, Glasgow 
(pAL356HLA-A2 gift from Dr Steve Mann from Cardiff, was cut A2 and put in 
pBlueScriptll SK(+).
pcDNA6/V5-His/V*J0007 expression vector tagged with V5 epitope and carrying 
bovine non-classical {N"^50001) gene in Hindlll/Xbal, under the control of 
immediate early (IE) promoter of cytomegalovirus (CMV), (from Dr Shirley Ellis, 
Institute of Animal Health, Compton).
pcDNA6/V5 His/ HLA-A2 a plasmid carrying HLA-A2 cloned in Hindlll/Xbal, 
was excised from pBlueScriptll SK(+) in Hindlll/Xbal sites. 
pcDNA6/V5/HLA-E a plasmid canying HLA-E cloned in Hindlll/Xbal, excised 
from pBlueScriptll SK(+) in KnpI/BamHI sites.
pZipneo empty expression vector o f Molony murine leukaemia virus (MoMuLV) 
pZip-4E5 expresses BPV-4 E5 protein under the control o f MoMuLV long 
terminal repeat LTR promoter, (available in laboratory).
pFLAG CMV-1 the amino-terminal FLAG fusion expression vector (Sigma), 
allows transient or stable transfection with neomycin (G418) selection marker.
74
Chapter 2: Materials and Methods
pFLAG C M V 0001 expresses bovine non-classical MHC class I, cloned in 
Hindlll/Xbal sites and under transcriptional control of promoter regulatory region 
of HCMV.
2.1.11. Miscellaneous
-Amersham International pie (Buckinghamshire, U.K.)
Flyperfilm ECL
-Whatman International Ltd., Maidston, Kent, England
Whatman 1 filter paper
-Applied Biosystems Ltd (Warrington, U.K.)
Real-time PCR 96 well plates and their caps.
-Elkay International (Basingstoke, U.K.)
Microcentrifuge tubes
-Sigma Chemical Co. Ltd (Dorset, U.K.)
Formaldehyde
-Whatman International Ltd (Maidstone, U.K.)
Whatman 3 MM filter paper 
-Dakocytomation
Pap pen
-VWR International Ltd
Lab-Tek II chamber slide 
-Invitrogen life technologies
Lipofectamin Reagent 
Plus Reagent
NuPAGE 4x EDS sample buffer 
NuPAGE 1 Ox sample reducing agent
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NuPAGE Antioxidant
-Roche Diagnostics, Mannheim, Germani
Protease inhibitor cocktail tablets 
-vector lab, USA
VECTABOND
-Camlab, Cambridge, England
1.5 ml Screw Top Microtubes 
-Morison store
Marvel (Dried skimmed milk)
2.1.12. Water
Distilled water (dH20) for the preparation o f buffer stocks was obtained from a 
Millipore MilliRo 15 system, and when used for protein, enzyme, RNA or 
recombinant DNA procedures was further purified on a Millipore MilliQ system to 
18MQ/cm.
Sterile distilled water for making up tissue culture media was supplied by the 
Institute of Comparative Medicine Technical Service.
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2.2Methods 
2.2.1 Samples collection
Bovine papillomas hom  the palate, rumen and oesophagus, as well as samples 
from palate, tongue and buccal mucosa were collected post-mortem from animals 
that were refened to the University of Glasgow Veterinary School. Tissue samples 
were immersed in freshly prepared 10% formaldehyde in phosphate buffer at pH
7.5 in order to preserve tissues from decomposition. After overnight fixation, 
samples were histologically examined, trimmed for proper size and made ready for 
processing,
2.2.2 Processing
Fixed tissue samples were placed on small hollow metal cassettes to allow liquids 
passage and then covered with a lid prior to processing. Tissues were processed 
automatically in a tissue processor, which moves the tissues around the various 
agents on a preset time scale. The first process was performed with a series of 
alcohols (30 % ETOH in ddH 20 1-2 hours, 50% ETOH in ddH20 1-2 hours, 70 % 
ETOH in ddH 20 1-2 hours, 95% ETOH 3 hours, 100 %ETOH Ihour) in order to 
remove water gradually from tissue. The second process was performed with three 
sets of xylene (30 minutes, 1 hour, 30 minutes) to clear the alcohol. Tissues were 
transferred from cassettes, orientated on the mould and tissues were embedded 
with three sets of paraffin in order to protect tissue from collapse after water
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removal. The tissues were waxed by pouring molten paraffin on them and then the 
blocks placed on cold plate at 4°C prior to sectioning.
2.2.3 Raft cultures
Organtypic epithelial raft cultures are tissue culture systems that allow keratinocyte 
monolayers to stratify and achieve full differentiation via culturing o f the cells on 
collagen gels at the air-liquid interface. The immortalized human keratinocyte 
HaCaT cells were stably transfected with 4pg pcDNA, pL2, pcl6-E5 or pL2 16-E5 
per 1x10^ cells using Lipofictamine Plus (Invitrogen) according to manufacturer's 
instructions. The transfected cells were selected in DMEM medium containing 
500pg/ml 0418 (Invitrogen) for 21 days (Ashiafi et a l ,  2005). The culture method 
used for stratification and differentiation of kératinocytes was performed by Dr 
Sheila Graham, IBLS, Glasgow. The collagen matrix solution was made on ice 
with concentrated Ham’s F I2 medium, reconstitution buffer and 3T3 J2 
fibroblasts. One millilitre of the collagen matrix solution was poured into 24-well 
microtiter plates and then equilibrated with 1 ml of growth medium and incubated 
overnight at 3TC. The E5-transfected HaCaT cells were seeded on the top of the 
gels and maintained submerged for 24-48 h. The collagen rafts were raised and 
placed onto stainless steel grids at the interface between air and culture medium. 
The growth medium was a mixture o f F 12, Dulbecco’s medium supplemented with 
0.5 pg/ml hydrocortisone, lOng/ml EGF, 10% FCS, ImM/L sodium pyruvate, 
2mM/L L-glutamine, lOmM/L HEPES, 5 pg/ml insulin, and 5 pg/ml transferrin. 
HaCaT cells were allowed to stratify for 14 days, the medium being replaced every 
other day. The cultmes were then harvested, fixed in 10% formalin buffer, and 
embedded in paraffin.
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2.2.4 Preparation of slides
Glass slides were cleaned with acetone and immersed in VECTABOND solution 
(vector lab, USA) for five minutes. The solution was prepared by mixing 7 ml of 
the stock into 350ml acetone. The slides were then washed in distilled water, air- 
dried at room temperature.
2.2.5 Sectioning
Wax embedded tissue blocks of papillomas and CIN biopes (kind gift from Dr 
David Millan, NHS, Glasgow), and Raft cultme blocks, were cut on microtome 
(Shandon Finesse, UK) in serial sections at thickness 1.5pM, then floated on warm 
water at 40°C to soften and flatten tissue sections. These sections were transferred 
onto coated slides (Vector lab, USA) to increase adhesion of the sections, which 
were later subject to heat-mediated antigen retrieval pre-treatment. The sections 
were allowed to dry overnight at 60°C and stored at room temperature until use.
2.2.6 Iramunohistochemistry principles
Immunohistochemistry is a technique which allows detection of antigens in tissue 
sections by the use of labelled antibodies as specific reagents through antigen- 
antibody interactions. The resulting antigen-antibody complex can be detected by 
either direct labelling of the antibody or indirectly by use of a biotinyiated 
secondary antibody. The method undertaken for this evaluation was an indirect 
labelling technique that utilises a streptavidin-biotin complex to amplify the signal. 
This complex consists of the unlabelled primary antibody bound to the antigen, 
which is subsequently bound by the biotinyiated secondary antibody. A third layer 
is used which involves applying a complex of streptavidin and horseradish
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peroxidase (HRP). The avidin and biotinyiated HRP are mixed at appropriate 
concentrations allowing a complex to form. The pre-formed complex is then 
attached to the biotinyiated secondary antibody. The culmination of the procedure 
is the attacliment of a marker in order to visualise the complex. The marker used in 
this study was 3,3 diaminobenzidine tetrahydrochloride which produces a brown 
end product which is highly insoluble in alcohol and other organic solvents. 
Potential non-specific antigens were blocked by application o f the appropriate 
unlabelled normal serum,
2.2.7 Preabsorption of BPV-4 E5 antiserum
Preabsorption of the antisera with the respective antigens by using the 
complementary peptide results in abolition o f the staining. This was used to verify 
the specificity of the immunostaining of BPV-4E5. Typically, 30pl (Img/ml) of a 
synthetic E5 peptide representing the C-tenninal fragment of BPV-4E5, against 
which the antiserum was raised, was mixed with lOpl of E5 antiserum in sterile 
eppendorf tube in lOOpl total volume of PBS. The mixture was incubated for 1 
hour at 4°C while being continuously stirred. A mixture of E5 antiserum with a LI 
peptide instead o f the E5 peptide was incubated under the same conditions. The 
samples were centrifuged at 14,000 rpm for 10 min at 4°C and the supernatant was 
transferred to new sterile tube.
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2.2.8 Antibody optimisation
In immunohistochemistry, the optimum antibody titre may be defined as the 
highest dilution of an antibody that results in the maximum amount o f specific 
staining with the least amount of non-specific background staining.
The optimum condition for each of the antibodies was determined by incubation of 
the antibody with the appropriate control tissues containing specific target 
antigens. Twelve serial sections from each o f the control tissues were cut in order 
to optimise the dilution and staining procedure. Two sets of six serial sections were 
stained with the designated antibody. A range of dilutions from 1/50, 1/100, 1/500, 
1/1000 and 1/5000 was performed. One of sections received no antigenic 
unmasking pre-treatment; another set underwent a heat-mediated antigen retrieval 
procedure in a pressure cooker. Each set of sections include a section that was 
treated exactly as the other sections except that it was incubated with normal serum 
instead of the primary antibody. This was used as a negative control. The staining 
was carried out as per immunohistochemistry protocol.
After completion o f staining, sections were analysed by light microscopy. 
Evaluation consisted of looking for the sections that stained the strongest, along 
with having the lowest level of background interference. The antibody dilution that 
showed this was considered optimal and was the dilution at which the material 
being investigated was stained.
2.2.9 Immunohistochemical staining
Sections were deparaffinised in histo-clear (National Diagnostics,USA) for five 
minutes and rehydrated through absolute alcohol , 80% , 70% for Imin each and 
then passed in rumiing water. Sections were placed in 0.5% H 202 in methanol
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solution for twenty minutes to block endogenous peroxidase, followed by rinsing 
in distilled water for five minutes. Antigen retrieval (AR) is an unmasking 
technique carried out on sections to remove formalin cross-linking with antigenic 
epitopes. AR was used with the paraffin sections prior to MHC class I and Ki67 
staining for seventy five seconds of pressure cooking at fifteen pounds per square 
inch (PSI), 0.0IM  Sodium citrate buffer was pre-heated to boiling prior to 
immersion of sections. The pressure cooker (Prestige,UK) heating was timed from 
the moment it reached the required operating pressui’e indicated by a valve at 15 
PSL Sections were rinsed inTween 20 (BDH, UK) 0.0IM TBS pH 7.5, slides were 
wiped and sections circled with Dako pen. Sections were incubated with 
appropriate 0.1% normal unlabelled serum (Scottish Antibody production unit, 
UK) diluted in 0.0IM  TBS for thirty minutes in a humidified chamber. Normal 
serum was applied to block any non-specific binding by secondary antibody. The 
excess serum was then removed and the appropriate primary antibody was applied 
at the optimum dilution. For human and bovine MHC class I staining, sections 
were incubated for 1.5 h at room temperature with dilution 1:2000 of mAb HCIO 
and 1:100 of mAb IL-A88 respectively. For HLA-E staining, sections were 
incubated for 1.5 h at room temperature with dilution 1:100 of mAh MEM-E/02. 
For BPV-4 E5 staining, sections were incubated with two different E5 antisera 
raised in rabbit against E5 C-terminus domain; anti E5 (274) at dilution 1:2000 and 
anti E5 (275) at dilutionl:5000. The specificity of E5 staining was verified by 
incubation of sections with pre-absorbed E5 antisera at 1:10. For HPV-16 E5 
staining, sections were incubated with ratio 1:1 o f antisera raised in rabbit against 
HPV-16 E5 C-terminus and E5 N-terminus domains at dilution 1:500 For Ki67 
staining, sections were incubated with mAb MIB (Dako) at 1:200. For detection of
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BPV-4 E7, papilloma sections were stained with dilution 1:250 of rabbit antisera 
11547 and 11823, which were raised against a p-galactosidase-BPV-4 E7 fusion 
protein. In all experiments, antibodies were diluted in sodium Azide buffer (0.1 g of 
Bovine Serum Albumin (BDH, UK), 0.01 g o f Sodium Azide (BDH, UK) in 100 ml 
M TBS (PH7.5). Sections were immersed three times for 5 minutes each in 
washing buffer (Tween 20 0.0IM  TBS (pH 7.5) before incubation with secondary 
antibody. For sections stained for MHC I and Ki67 detection, biotinyiated rabbit 
anti-mouse secondary antibody (Dako, UK) was applied at a standardised dilution 
1/200 for 30 minutes at room temperature. Biotinyiated swine anti-rabbit (Dako, 
UK) was applied to sections that were incubated with primary Ab for BPV-4 E5, 
E7 and HPV-16 E5 detection. After washing as above, sections were incubated 
with HRP conjugated streptavidin-biotin complex (Dako, UK) for forty-five 
minutes, as per manufacturer’s instructions. Antibody-antigen interaction was 
visualised by covering sections with 3,3 DAB, used as chromogen with H 202 as 
substrate. This forms a stable insoluble complex, which can easily be seen under 
microscope. The DAB was reconstituted in five ml tap water as per manufacturers 
instructions, it was observed that final staining was stronger when DAB was 
reconstituted in tap water than in distilled water because of metal ions contained in 
tap water that enhance reaction. Incubation with DAB was timed up to five 
minutes, during that time, sections were microscopically checked to maximise the 
staining and minimise any background. The sections were then counterstained with 
Gills haematoxylin and any back ground staining was removed by placing sections 
inl%  acid alcohol for 10 seconds prior to rinsing in Scott’s tap water substitute 
(STWS) to stain the nuclei blue. The sections were dehydrated through three 
alcohol dilutions, 70%, 80%, absolute, then cleared in histo-clear, transferred into a
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fume hood where they were permanently mounted with DPX mountant (BDH) and 
coverslipped before examination under microscope.
2.2.10 Imaging
Images were captured and analysed using computerized images analyser (Zeiss 
KS300) through a video camera connected to a light microscope. This system 
operates on the principle o f converting light images from the microscope into a 
digitalized value of optical density for a given unit of area in the observation field. 
The entire mounted section was first examined by a light microscope using a xlO 
objective to allow observation o f whole sections. Selected patches were enlarged at 
high power magnification. Images were digitized using a digital video camera 
(JVC KY-55B, Imaging Associates, Thame, UK) with a resolution of 150 x 150 of 
captured area before being converted into micrometers. Images analysis was 
performed using images analysis software (Zeiss KS300 Release 3.0, Imaging 
Associates, Thame, UK).
2.2.11 Cell Culture
All cell culture work was performed using strict aseptic techniques inside a laminar 
flow hood (class II Microbiological Safety Cabinets, Gelaire BSB4). Cells were 
grown in T175 cm^ culture flasks with loosened caps to allow for sufficient gas 
exchange, incubated at 37°C in a dry atmosphere containing 5% (v/v) CO2 (Nopco 
Scientific).
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2.2.12 Maintenance of cells in culture
The cultured cells were examined daily by observation of the morphology, the 
colour of the medium and the density o f the cells. In suspension culture, cells were 
grown in 1640 RPM medium supplemented with 10% FCS and fed by dilution into 
fresh medium. Confluent cells were centrifuged at 1000 rpm for 5 minutes at room 
temperature and the cell pellet was resuspended in fresh medium and divided into 
flasks according to the density. Adherent cells that did not need to be divided were 
fed by replacing the old medium with fresh D-MEM medium supplemented with 
ImM Sodium Pyruvate, 2mM L-Glutamine and 10% FCS. In the confluent 
adherent cultures, the medium was aspirated and the cells washed once with 10 ml 
phosphate-buffered saline (PBS). The PBS was removed and cells were treated 
with 3 ml of pre-warmed trypsin solution (0.25% trypsin in Ix PE buffer; PBS with 
the addition o f EDTA to 1 mM). Trypsin-treated cells were incubated at 37°C until 
the cells had detached from the flask. Complete medium was added and the cell 
suspension transferred to a sterile universal tube. The cells were centrifuged at 
lOOOrpm for 5 minutes at room temperature. The pellet was then resuspended in 
fresh growth medium and the cells reseeded in 2 flasks.
2.2.13 Preservation and Storage of the cells
To freeze cell stocks for storage, confluent suspension cultures were centrifuged 
and confluent adherent cultures were trypsinised and pelleted as described above. 
In both cases, pellets were resuspended in growth medium containing 10% (v/v) 
DMSO. DMSO is a cryoprotective agent which acts to lower the freezing point but 
causes toxicity to cells at room temperature and for this reason all solutions must 
be chilled. Suspensions were divided into 1 ml aliquots in 1-2 ml Nunc cryotubes
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and placed in a polystyrene box. The cells were slowly cooled by storage at ~70°C 
for 4 hours to overnight in order to allow the water to move out of cells before it 
freezes. The ampoules were then immediately placed in the liquid nitrogen storage 
bank containing labelled rack until required. Frozen stocks were recovered by 
removing the ampoules from liquid nitrogen and placing them into a small, 
covered bucket of water at 37°C. Cells were immediately diluted into 10ml of the 
appropriate pre-warmed growth medium, centrifuged, resuspended in fresh growth 
medium and transferred to 175 cm^ flasks.
2.2.14 Counting cells
The concentration of viable cells was determined using trypan blue dye which 
stains dead cells dark blue. In 1.5 ml tube, 50 pi of culture suspension was mixed 
well into 50 pi o f trypan blue (Gibco BRL, UK). A cover slip was fixed on a 
haemocytometer counting chamber and mixing sample was loaded until an area of 
1mm X 1mm x 0.1mm depth of chamber was filled. The number of cells in each of 
the large corner squares was counted under 10 x objective and a mean of these 
counts was taken. This mean multiplied by Ix 10"^  represented the number of cells 
per ml.
2.2.15 P815 cells
Mouse mastocytoma P815 cells expressing either bovine classical N*01301or non- 
classical N*50001 MHC class I were a kind gift from Dr Shirley Ellis (IAH), 
Either classical or non classical genes were firstly cloned in expression plasmids 
under the transcriptional control of the universal IE promoter of CMV in pcDNA6 
with Blasticidin gene resistance. P815 cells were transfected with bovine MHC
86
Chapter 2; Materials and Methods
class I genes and then selected in medium containing 10pg/ml Blasticidin for 21 
days.
2.2.16 BPV-4 ES expression vectors
The BPV-4 E5 open reading frame (ORE) from 332 to 458nt of the BPV-4 genome 
was cloned in two different expression plasmids, either under the transcriptional 
control of the universal IE promoter of CMV in pcDNA3 or expressed under the 
control of the Moloney murine leukemia virus in the vector plasmid pZip-neo.
2.2.17 Transfection of P815 cells with BPV-4 E5 gene using Gene Juice
Aliquots of Ix  lO*’ P815 cells expressing either bovine classical or non classical 
MHC class I were placed in 6-well plates contain 3 ml/ well of RPM -1640 medium 
supplemented with 10 % FCS and the cells were grown overnight at 3T C  in 5% 
C02. Transfection reagent was prepared with 100 pi RPM -1640 serum-free 
medium, 3 pi Gene Juice for each transfectant. The mixture was spun around on 
vortex and incubated at room temperature for 5 minutes. 1 pg of pcDNA, pZip neo, 
pc-4 E5 or pZip-4 E5 was added and the transfection reagent was mixed and 
incubated at room temperature for 15 minutes. In a sterile hood, the cells were 
transfected with Ipg  DNA and the transfection reagent was added as drops to 
distribute all over the surface of the plate and further distribution of transfection 
reagent over the cells was made by moving the plates around, forward and 
backward. Each transfection was performed in duplicate and a negative control for 
transfection was performed. The plates were incubated overnight at 37°C and then 
3 ml of fresh RPM -1640 medium supplemented with 10% FCS was added to each 
transfectant and re-incubated overnight at 37°C. Transfected and non transfected
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cells (control) were centrifuged at 1000 rpm and resuspended in RPM -1640 
medium containing 500pg/ml G418 (Invitrogen). The cells were kept under 
selection for tlnee weeks.
2.2.18 Transfection of P815 cells with BPV-4 E5 gene using Neoclufector
Mouse mastocytoma P815 cells expressing either bovine classical or non classical 
MHC class I were stably transfected with two different plasmids carrying BPY- 
4E5 using Nucleofector (Amaxa- Germany) according to manufacturer's 
instructions. Transfection reagent was first prepared by mixing (2.25ml Mouse T 
cell Nucleofector solution, 0.5 ml Mouse T cell solution supplement) and left at RT 
until use. After adding 1ml of component A to 100ml of Mouse T cell 
Nucleofector medium, each well of 12-well plates was supplied with 1ml of 
medium, then 10 pi of component B. The plate was pre-incubated at 37°C for 30 
minutes at least prior to adding transfectants. Aliquots of 1x10^ cells were 
centrifuged at 90X for 10 min, resuspended in 100 pi transfection reagent. After 
adding 4pg of plasmid DNA, cells were mixed well and transferred to a cuvette 
before applying to Nucleofector. After introducing DNA, cells were seeded in pre- 
incubated medium for 48h. Cells were selected in RPM -1640 medium containing 
G418 for three weeks. Cells transfected with 2.5pg puma-GFP/sample were used 
as a positive control and microscopically checked 24 hours after tarnsfection.
2.2.19 Transfection of P81S cells with HPV-16 E5 gene
Mouse mastocytoma P815 cells were stably transfected with either universal 
plasmid carrying empty vector (pcDNA) or carrying HPV-16E5 (pc-16 E5) using 
Nucleofector (Amaxa- Germany) according to manufacturer's instructions.
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Introduction of HPV-16E5 into P815 cells was performed as BPV-4 E5 
transfection protocol.
2.2.20 Cloning of HLA-E gene in pcDNA6 plasmid
The HLA-E gene was constructed in pcDNA6 plasmid by PCR-amplifying the 
cDNA of HLA-E from the pBLuescript II SK (+) plasmid using the following 
primers: forward primer was made to include some base pairs from pBL plasmid, 
Hind III site, Kpn I, and base pairs from HLA-E 
sequencers’GGGCGAATTGAAGCTTGGTACCGATTCG ‘3. The reverse primer 
was designed to contain some base pairs of pBL, Xbal, and BamH I; 5’ 
GGTGGCGGCCGCTCTAGAACTAGTGGATCCA-G. To amplify HLA-E, 5 ng 
of pBL/HLA-E was mixed with 100 ng o f each forward and reverse primers, with 
Ix  PGR kit buffer, MgC12, 2 units Taq DNA polymerase and dNTPs (32 pM of 
each dATP, dGTP, dCTP and dTTP) in a total volume of up to 50 pi dH 20 and 
then aliquoted into 0.5 ml GeneAmp PGR reaction microfuge tubes. The tubes 
were placed into the PGR machine (PTG-200 Peltier Thermol Gycle) to make PGR 
products. For PGR amplification, the sample was heated to 95°G for 3 minutes to 
inactivate DNase and ensure all DNA duplexes were melted, in addition to 
activating the Taq DNA polymerase. The DNA was then amplified for 28 times as 
follows: the sample was heated to denature double stranded DNA at 94°G for 30 
seconds, 57°G for 30 seconds for annealing and 72°G for 30 seconds to elongate 
DNA. After completion of the cycles, the reaction was incubated at 72°G for a 
further 7 minutes to ensure full extension and then cooled to 4°G. After PGR 
amplification, 5 pi of the sample was analysed by agarose gel electrophoresis by 
using appropriate marker to check the correct product was amplified. The PGR
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product was digested by using restriction enzymes and appropriate reaction buffer 
and then purified by using PGR purification kit. The pcDNA6 vector was digested 
with Hind III and Xba-I sites by using appropriate restriction enzymes and reaction 
buffer according to the manufacturer’s instructions. The digestion of the pcDNA6 
vector was monitored by using agarose gel electrophoresis and the cut DNA was 
purified by using gel extraction kit. The HLA-E fragment was ligated into the cut 
vector with different inserts:vectors ratio, 1:1, 3:1, 1:3 using 1 pi (4 Units) of T4 
DNA ligase in Ix ligase buffer in a 15 pi reaction volume The best ratio of 
inserts: vectors was 3:1 for ligation. 5 pi o f the ligated samples was transformed in 
E. coli DH5-a competent cells. 50 pi of transformation mixes were spread on LB- 
agar plates containing the appropriate antibiotic (100 pg/ml Ampicillin) and 
incubated at 37°G overnight. A single bacterial colony was used to inoculate 5 ml 
L-broth medium containing the appropriate antibiotic in Bijoux tubes and grown 
overnight at 37°G (to select 10 colonies in 10 Bijoux tubes). Plasmid DNA was 
prepared from the colony using the QIAprep Spin plasmid miniprep kit according 
to the manufacturer’s instructions. The plasmid DNA was sequenced and 
transfected into either P815-pcDNA or P815-pcl6E5 cells.
2.2.21 Cloning of HLA-A2 gene in pcDNA6 plasmid
HLA-A2 gene was excised from pBLuescript II SK (+) plasmid by digestion of 10 
pg of pBL vector in appropriate restriction enzymes and buffer in total volume 100 
pi of DW. The mixture was incubated at 37°G for 3 hours and then run on 1 % 
agarose gel. The digested HLA-A2 fragment was purified by using gel extraction 
kit. The pcDNA6 was digested with Hind III and Xba-I sites by using appropriate 
restriction enzymes and reaction buffer according to the manufacturer instructions.
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The digestion of the pcDNA6 vector was monitored by using agarose gel 
electrophoresis and the cut DNA was purified by using gel extraction kit. The 
HLA-A2 fragment was ligated into the cut vector with different inserts:vectors 
ratio, 1:1, 3:1, 1:3 using 1 pi (4 Units) o f T4 DNA ligase in Ix ligase buffer in a 15 
pi reaction as bove. After plasmid preparation and DNA sequence, pcDNA6/HLA- 
A2 plasmid was transfected into either P815-pcDNA or P815-pcl6E5 cells.
2.2.22 Cloning o f N *50001 in pFLAG
Bovine non-classical MHC class I heavy chain was excised from pcDNA6 by 
digestion o f 10 pg of pcDNA6/A*50007 with appropriate restriction enzymes and 
buffer in 100 pi reaction volume and incubated for 3hours at 37°C. After gel 
electrophoresis, the 50001 fragment was purified by using gel extraction kit. 
The pFLAG vector (Sigma) was digested with Hind III and Xba-I and reaction 
buffer according to the manufacturer instructions. The digestion o f the pcFLAG 
vector was monitored by using agarose gel electrophoresis and the cut DNA was 
purified by using gel extraction kit. The HD59 fragment was ligated into the cut 
vector with different inserts:vectors ratio, 1:1, 3:1, 1:3 using 1 pi (4 Units) of T4 
DNA ligase in Ix ligase buffer in a 15 pi reaction volume as above.
2.2.23 Restriction Enzyme Digestion of DNA
Restriction digests were carried out in small reaction volumes using enzymes and 
their appropriate concentrated buffer solutions according to the manufacturer’s 
instructions. Plasmid DNA was incubated with 0 .5-lp l (5-10 units) enzyme/pg 
DNA in a compatible buffered solution. Any possibility of inhibition o f digestion 
by enzyme storage buffer was avoided by ensuring that the total volume of enzyme
91
Chapter 2: Materials and Methods
added did not exceeded 10% of the final reaction volume. Small quantities of 
plasmid DNA (<5pg) were routinely digested in a 20pl reaction volume as 
specified by the manufacturer for 1 hour at 3T^C. Large digests were carried out in 
proportionally larger reaction volumes for 5 hours at 37°C. The digestion 
fragments were analysed by agarose gel electrophoresis as described below.
2.2.24 Agarose Gel Electrophoresis
Agarose gel electrophoresis was performed using a horizontal gel cast apparatus 
(Biorad). Generally, 1% (w/v) agarose gels were used, but small fragments (100- 
400bp) were separated on 2-4% gels. In order to isolate and purify required DNA 
restriction fragments, 1% concentration of low melting point agarose was 
dissolved in 0.5 x TBE buffer (5x TBE : 40 mM Tris base, 16 mM acetic acid, 
ImM  EDTA, pH 8.0). The gel mix was heated in a glass conical flask in a 
microwave oven until the particles of agarose gel had completely dissolved. To 
enable fluorescent visualization of the DNA fragments under UV light, 5% of 
ethidium bromide (10 mg/ml, Sigma) was added when the gel was hand hot and 
mixed well. The gel cast apparatus was assembled with a comb containing the 
appropriate number and size of teeth to form the sample wells and the gel was 
poured. The comb was removed from the solid gel and the gel placed in a tank, 
then 0.5x TBE buffer was added until the gel was covered by approximately 3mm. 
The samples in 1 x loading buffer were loaded in each well along with an 
appropriate size marker (e.g. 100b ladder, 1Kb ladder) into the first and/or last well 
in the gel and run at 70-100 constant voltage usually until the samples’ blue dye 
front was 1-3 cm from the end of the gel. The separated DNA was visualised by
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illumination with short wave (312nm) UV light and photographed through a red 
filter onto video print paper using an UVP gel documentation system.
2.2.25 Isolation and Purification of DNA Restriction Fragment 
from Agarose Gels
The DNA fragment to be used for cloning was recovered from low melting point 
agarose gel and visualised as described. Under UV light, the fragment was excised 
from the gel with a clean scalpel blade and the gel slice placed in an eppendorf 
tube. The DNA fragment o f interest was extracted from the agarose gel using a 
Qiagen Qiaquick gel extraction kit following the manufacturer’s instructions.
2.2.26 Ligation of DNA Fragments
DNA ligations are performed by incubating DNA fragments with appropriately 
linearized cloning vector in the presence o f buffer and T4 DNA ligase. To prevent 
re-ligation, the 5 phosphate residues o f linearised vector DNA were 
dephosphorylated by adding Ip  (1 unit) Calf Intestine Alkaline Phosphatase 
(CIAP). The reaction mixture was incubated for 1 hour at 37°C followed by a 
second incubation at 70°C for 10 minutes to stop all enzyme activity. The plasmid 
DNA and DNA fragments were purified using a Qiagen Qiaquick PCR purification 
kit. Quantification of the cut vector and DNA fragment was performed by running 
Ip l of the vector, 2pl o f DNA fragment and 2pg (pxl74 RF DNA on 1.5% agarose 
gel. Ligation reactions were performed are 1:3 vector: insert. The DNA fragment 
was ligated into the cut vector using Ip l (lunit) of T4 DNA ligase (Invitrogen) in 
Ix ligase buffer in a 20 pi reaction volume. This was carried out according to the 
manufacturer’s instructions. An excess o f DNA fragment compared to vector and a
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negative control (vector without DNA fragment) were used for ligation reactions. 
Reactions were routinely incubated overnight at 16°C.
2.2.27 Transformation of Competent Bacterial Cells
Plasmids were propagated in commercially available E. coli D H 5a competent cells 
supplied as frozen stocks (Invitrogen) stored at -70°C until use. Transformation of 
bacterial cells was performed in accordance with manufacturer’s instructions. 
Competent cells were thawed slowly on ice, and 20pl of aliquots placed into 
prechilled 1.5ml tubes. 10pi of ligation reaction or 5ng of the appropriate plasmid 
DNA was added and gently dispersed with bacterial cells. The cells were then 
incubated on ice for 30 minutes before being heat shocked for 45 seconds at 42°C. 
The tube was then immediately placed on ice for 3 minutes. The transformed cells 
were then supplemented with 180 pi o f room temperature SOC Medium (25 
bactotryptone, 0.5% yeast extract, 10% mM NaCl, 2.5% mM KCl, 10 mM MgCh, 
10 mM MgS0 4 , 20mM glucose) to each transformation reaction. The tubes were 
then transferred to a shaking 37®C incubator (approximately 225rpm) for 1 hour to 
allow expression of the antibiotic resistant marker. The transformation mixes were 
spread on L-agar plates containing the appropriate antibiotic, plates were inverted 
and incubated overnight at 37°C to allow colony formation.
2.2.28 Glycerol Stocks
The transformed bacterial cells were stored as glycerol stocks for future retrieval. 
800pl of an overnight culture was mixed gently in 80% sterile glycerol in a 1.5 ml 
Nunc Cryotubes and stored at -70^C. A sterile yellow pipette tip was used to scrape 
the top layer of frozen cells when growing up from glycerol stocks required.
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2.2.29 Small Scale Preparation of Plasmid DNA (Miniprep)
Small amounts of plasmid DNA were obtained from transformed bacterial colonies 
to allow the identification o f positive transformants. A single colony from streaked 
selected plates was picked up using a sterile yellow pipette tip, inoculated in 5ml 
culture of L-Broth (1% w/v Bactotryptone, 0.5% w/v yeast extract, 1% w/v NaCl) 
containing antibiotic (50pg/ml Ampicillin) and incubated at 37°C with vigorous 
shaking overnight. 10 separate colonies were generally picked for screening at any 
one time. 1.5 ml of bacterial culture was pelleted by centrifugation in a microfuge 
(14 000 rpm, 10 min). Plasmid DNA was prepared from the colony using the 
QIAprep Spin plasmid miniprep kit according to manufactuier’s instructions.
2.2.30 Determination of ligation by restriction enzymes
The presence o f ligated DNA fragment was determined by incubation 10 of pi of 
plasmid miniprep with appropriate enzymes and buffers at 2>TC for 3 hours. The 
digested and undigested samples were run on 1% agarose gel and separated DNA 
fragments were visualised and photographed as described.
2.2.31 Large Scale Preparation of Plasmid DNA (Maxiprep)
One colony o f the overnight bacterial culture was used to inoculate 200 ml of L- 
broth containing the appropriate antibiotic in 500 ml glass conical flask. The 
culture was placed in incubator shaker at 37°C overnight. Bacterial cells were 
transferred in a Beckman tube and centrifuged at 6000g, 10 min, 4°C using a 
Beckman J2-21 centrifuge. The bacterial pellet was resuspended in 10 ml P l(  50 
mM Tris-Cl (pH8.0), 10 mM EDTA, lOOpg/ml RNase A) and transferred to a
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medium centrifuge tube (JA-20), then gently mixed with 10 ml P2 (200mM NaOH, 
1% SDS (w/v) and left for 5 minutes at room temperature to ensure efficient lysis. 
The mixture was neutralized by the addition of 10 ml of ice cold P3 (3 M 
potassium acetate pH5.5) and the contents were mixed by inverting the tube 
vigorously several times. The solution was incubated on ice for 30 minutes and 
then centrifuged at 13 rpm for 30 min at 4°C. The supernatant was filtered through 
nylon gauze and loaded onto a QIAfilter Mega Cartridge and bacterial debris, 
formed in a tight pellet at the bottom of the tube, was discarded. The column was 
washed twice with 30ml o f QC (IM  NaCl, 50mM MOPS pH7, 15% isopropanol 
(v/v), 0.15% Triton (v/v)). The plasmid DNA was eluted by 15ml of QF (1.25M 
NaCl, 50mM Tris-Cl pH 8.5, 15% isopropanol (v/v)). DNA was precipitated by the 
addition of 10.5ml isopropanol. Nucleic acid was pelleted by centrifugation at 
12000 ipm for 30 minutes, the pellet was marked and the supernatant carefully 
discarded. The pellet was washed with 1 ml 70% ethanol (v/v), transferred to a 
micro-centrifuge tube and pelleted by centrifugation at 14000 rpm for 10 minutes. 
After removing the supernatant, the pellet was resuspended in 400 pi dHzO and 
DNA quantification was determined as described.
2.2.32 Polymerase Chain Reaction (PCR)
All reagents were provided in the GeneAmp® PCR core Reagents kit purchased 
from Applied Biosystems. Primer sequences are described in table 1. PCR reaction 
containing Ing of DNA template, 20pmol of each primer, 200pM each dNTP, 
3mM M gCh (25mM Mn(0AC)2 , 0.5pi (2.5 units) AmpliTaq® DNA polymerase 
in a total volume of 50pl containing Ix  PCR buffer was pipetted into a 0.5ml 
GeneAmp PCR reaction microfuge tube. A negative control containing no template
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and a positive control were always included with each set of PCR reactions. PCR 
amplification was carried out using a MJ Reasearch PTC-200 gradient cycler.
Samples were heated to 94°C for 1 min (denaturing step), 50°C for 1 min
(annealing step) and 72°C for 1 min (elongation step). This cycle of denaturing, 
annealing and elongation was repeated 25 times. The amplified product was 
determined by gel electrophoresis of 10 pi of PCR reaction.
Table 2: Oligonucleotide PCR primers
BPV-4 E5 Forward 5’ CCA TAC GAT GTT CCA
GAT TAC GCT 3’
BPV-4 E5 Reverse 5’ CCA TCC ATC TAA CCG
AGT A AT A G T 3’
2.2.33 DNA sequencing
The correct orientation o f nucleotides sequence in all new plasmids was 
determined using Taq terminator sequencing on an Applied Biosystems Prism 
3100 Genetic Analyzer DNA sequencer. The DNA of interest to be sequenced was 
first prepared as a single strand and underwent PCR amplification. Reaction 
containing 0.5 pg plasmid DNA, 3.2pmoles of the appropriate primer, 2pi 5x 
sequencing buffer and 4pi o f BigDye™ Terminator Ready Reaction Premix 
(Applied Biosystems) were made up with distilled H2O to a total reaction volume 
of 20pl. 250 pi thin eppendorf tubes were used for all sequencing PCR reactions. 
The samples were placed in a MJ Research PTC-200 Peltier Thermal Cycler and 
exposed to 25 cycles o f 96°C for lOseconds, 50°C for 5 seconds and 60°C for 4
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minutes. The PCR products were purified using PERFORMA® DTR Gel Filtration 
Cartridges. The columns were first spun at 3000rpm for 2 minutes to remove 
buffer. The columns were then transferred to sample collection tubes. The PCR 
sequencing reaction mix was then loaded onto the centre of the gel column. The 
column was spun for 3000rpm for 2 minutes. The sample was then dried under 
vacuum for 15-20 minutes and then resuspended in 25 pi formamide.
The Samples were loaded and run on the ABI PRISM® 3100 Genetic Analyzer 
(PE Applied Bio systems, UK), under standard sequencing conditions for 
generation o f automated sequence data. The ABI PRISM® 3100 Genetic Analyzer 
is a multi-colour fluorescence-based DNA analysis system using the proven 
technology of capillary electrophoresis with 16 capillaries operating in parallel. 
The Genetic Analyzer is fully automated from sample loading to data analysis. The 
sequence was evaluated by examination of chromatogram output using Chromas 
software.
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Table 3: Oligonucleotides used for sequencing
Primer Nucleotide Sequence
Forward
Reverse
T7 forward
Plasmid
Sequenced
pFLAG-CMVl
pFLAG-CMVl
5’GTC TAT AT A AGC 
AGA
GCT CGT TTA GTC AAC 3’
5’CTG GTG GGC ACT GGA 
GTG GCT ACT TCC AGG
3’
5’ATT AAT ACG ACT CAC pcDNA6 
TAT AGG G A 3 ’
BGH
reverse
5’CTA GAA GGA ACA GTC 
GAG GC 3’
pcDNA6
2.2.34 DNA preparation from P815 cells
For DNA extraction, P815 cells were grown until 80% confluent and washed twice 
with PBS. The cell pellet was resuspended in 500 pi PBS and then applied to the 
Capture column by using Generation Capture column kits (Centra Systems, USA), 
After quick centrifugation, the cells were washed twice with 500 pi purification 
solution and quickly centrifuged (2-3 seconds). Next, the cells were washed once 
with elution solution and pelleted by a quick centrifugation. 200 pi of elution 
solution was added again and the top of the tubes was wrapped with parafilm and 
the tubes were put in boiled water (99°C) for 10 minutes and then spun down as
99
Chapter 2: Materials and Methods
above. After quantification, DNA was amplified and the PCR products were 
electrophoresed in order to determine the fragment of BPV-4E5 gene.
2.2.35 RNA preparation
RNA extraction from P815 cells was carried out using a Qiagen RNeasy Kit with 
QIAshredder columns. Cells (maximum Ix 10^) were used, centrifuged and 
washed twice with Ix ice-cold PBS. The cell pellet was lysed by addition of 600pl 
of RTL (lOpl 2-Mercaptoethanol, 1ml RTL buffer) and mixed well using vortex. 
After adding 600pl of 70% ethanol, the lysate was transferred to QIAshredder spin 
column then centrifuged to homogenise the sample at 8-1 Ox 10  ^ rpm for 15 
seconds. The flow through was added to a RNeasy mini column and centrifuged as 
above. Subsequently, contaminants were removed by washing the column with 
700pl of RW l once, and with 500pl RPE twice. The purified RNA was eluted 
from the column in 30pl of RNase-free water.
2.2.36 Purification of RNA
RNA extract was treated with DNase to remove residual amounts o f DNA in order 
to optimise the efficiency of TaqMan RT-PCR analysis. Typically, Ipg  o f RNA 
extract was added to Ip l (1 unit) DNase I Amplification Grade, Ip l o f lOx DNase I 
reaction buffer and the reaction made up to 10pi of DEPC-treated water. After 
incubation for 15 minutes at room temperature, the DNase I was inactivated by the 
addition of Ip l of 25 mM EDTA solution to the reaction mixture. RNA sample 
was heated for 10 minutes at 65°C prior to reverse transcription.
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2.2.37 Quantification of Nucleic Acids
The concentration of nucleic acid in a solution was determined 
spectrophotometrically in a WPA U V llO l Biotech spectrophotometer. Samples 
were diluted in dHiO and transferred to a quartz cuvette with a pathway of 1cm. 
The spectrophotometer was initially calibrated using dHiO only as a blank. The 
optical density reading were obtained at 260nm and 280mn; an O.D. reading o f 1 
at 260nm (A260 = 1) corresponds approximately to a concentration of 50 pg/ml of 
double stranded DNA, for oligonucleotides an A260 reading of 1 was taken to 
correspond to -3  5 pg/ml, and for RNA an A260 readingof 1 was taken to correspond 
to 40pg/ml. The ratio between readings at 260mn and 280nm (A260^A28o) provided 
an estimate of the sample purity; a ratio of -1 .8  indicated that preparations 
contained essentially no protein or phenol contamination.
2.2.38 Real-time PCR detection of mRNA quantity
Probes and primers for BPV-4 E5, HPV16 E5 and mouse p-actin were designed 
using the primer Express Software programme (Perkin-Elmer) and conditions used 
as per manufacturer instruction. Real-time RT-PCR was performed using 
TaqMan® EZ RT-PCR kit (Applied Biosystems) and PCR conditions were as per 
manufacturer instructions. Typically, final concentrations of Ix RT buffer; 3mM 
MnAc; 300pM dATP, dCTP, dGTP; 600pM dUTP; 200nM of each primer; 
lOOnM probe and 5U rTth polymerase were made for each reaction. Each reaction 
was performed in triplicate using lOOng of RNA. PCR reactions were performed 
on a sequence detection system (ABI prism 7700, Applied Biosystems) according 
to the manufacturer’s instructions by using universal PCR conditions (60°C for 30 
min, 95°C for 10 min, then 94°C for 20 sec and 62°C for 1 min, in 40 cycles).
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Standard curves were generated using 10 serial dilutions of lOOpg to 10'^ pg of 
each template DNA, which were used to quantify the relative levels of E5 and )3- 
actin niRNA. E5 mRNA levels were normalized to the P-actin controls.
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Table 4: Oligonucleotides used for Real Time RT-PCR
primers Nucleotide Sequence
BPV-4E5 5’ TGT CTT TGT GGC TTA TCT ATG TXT T G I 3’
Forward
BP V-4E5 5 ’ CCG AGT AAT AGT AGA AAT TA A C AG AAG
Reverse G T A C A C 3’
4E5 5’CTT TTC TGG TGT GCT TXT AAT TXT CTT
FAM/TAMRA GCA CTG TTA 3 ’
probe
HPV-16 E5 5 ’ TGA CAA ATC TTG ATA CTG CAT CCA 3 ’
Forward
HPV-16 E5 5’ CTG CTG TTA TCC ACA ATA GTA ATA
Reverse CCA ATA 3’
HPV-16 E5 5’ AAC ATT ACT GGC GTG CTT TXT GCT TTG
Probe C T 3 ’
Mouse p actin 5’ GCT CTG GCT CCT AGC ACC AT 3’
Forward
Mouse p actin 5’ GCC ACC GAT CCA CAC AGA GT 3’
Reverse
Mouse p actin 5’AAG ATC ATT GCT CCT CCT GAG
Probe C G A A A G 3’
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2.2.39 Transient Transfection of PalF cells
PalF-4E5 cells were transiently transfected using LIPOFECTAMINE PLUS™ 
Reagent (Invitrogen) according to the manufacturer’s instructions. Subconfluent 
cells were trypsinised, resuspended in growth medium and aliquots of Ix  10"^  cells/ 
well were plated in 24-well plate containing 13mm round cover slips. After 
overnight incubation, the medium was replaced by adding 200ql/well serum-free 
D-MEM Medium. For each sample, construct of 0.5qg of either pFlag-A*5000f 
(bovine non-classical MHC I) or GFP-B275 (human classical MHC I) was diluted 
in 25ql D.MEM Medium without serum and mixed before adding Iq l PLUS 
Reagent. In another eppendorf tube, Iq l Lipofectamine Reagent was mixed in 25 ql 
Medium without serum. Following incubation for 15 min at room temperature, 
diluted DNA and Lipofectamine were combined, incubated as above and 
transfected into the cells. After incubation at 37°C at 5% CO2 for 3 hours, 250ql of 
medium containing 20% FCS was added to transfectant to bring the concentration 
of FCS to normal (10%) in total volume 500ql. 24 hours later, the medium was 
removed and the transfected cells were grown in fresh growth medium for 24 hours 
before staining.
2.2.40 FACS analysis for MHC class I expression in P815 cells
P815- N*01301 and P815- N*50001 cells either expressing BPV-4E5 or canying 
empty vector and P815/HLA-A2 or P815/HLA-E expressing HPV16E5 or 
carrying empty vector were grown in T175 cm^ flasks until subconfluent. 
Following centrifugation, cell pellet was washed once with PBS and resuspended 
in PBS/1 % bovine serum albumin at a concentration of lO^cells/ml. For the 
detection of surface expression of bovine MHC class I molecules, aliquot of 10*^
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cells were incubated for Ih at 4°C with 1:10 dilution monoclonal Antibody (niAb) 
IL A88 in 1%BSA in PBS. For detection of HLA-A2, aliquot o f 10  ^ cells 
suspended in 100 ql PBS were incubated for Ih  at 4°C with 1: 100 dilution of 
monoclonal antibody W6/32 Ab, (Serotec), in 1%BSA in PBS. For detection of 
HLA-E, aliquot of 10  ^cells suspended in 100 ql PBS were incubated for Ih at 4°C 
with anti-HLA-C/E mAh DT9 (1:50; a kind gift from Dr. Véronique Braud, Centre 
National de la Recherche Scientifique, Sophia Antipolis, France). For detection of 
mouse MHC I (H2D^), aliquot of 10  ^ cells suspended in 100 ql PBS were 
incubated for Ih at 4“C with 1:80 dilution of anti- H2D‘* mAh (Cederlane). After 
washing twice with PBS, cells were incubated with 1:100 dilution of goat 
antimouse IgG-FITC (Sigma, St.Louis, Mo) for 30 min at 4°C in the daik. The 
cells were then washed as above, resuspended in 500 ql PBS and analysed by flow 
cytometry. If the flow cytometry analysis was not carried out immediately, the 
cells were resuspended in 500 ql of 3% paraformaldehyde in PBS and kept at 4°C. 
P815 cells not expressing bovine or human MHC class I were used as a negative 
control. Cells incubated with secondary antibody were also used as control. For the 
detection of intracellular MHC class I, firstly, the cells were permeabilized with 
0.1% saponin in PBS-B for 30 min at RT. Secondly; the cells were then incubated 
with primary antibody as described above. All samples were examined in a 
Beckman coulter EPICS Elite analyzer equipped with an ion argon laser with 
I5mV of excitation at 488 nm. Data were analyzed using Expo 2 soft were.
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2.2.41 Immunofluorescence detection of MHC class I in PalF-4E5 cells
In all experiments, PalF cells (Ix  lO"^ ) were aliquoted into 24-well plate containing 
coverslips and grown overnight. After removal of the medium, cells were washed 
twice with PBS and fixed in 5% formaldehyde in PBS containing 2% sucrose for 
10 minutes at RT. After that time, cells were washed twice and incubated in 
permeabilizing solution (0.5% NP-40, 10% sucrose in PBS) for 10 minutes at RT 
and then washed twice as above. To analyze the localization of non-classical MHC 
class I in BPV 4E5- expressing cells, fixed and permeabilized cells were first 
incubated with dilution 1:1000 BODIPY ceramide texas red (Invitrogen), (2.5% 
Hepes in serum-free D MEM Medium) for 30 minutes at 4°C. After removal of 
BODIPY, cells were incubated in 2.5% Hepes in serum-ffee D MEM Medium for 
30 min at 3TC , followed by two washes in PBS. For detection of bovine non 
classical MHC class I, cells were incubated with 1:2000 dilution of Anti-Flag® M2 
Monoclonal Antibody (Sigma) in PBS containing 5% BSA. After washing twice in 
PBS, cells were then incubated with 1:1000 dilution of antimouse FITC (Sigma), 
for 1 hour in the dark. To determine whether the C-terminal truncated BPV-4E5 
(4E5T) protein still preserves its ability to down regulate MHC class I, PalF cells 
expressing either 4E5T or E7 were incubated with a dilution 1:10 mAh IL-A88 in 
1% PBS for 1 hour. To analyze the localization of classical MHC class I in E5- 
expressing cells, construct of GFPB2705 was transfected into PalF cells either 
express E5 or E7. 48h later, cells were fixed, permeabilized and incubated with 
BODIPY ceramide for Golgi staining as described above. Following incubation 
with BODIPY ceramide, cells were washed 3 times and the cover slips were 
mounted onto slides using Citifluor.
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2.2.42 Immunofluorescence detection of MHC class I in P815 cells
As these cells grow in suspension, an eight-well slide (Chamber slides lab-tek, 
VWR international) was washed with alcohol, air dried and treated with 40ql/well 
poly-L Lysine hydrobromide (Sigma) for 10 minutes to allow cell adhesion. After 
removal of poly-1 lysine, the slide was washed with distilled water and air-dried. 
Following centrifugation, cells were washed twice in PBS and resuspended in 
fixing solution (5% formaldehyde in PBS containing 2% sucrose) for 10 minutes. 
After two washes, cells resuspended in PBS containing 1% FCS, 2x lO"^  cells/well 
were dispersed into the wells and left for 15 minutes to settle down. After removal 
of PBS, cells were covered in permeabilizing solution (0.01% Tween-20 in PBS) 
for 10 min. After two washes, cells were incubated with 1:1000 dilution of 
BODIPY ceramide (2.5% Hepes in serum free 1640 RPM Medium) for 30 min at 
4°C. After removal of BODIPY, cells were incubated in 2.5% Hepes in serum-free 
1640 RPM Medium for 30 min at 37”C. For localization of bovine MHC class I, 
cells were first incubated with 1:10 dilution of IL-A8 8  antibody. For localization of 
HLA-A2, cells were incubated with 1:50 of mAh W6/32. For localization of non 
classical HLA-E, cells were incubated with anti-HLA-C/E mAh DT9 at 1:50. For 
localization of mouse MHC I, cells were incubated with anti-H2D^ mAh at 1:80. 
All cell lines were incubated with primary antibodies for Ih  at RT followed by 
incubation with 1:1000 dilution of antimouse IgG-FITC for Ih  in the dark with two 
washes in between. After that time, cells were washed three times and the slide 
was mounted with 60mm coverslip using Citifluor.
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2.2.43 Imaging
Images were captured using a Leica TCS SP2 true confocal scanner roscope (Leica 
Microsystems, Heidelberg, Germany) and a wavelength of 488 nm (MHC class I) 
or 543 nm (GA). The merge between the FITIC and TRÎTC; GFP and TRITC 
fluorescent signal was accomplished using the Leica TCS SP2 accompanying 
software.
2.2.44 Protein extracts preparation
Aliquots of confluent P815 cells grown in 1640RPM medium were centrifuged at 
1000 rpm for 5 min and washed two times with 5ml of ice cold PBS. The cell 
pellet was then resuspended in 1ml of ice cold PBS, transferred to a 1.5ml 
eppendorf tube and pelleted. The pellet was vigorously resuspended in 300ql of 
lysis buffer (0.5% NP40, 50mM Tris PH 7.8, 150mM NaCl with a protease 
inhibitor cocktail (Roche, Lewes, UK) dissolved in the lysis buffer). Following 
incubation on ice for 30 min, the extracts were then centrifuged in a refrigerated 
microfuge for 10 minutes at maximum speed at 4°C. The supernatant was 
transferred to another tube and the cell debris discarded. The protein concentration 
was quantified using the BCA/CUSO4 assay. For determination of the stability of 
MHC class I heavy chain protein in BPV-4E5-expressing cells, aliquots of 2x 10*^  
E5 or empty vector transfected cells, expressing either bovine classical or non- 
classical MHC I, were treated with lOOpl/ml Cyclohexamide (Sigma) and 
incubated at 37®C, 5% CO2. As DMSO is the solvent for cyclohexamide, half of 
the cells were treated with Iql/m l DMSO (Sigma) alone. The treated cells were 
then harvested after Ih, 2h, 5h, lOh and 24h, washed two times with ice cold PBS,
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pelleted and kept at-70°C. The pellets were re suspended in lOOpl/pellet lysis buffer 
as described above.
2.2.45 SDS-Polyacrylamide Gel Electrophoresis
The gels used to separate protein were NuPAGE® 4-12% Bis-Tris-HCl buffered 
(pH 6.4) poly-acrylamide gels purchased from Invitrogen Ltd. Protein samples 
were mixed with 4x NuPAGE® LDS sample buffer (40% Glycerol, 500mM Tris- 
HCl (pH 6 .8 ), 8 % SDS, 0.075% Serva blue G250, 0.025% phenol Red), and lOx 
NuPAGE® Reducing Agent (0.5M DTT), at a ratio of 40:10:4 for sample:loading 
buffer:reducing agent respectively. Following mixing, samples were heated at 70°C 
for 10 minutes prior to loading. The gel tanks used to separate the proteins were 
the Xcell Surrlok Mini-cell tanks purchased from Invitrogen Ltd and the 
electrophoresis was performed as per manufacturer’s instructions. The gel was 
uncovered, placed in tank to allow the migration of samples towards the positive 
pole and the lower chamber was filled with 2Ox MES SDS Running buffer (IM  
MES, IM  Tris Base, 69.3mM SDS and 20.5mM EDTA) (purchased from 
Invitrogen Ltd). After filling the upper chamber with 200ml MES SDS containing 
500ql Antioxidant (Invitrogen), each sample was loaded into the well o f the gel 
with at least one well contains the See-Blue coloured protein marker (Invitrogen). 
The electrophoresis was performed in MES SDS Running buffer at a constant 
voltage 200V for 60 minutes.
2.2.46 Electrophoretic Transfer of proteins
Separated protein samples were transferred to nitrocellulose membranes by wet 
electrophoretic transfer using a Xcell II™ blotting apparatus (Invitrogen). Blotting
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protocol was as per manufacturer’s instructions. 20x NuPAGE® transfer buffer 
(Invitrogen Ltd) (0.5M Bicine, 0.5 Bis-Tris, 20.5mM EDTA, ImM  Chlorobutanol) 
was diluted in Ix NuPAGE® transfer buffer containing 10% methanol, 1ml 
Antioxidant in final volume o f IL distilled water. Two sheets of Whatmann paper, 
a piece of nitrocellulose membrane (Hybond ), and four blotting pads were 
soaked in transfer buffer and left until use. After electrophoresis, one o f the gel 
cassette plates was removed and the wells were cut away. Two blotting pads were 
placed on the bottom plate (cathode) o f the blotting apparatus, followed by a sheet 
of filter paper, then the gel, then the nitrocellulose membrane, then a sheet of filter 
paper and finally two blotting pads. Any trapped air bubbles were removed and the 
blotting was performed at constant voltage 30V for 80 minutes in Ix NuPAGE® 
transfer buffer containing 10% methanol. Transfer was checked by staining the 
nitrocellulose membrane with Ponceau S solution (Sigma).
2.2.47 Immunoblotting
Any non specific staining was avoided by blocking the membranes in 5% milk in 
phosphate buffer saline (PBS) containing 0.1 % Tween 20 for lb  at RT or 
overnight at 4°C. For detection of bovine MHC class I heavy chain, the membranes 
were incubated with 1:100 dilution o f mAb IL-A8 8  antibody in 5% milk in PBS- 
0,1% Tween 20 for 2 hours at RT on shaker at lower speed. For detection of HLA- 
A2, the membrane was incubated with 1:1000 dilution of mAh HC-10 antibody in 
5% milk in PBS-0,1% Tween 20. For detection of HLA-E, the membrane was 
incubated with 1:1000 dilution HLA-E antibody MEM-E/02 (Abcam^) in PBS- 
0,1% Tween 20. For detection of mouse H2d, the membrane was incubated with 
1:100 dilution anti-H2d antibody (Cederlane^) in PBS-0,1% Tween 20. Protein
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samples extracted from cyclohexamide and DMSO treated cell were incubated 
with mAb IL-A8 8  antibody at 1:100 in 5% milk in PBS-0,1% Tween 20. After 
2x15 minutes wash in T-PBS for 15 minutes each, the membranes were incubated 
with 1:5000 dilution of sheep anti-mouse IgG hourseradish peroxidase linked 
whole antibody (Amersham Biosciences) in 5% milk in Ix T-PBS for Ihour at RT 
on an orbital shaker at lower speed. Following two washes as above, bound 
antibody was detected by incubating the membrane for 5 minutes at RT with ECL 
plus western blotting detection system (Amersham Bio sciences). Any excess 
detection reagent was drained; the membrane was covered with a piece of saran 
wrap and placed in an x-ray film cassette (Hypercassette™ -  Amersham 
Bioscences). In the dark room, a sheet of 18x24 X-ray film (Hyperfilm ™ 
Amersham Bioscences) was exposed to the membrane and developed in automatic 
x-ray film processor (Xograph IMAGING SYSTEMS- Compact X4). To carry out 
a control for these experiments, bound primary and secondary antibodies were 
removed from the membranes. The membranes were submerged in stripping buffer 
(lOOmM 2-Mercaptoethanol, 2% SDS, 62.5mM Tris-HCl pH6.7) and incubated at 
50°C for 30 minutes with occasional shaking. After 2x10 minutes wash in T-PBS, 
the membranes were blocked in 5% milk in T-PBS for 1 hour at RT prior to re- 
incubating with 1:20000 dilution of anti-Actin antibody (Ab-1, CALBIOCFIEM). 
Following 2 hours incubation with anti-actin Ab, the membranes were washed two 
times in T-PBS and incubated with anti-mouse IgG horseradish as described 
above.
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3 Results 
3.1 BPV-4 E5 protein down regulates MHC class I in bovine papillomas
3.1.1 Introduction
Infection by BPV-4 leads to the formation of proliferative lesions (warts) at the site of 
infection which start after four weeks of viral latency in the basal layer. The vast 
majority of papillomas regress through an activated T-cells immune response after a 
significant period of persistence which lasts for several months to one year. It has 
been suggested that persistence of papillomas is due to the inability of the immune 
system to recognize the viral antigens during the course of infection.
The analysis of BPV-4 DNA sequence revealed that it contains two transforming 
genes, E5 ORE and E7 ORE. The BPV-4 E5 ORE encodes a polypeptide only 42 
amino acids long with a putative transmembrane domain comprising a highly 
hydrophopic N-terminal 30 residues and a hydrophilic C-terminal tail o f 12 residues. 
It is mainly localized at the endosomal membranes, Golgi apparatus and occasionally 
the plasma membranes (Pennie et al 1993), and is expressed in the deep layers of 
eai'ly stages papillomas of the upper alimentaiy canal (Anderson et al 1997). E5 
contributes to cell transformation by binding to ductin and inducing down-regulation 
o f gap junction intercellular communication (GJIC) in transformed PalF cells (Faccini 
et al 1996). Furthermore, E5 increases cyclin A protein and cyclin A associated kinase 
activity, and inhibits the functions o f the negative regulator of cell cycle p27^‘^  ^
(O'Brien and Campo 1998). Previous studies have shown that cells transformed by 
BPV-4 E5 show retention o f MHC class I molecules in the Golgi apparatus and 
inhibition of transport of the complex to the cell surface (Ashrafi et al 2002; Marchetti 
et al 2002; O'Brien and Campo 2002). The MHC class I molecules play a fundamental 
role in the eradication of virally infected and transformed cells, since the cytotoxic T
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cells can not recognize the infected cells unless foreign peptides are presented by 
MHC class I on the cell surface (Doherty and Zinkernagel 1975). The importance of 
MHC class 1 in virus clearance has led many viruses to establish numerous 
mechanisms of interference with the MHC class I pathway (Yewdell and Bennink 
1999). The MHC class I molecules ai’e subdivided into two families, MHC class la or 
classical, and MHC class lb or non-classical. The classical MHC class I molecules are 
polymorphic cell surface glycoproteins characterized by their ubiquitous expression in 
all nucleated cells. The lack o f surface expression of these molecules as result of 
interference with their pathway hampers infected cell presentation of antigenic 
peptides to CD8 cells, leading to a decrease in immunological surveillance. It has 
been observed that expression of bovine papillomavirus E5 proteins in cultured 
bovine PalF cells induces dramatic reduction o f surface expression of MHC I as well 
as it reduces the total amounts of MHC I to the half of amount compared with control 
cells (figure 4). The aim of this pait of the study is to extend these observations to 
investigate whether BPV-4 E5 can down regulate MHC class I in natural infection.
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Figure 4. BPV-4E5 downregulates MHC class I in bovine PalF cells. The mean 
forward fluorescence was calculated from the flow cytometry profiles of surface and 
total MHC class I in control (PalF, no E5 cells), and transformed cells expressing 
BPV-4E5 (Ashrafi et ah, 2002).
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Figure 4 BPV-4E5 down-regulates MHC class I in bovine PalF cells
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3.1.2 Expression of MHC class I in normal upper gastrointestinal tract
MHC class I genes encode glycoproteins expressed at the cell surface o f almost all 
nucleated cells. To determine the feasibility of using the mAh IL-A8 8  to stain 
normal mucosa of bovine tissues and for evaluation the expression pattern of MHC 
I, sections from normal palate, tongue, buccal mucosa, and lymph node were 
deparaffmized and re-hydrated through a graded series of alcohol and endogenous 
peroxidase was inhibited in methanol containing 1.5% hydrogen peroxide. After 
antigen retrieval and blocking of sections with normal rabbit serum, sections were 
incubated with mAb IL-A8 8 , which detects the heavy chain o f bovine MHC I 
(Toye et al 1990). Sections were incubated with biotin-labeled rabbit anti-mouse 
secondary antibody. Signal was amplified by staining sections with avidin-biotin- 
peroxidase. MHC class I staining was visualised in brown colour by applying DAB 
to sections as described in section 2.2.9. In the epithelium, on the cell membranes, 
MHC I staining was observed with IL-A8 8  in almost all normal tissue specimens. 
There were slight differences in the pattern and the intensity of MHC I staining 
between the tissues; in normal buccal mucosa, the epithelium was stained 
throughout most of its thickness and staining on the surface of the cells was 
particularly clear in cells of the basal and suprabasal layers (figure 5-a). Although, 
all sections from tongue, hard palate, oesophagus, MHC I staining was mainly 
observed in the lower epithelial layers (figure 5-b,c and d respectively), some cells 
from basal and suprabasal layers did not show MHC I staining (figure 5-b,c). In 
contrast to epithelium, staining o f lymph node with IL-A8 8  showed strong MHC I 
staining on the cell membrane o f almost all T cells in a section (figure 5e). There 
was strong staining of the capillaries and stromal cells. The specificity o f MHC I
117
Chapter 3: Results
staining was confirmed by incubating normal sections without mAb IL-A8 8  (figure 
5“f,g).
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Figure 5. Expression o f MHC class I in paraffin sections from bovine normal 
samples stained with IL-A8 8 . (a) buccal mucosa; MHC class I staining is observed 
on the cell surface throughout the whole thickness of epithelium from the basal 
layer (B), suprabasal (S) and granular layers (G) as indicated by arrows; (b,c) 
expression of MHC class I in tongue and hard palate respectively; some cells in 
basal (B) and suprabasal layers (S) do not express MHC class I as indicated by 
arrows; (d), MHC class I expression in oesophagus; there is clear cell surface 
staining in basal (B) and suprebasal layers (S) with no MHC staining in the upper 
layers (G) as indicated by arrows, (e), there is clear MHC class I expression on the 
cell surface o f lymphocytes in a section o f lymph node; (f,g), normal sections 
from buccal mucosa and oesophagus respectively were stained with secondary 
antibody only to verify the specificity o f MHC class I staining, (a, b, d, e and g) 
x200 magnification, (c) x400 magnification, f  xlOO magnification.
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Figure 5 Expression o f MHC class I in normal upper gastrointestinal tract
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3.1.3 Expression of E5 in papillomas
To determine the expression of BPV-4E5 protein in natural infection, papilloma 
sections from the palate, rumen and oesophagus were deparaffmized and re­
hydrated through a graded series o f alcohol and endogenous peroxidase was 
inhibited in methanol containing 1.5% hydrogen peroxide. After blocking of 
sections with normal swine serum, sections were either incubated with 274 or 275 
rabbit antiserum that was raised against a synthetic peptide representing the 12 C- 
terminal amino acids o f the protein (Anderson et al 1997). Sections were incubated 
with biotin-labeled swine anti-rabbit secondary antibody. Signal was amplified by 
staining sections with avidin-biotin-peroxidase. E5 staining was visualised in 
brown colour by applying DAB to sections as described in section 2.2.9. E5 
staining was observed exclusively in the cytoplasm of epithelial cells, from the 
basal and parabasal layers (figure 6 -a,b) to the spinous and squamous layers (figure 
6 -c,d). Expression of E5 was, however, discontinuous; no papilloma was stained in 
all cell layers. The specificity of E5 staining was verified using several controls; 
pre-absorption of E5 antiserum was one o f these controls, lOql of E5 antiserum 
was incubated with 30ql (1 mg/ml) o f a synthetic E5 peptide representing the C- 
terminal fragment of BPV-4E5, against which the antiserum was raised, for 1 hour 
at 4°C. The complex of E5 peptide/ E5 antiserum bound was precipitated by 
centrifugation and the supernatant was used to investigate the elimination of E5 
reactivity both in vitro and in vivo experiments. In vivo, the specificity of E5 
staining was verified by incubation of papilloma section with preabsorbed E5 
antiserum (figure 6 -e). In vitro experiment was performed by B. Marchetti who 
showed that preabsorbed E5 antiserum failed to precipitate E5 (figure 6 -f  lane 3) 
compared with lane 2 in which E5 immunoprecipitated with E5 antiserum. In
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addition, E5 reactivity was eliminated when serial section of papilloma 386 was 
incubated with secondary antibody only (figure 6-g).
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Figure 6. Expression of BPV-4E5 in bovine papillomas. Tissue sections were 
immunostained for BPV-4E5 using two different E5 antisera (274, 275), raised in 
rabbit against E5 C-terminus domain. E5 expression was detected in cytoplasm of 
papilloma cells as indicated by arrowheads. E5 was mainly detected in basal and 
suprabasal layers using E5 antiserum 275 at dilution 1:5000 (a,b), and in the upper 
layers using E5 antiserum 274 at dilution 1:2000 (c,d). The specificity o f E5 
staining was verified by incubation of papilloma section with E5 antiserum 
preabsorbed with C-terminus peptide(e); (^ ; preabsorbed E5 antiserum failed to 
precipitate E5 (lane3); lane 1, E5 protein; lane 2, precipitated E5 protein by E5 
antiserum, (g), staining o f papilloma section with pre-immune serum, (a, b, d, e 
and g) x200 magnification, (c) xlOO magnification.
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Figure 6 Expression o f BP V-4E5 in papillomas
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Expression of MHC class I in papillomas
To associate the expression of E5 with down regulation of MHC I, serial 
papillomas sections from the palate, rumen and oesophagus were either incubated 
with 274 or 275 E5 antiserum for detection of BPV-4 E5 or with mAb IL-A88 for 
detection of MHC I. Sections were incubated with biotin-labelled swine anti-rabbit 
secondary antibody for E5, while biotin-labelled rabbit anti-mouse was used for 
MHC I. Signal was amplified by staining sections with avidin-biotin-peroxidase. 
E5 or MHC I staining was visualised in brown colour by applying DAB to sections 
as described in section 2.2.9. Papilloma section stained with E5 antisera showed 
expression of E5 within the suprabasal and granular' layers (figure 7a), however a 
serial section stained for MHC I with antisera IL-A88, revealed that the cells 
expressing E5 were negative for MHC I whereas cells without E5 expression 
demonstrated some staining for MHC I (figme 7b). MHC I was also strongly 
detected in stroma and capillaries. In all samples of papillomas, it is obvious that 
papilloma cells which did not show E5 staining (figure 7c), had detectable MHC I 
(figure 7d), and vice versa, cells lacking MHC I staining (figure 7d) had detectable 
cytoplasmic staining o f E5 (figure 7c). Independently, of where cells expressing E5 
localize within epithelial layers, expression o f MHC I is not compatible with 
expression of E5. In agreement with previous work in vitro we conclude that 
expression of BPV-4 E5 in natural infection in vivo causes a remarkable reduction 
of MHC I expression on the surface of papilloma cells, thus potentially allowing 
virus to escape immune recognition.
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Figure 7. Expression of MHC class I in papillomas. Serial sections of papillomas 
were stained with either mAb IL-A88 or with E5 antiserum. Slides were 
microscopically examined by looking at E5 staining patterns in particular areas and 
matching them with the same areas in the section stained for MHC class I. Images 
were captured using computerized images analyser (Zeiss KS300) at x 200 
magnification. Papilloma cells that expressed E5 (a) did not express MHC I (b) as 
indicated by rectangles. Vice versa, papilloma cells which did not express E5 (c) had 
detectable MHC class I (d) as indicated by enlarged squares, (a and b) and the 
bottom of c and d x200 magnification, the top of c and d xlOO magnification.
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Figure 7 Expression o f MHC class I in papillomas
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Down-regulation of M HC class I is due to expression of E5 but not of E7
It has been reported that E7 proteins of HPV-16 and -11 are implicated, 
respectively, in the down-regulation of MHC I either through inhibition of the 
transcriptional promoter o f the MHC I heavy chain (Georgopoulos et al 2000) or 
indirectly thi'ough inhibition of TAP, the transporter associated with peptide 
(Vambutas et al 2001). To ensure that the absence of MHC I in bovine papillomas 
was due to E5 and not to E7, serial papillomas sections were either incubated with 
mAh IL-A88 for detection of MHC I, with E5 antiserum for detection of BPV-4 E5 
or with rabbit antisera 11547 and 11823, which were raised against a f3~ 
galactosidase-E7 fusion protein (Anderson et al 1997) for detection o f BPV-4 E7. 
Sections were incubated with biotin-labeled swine anti-rabbit secondary antibody 
for labelling E5 Ab/Ag bound and E7 Ab/Ag bound, while biotin-labeled rabbit 
anti-mouse was used to label inAb L-A88/ MHC I bound. Signal was amplified by 
staining sections with avidin-biotin-peroxidase. E5, MHC I and E7 staining were 
visualised in brown colour by applying DAB to sections as described in section
2.2.9. Cells expressing either E5 or E7 alone were seldom detected because E5 
ORE is located between the long control region and the E7 ORE and both E5 and 
E7 are co-expressed in the initial stages of the infection. Papilloma cells that 
express E7 (figure 8a), but not E5 (figure 8b), still had detectable MHC I (figure 
8c). Conversely, cells that did not express E7 (figure 8d) but expressed E5 (figure 
8e), there was little or no MHC I (figure 8f). These results confirm that expression 
of BPV-4E7, in contrast to HPV E7 is not responsible for down-regulation of 
MHC I and confirmed the previous observations that E5 is only the viral protein of 
BPV-4 responsible for down-regulation of MHC I.
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Figure 8. Expression o f BPV-4E7 does not interfere with expression o f MHC class 
I. Serial sections o f papillomas were either incubated with mAh IL-A88 for 
detection of MHC I, with E5 antiserum for detection of BPV-4 E5 or with rabbit 
antisera 11547 and 11823, which were raised against a y0-galactosidase-E7 fusion 
protein. Slides were microscopically examined by looking at E5 staining patterns 
in particular areas and matching them with the same areas in the section stained for 
MHC class I. Images were captured using computerized images analyser (Zeiss 
KS300) at X 200 magnification. Papilloma cells that expressed E7 (a), but not E5 
(b) still had detectable MHC class I (c) as indicated by arrows in enlarged areas. 
Papilloma cells that did not express E7 (d) but expressed E5 (e) had no MHC class 
I (f) as indicated by circles, (a, b and c) xlOO magnification, (d, e and ^  x200 
magnification.
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Figure 8 Co-expression o f  MHC class I and BPV-4E7 in bovine papillomas
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3.1.6 Evaluation of the cell proliferative state in papillomas
In vitro, E5 has been shown to have several biological activities which manipulate 
cell functions and lead to cell transformation. To evaluate the proliferative state of 
papilloma cells, proliferation marker Ki67 expression was used to assess the 
relationship between E5 expression and cellular proliferation. The Ki-67 is a 
proliferation antigen which is expressed during all phases o f the cell cycle. 
However, Ki67 antigen is consistently absent in quiescent cells (GO) and is not 
detectable during DNA repair processes (Hall et al 1993). The Ki67 antigen is 
predominantly localized in the perinuclear region and has an important role in the 
maintenance and regulation of the cell division. Ki-67 is currently considered to be 
the best proliferative marker for clinical use because of its reliability and simplicity 
(Brown and Gatter 1990; Mengel et al 2002). Serial sections of normal tissues and 
papillomas were either incubated with E5 antiserum or with mAb MIB-1 for 
detection of expression of the proliferation antigen Ki67 as described in section
2.2.9. As expected, in normal epithelium, expression of Ki67 was restricted to 
basal and suprabasal cells and was absent in differentiated cells (figure 9a) because 
these cells once differentiated are no longer permitted to proliferate. In contrast, in 
papilloma, expression of Ki67 was detected in the basal cells and in E5-expressing 
differentiated kératinocytes (figure 9b). Except from basal cells that did not show 
E5 expression, expression of Ki67 was remarkably associated with expression of 
E5 (figure 9c). Although, sequences analysis has revealed that BPV-4E7 shares 
homology with HPV-16E7, it contains an LXCXE motif that binds the Rb protein 
thus contributing to cell cycle progression. However, it is not proved yet whether 
BPV-4E7 contributes to cell cycle progression by interfering with Rb function. In 
contrast, based on in vitro data, BPV-4E5 has been shown to induce proliferation
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of cells maintained in suspension and in low serum and cellular growth was 
correlated with an increase in cyclin A and cdk expression (O'Brien and Campo 
1998). For BPV-4, expression of E5 has been shown in previous literature (O'Brien 
and Campo 1998) to be more effective on the cell cycle progression than BPV- 
4E7. It should be noted however, that although BPV-4E7 possess the relevant 
m otif associated with binding o f Rb, this has not been formally proven. In addition, 
no correlation was made between BPV-4 E7 and Ki67 expression in papillomas. 
These results would suggest that expression of BPV-4 E5 in papillomas delays 
cellular differentiation by interfering with normal regulators of cell cycle and 
induces post-mitotic cells to re-inter S-phase and establish proliferation.
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Figure 9. Expression of the proliferation marker Ki67 in papillomas. 
Representative papilloma sections were either incubated with mAh MIB-1 at 
dilution 1:200 for detection o f Ki67 or with E5 antiserum at dilution 1:2000 for 
detection o f BPV-4 E5. Normal sections from gastrointestinal tract were also 
stained with mAb MIB-1. Slides were microscopically examined by looking at E5 
staining patterns in particular areas and matching them with the same areas in the 
section stained for Ki67. Images were captured using computerized images 
analyser (Zeiss KS300) at x 100 and x 200 magnification, a) In normal section, only 
a few cells in the basal layer were positive for Ki67. b) In papillomas, in addition 
to its detection in the basal cells, Ki67 was detected in the cells o f the upper layers 
which had detectable BPV-4E5 (c) as indicated by rectangles and enlarged areas, 
(a and the bottom of b and c) x200 magnification, the top o f b and c xlOO 
magnification.
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Figure 9 Co-expression o f Ki67 and BPV-4E5 in bovine papillomas
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3.2 BPV-4 E5 protein does not down regulate bovine non classical MHC I 
3.2.1 Introduction
BPV-4 E5 protein causes a significant reduction in the expression o f MHC class I 
molecules on the cell surface. Cells that express no or low levels of MHC class I 
on the cell surface are subjected to natural killer NK cell lysis. It has been shown 
that human non classical molecules of MHC class I (HLA-E) is a major legend for 
the CD94-NKG2 receptors expressed by natural killer (NK) cells. Interaction 
between HLA-E and NK receptors blocks the action of the activation receptors and 
inhibits the NK cells from being activated. Therefore, the presence o f non classical 
molecules on the cell surface protects cells from NK cytotoxicity. The non- 
classical MHC class I molecules show homology to classical class I molecules but 
generally have limited polymorphism, low cell surface expression, and more 
restricted tissue distribution (Shawar et al 1994). It has been shown that several 
viruses are capable of inhibiting classical MHC I but do not inhibit non-classical 
MHC I thus escaping both CTLs and NK cells. It has been demonstrated that the 
human immunodeficiency virus (HIV) N ef and human cytomegalovirus (HCMV) 
US10/UL40 proteins down-regulate HLA-A/B but do not dovra-regulate HLA- 
C/E, which are mostly involved in positive selection of inhibitory receptors on NK 
cells (Brand et al 2002; Wang et al 2002).
3.2.2 Generation of mouse F815 cells expressing bovine MHC class I
Unlike human non classical HLA-E which, can be detected by specific antibody, 
non classical MHC class I can not be detected in bovine cells expressing classical 
molecules, because the available antibody IL-A88 cross reacts with all bovine
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MHC class I heavy chains. To determine whether BPV-4 E5, like HPV-16 E5 
(Ashrafi et al 2005), is incapable o f down-regulating certain non-classical MHC 
genes, we used a mouse mastocytoma P815 cell line either transfected with bovine 
classical (pcDNA6-V5-His-V*(?75f?/^, or bovine non classical (pcDNA6-V5-His- 
N*50001;M HC class I.
N^01301 is one o f bovine classical MHC I genes originally termed HD6. N^0I301  
belongs to the A18 haplotype, which is one of the extensively characterized 
haplotypes (Ellis et al 1996). N*50001 is a bovine non-classical class I gene, first 
identified in 1995 when it was termed G em  X  and more recently termed HD59 
(Ellis et al., 1996). N"^50001 and other putative bovine non-classical class I gene 
HD 15, are not closely related to any of the bovine classical class I genes (Holmes 
et al 2003). N'^SOOOl encodes a HC with a truncated cytoplasmic domain (8 rather 
than 28 amino acids), and in this respect resembles human HLA-G (Geraghty et al 
1987). The N^50001 cDNA and N*01301 cDNA were introduced into the mouse 
cell line P815, giving rise to P815-N*50001 cells and P815-N*01301 cells. There 
was no need to co-transfect the bovine microglobulin (Pzm) gene with the 
bovine MHC HC genes into P815 cells because the bovine class I HC associates 
with mouse P2in, and when the complex reaches the cell surface it rapidly 
exchanges mouse Pzm with bovine (32m provided by the foetal calf serum in the 
culture medium (Ellis et al., 2005). Transfected PS 15 cells were selected in 
medium containing lOpg/ml Blasticidin for 21 days. Positively selected cells were 
screened for PIC expression by FACS analysis (figure 10a) and western blot (figure 
10b) with mAh IL-A88. Both sets of results showed that bovine classical and non 
classical MHC I are expressed in P815 cells. No cross reaction o f mAb IL-A88 
with mouse MHC I was observed (figure 1 Ob lane 3)
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Figure 10. Expression o f N*01301 and N *50001 inP815 cells. Parental P815 cells 
were either transfected with bovine classical N*0130l or non classical N *50001 
MHC class I, selected in medium containing lOpg/ml Blasticidin for 21 days and 
positively selected cells were stained with mAb IL-A88 for MHC I expression, (a- 
1) FACS analysis histograms representing both surface and total expression of 
N*01301. (a-2) FACS analysis histograms representing both surface and total 
expression of N*50001. In a-1 and a-2, NPA represents N*01301 and N*50001 
cells stained with secondary antibody only, (b) immunoblotting of N*01301 (lane 
1) and N *50001 (lane 2) heavy chains, no cross reaction of mAb IL-A88 with 
mouse MHC I was observed (lane 3).
137
Chapter 3: Results
Figure 10 Expression o f bovine MHC class I in P815 cells
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3.2.3 BPV-4 E5 constructs
BPV-4 E5 ORE was available into two different vectors: pcDNA and pZipneo 
giving rise to pc4E5 and pZip4E5 respectively (obtained from Dr Ashrafi, 
University of Glasgow). pcDNA is a universal expression vector in which the 
inserted gene is under the control of the CMV early promoter, pZipneo is a plasmid 
in which expression is directed by MoMuLV long terminal repeat LTR promoter. 
The sequence coding for the influenza virus haemaagglutinin type-1 (H A l) epitope 
was inserted at the 5’ of the E5 sequences.
3.2.4 Transfection of BPV-4 E5 in P815 cells
Mouse mastocytoma P815 cell lines (control and expressing bovine HC) were 
stably transfected with a range of plasmid DNA, pcDNA, pc4E5, pZipneo, and 
pZip4E5, by using either transfection reagents (GeneJuice) or the Nucleofector 
apparatus (Amaxa- Germany), to investigate the role of BPV-4 E5 on MHC class I. 
One day prior to transfection, Ix 10^P815 cells were placed in 6-well plates with 
appropriate medium and incubated at 37°C in 5% CO2 overnight following the 
transfection protocol as described in section 2.2.18. For introduction o f BPV-4 E5 
by Nucleofector, Ix 10  ^cells were pelleted and resuspended in 100 pi transfection 
reagent (Mouse cells transfection kit). After adding 4pg of the plasmid DNA to the 
cell mixture, cells were applied to Nucleofector following the transfection 
protocol. Following transfection, the cells were selected in medium containing 
500pg/ml G418 for 21 days.
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3.2.5 Expression of BPV E5 in P815 cells
BPV-4 E5 is a very small hydrophobic protein, only 42 amino acids long and it is 
expressed at low levels in cells (Anderson et al 1997). Introduction of pZip4E5 
into PS 15 cells by using Gene Juice did not give satisfactory results and cells did 
not survive selection even after co-transfection with pZip plasmid carrying pT24 
activated ras gene and pZipBPV-4 E7 (Jaggar et al 1990; Pennie et al 1993). When 
the E5 plasmid was changed to pc4E5 instead o f pZip4E5, transfectants could be 
selected. E5 DNA was detected by PGR (figure 11a) using the following primers: 
4E5 Forward 5’ CCA TAG GAT GTT CCA GAT TAG GCT 3% 4E5 Reverse 5’ 
CCA TCC ATC TAA CCG AGT AAT AGT 3’. However, despite the presence of 
the E5 ORF, there was no E5 expression when examined by quantitative RT-PCR, 
although actin RNA was easily detected (figure 1 lb). Nucleofector is very useful 
tool for introducing genes of interest in many cell lines; this could be due to the 
production of high electrical pulses that help introducing the gene into the cell 
genome. By using Nucleofector, many more E5 transfectants were isolated from 
these cells. RNA was isolated, purified from any residual DNA and typically 1 pg 
of purified RNA from each sample was used for quantitative RT-PCR. We 
analysed two pc4E5 and two pZip4E5 pools expressing N"^01301 or 50001 for 
the presence o f E5 transcripts (figure 12a 1,2,3). In each experiment, additional 
reactions, with 10 fold serial dilutions of template DNA, were performed with each 
set of primers and probes on the same 96-well plates to generate standard curves. 
Quantitive RT-PCR was used to determine the relative amount of BPV-4 E5 and 
mouse P-actin inRNA in triplicate experiments for each E5 transfected cell line and 
cells carrying empty vectors by using a standard curve (figure 12b). The results 
show that all of the transfected cells (pc4E5 and pzip4E5) express the E5 gene but
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at 1,000 fold less than P-actin. As expected, no E5 RNA was detected in the 
control cells. This low level of E5 expression is in agreement with previous results 
in virto consistently obtained in all BPV-4 E5-transfected NIH 3T3 and bovine 
PalF cell lines (Ashrafi et al 2002; Marchetti et al 2002).
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Figure 11. Detection o f BPV-4E5 by PCR. DNA samples from P815 cells 
transfected with BPV-4E5 by using Gene Juice were extracted and amplified using 
appropriate primers for detection o f BPV-4E5 DNA. E5 fragment was detected in 
samples extracted from cells expressing N *01301 and N*50001. 11a; lane 1 DNA 
marker; lane 2, no template; lane 3, N*01301pcDNA; lane 4, N*01301pc-4E5; 
lane 5, N*50001pcDNA; lane 6, N*50001pc-4E5; lane 7, 4E5 plasmid. 
Quantitative RT-PCR shows no E5 expression in P815 cells in which E5 ORF was 
detected, although actin RNA was easily detected (b).
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Figure 11 Detection o f BPV-4E5 DNA but not E5 mRNA in P815 cells
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Figure 12. Taq-Man RT-PCR was used to determine the expression o f BPV-4E5 
mRNA in P815 cells transfected by using Nucleofector. (a) The expression of 
BPV-4 E5 RNA and actin mRNA was determined in P815 control cells (pcDNA 
and pZip) or cells expressing BPV-4E5 (two pc4E5 and two pZip4E5 pools 
expressing N*01301 or N*50001), a-1 represents expression of E5 mRNA in 
P815-N*01301 cells, a-2 represents expression o f E5 mRNA in P815-N*50001 
cells, while a-3 represents expression o f E5 mRNA both in P815-N*01301 and 
P815-N*50001 cells. The histograms represent the average with standard deviation 
of six independent measurements, (b) Note that the levels o f E5 RNA are three 
orders of magnitude lower than those o f p-actin RNA.
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Figure 12 Expression o f BPV-4E5 mRNA in transfected P815 cells
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3.2.6 Expression of bovine classical MHC class I in P815 cells expressing BPV- 
4E5
To determine the expression of classical N*01301 in E5 cells, flow cytometry 
experiments were performed as described in section 2.2.40. P815-N*01301 cells 
harbouring empty vector or expressing BPV-4E5 were incubated with mAb IL- 
A88, and analysed for levels o f both surface and total N*01301. The results show 
that in cells carrying pZip empty vector, there was a remarkable shift in 
fluorescence for both surface and total ofN *01301 when compared with cells 
stained with only FITC conjugated secondary antibody (figure 13a-l). In contrast, 
in cells expressing BPV-4B5, there was a remarkable reduction both in surface and 
total expression of N*01301 as indicated by a reduction of fluorescent shift when 
compared with control cells (figure 13a-2). To quantify the level of surface and 
total of N *01301, at least four experiments were performed and the mean of 
forward fluorescence shift was calculated. There was very little surface MHC class 
I, with a reduction of more than five fold compared to control cells carrying empty 
vector, and also the amount of total MHC class I was less than half o f that in 
control cells (figure 13b). There was no difference between results obtained with 
P815-N*01301-pc4E5 cells and with P815-N*01301-pz4E5. The results confirm 
that 4E5 is capable o f down-regulating MHC class I in agreement with previous 
work in vitro (Ashrafi et al 2002; Marchetti et al 2002). Also the results show that 
BPV-4E5 is capable o f down-regulating MHC class I in the absence o f any other 
viral oncogene.
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Figure 13. BPV-4E5 down-regulates surface and total classical N*01301 MHC 
class I. a-1) Example o f flow cytometry profiles of surface and total classical 
N*01301 MHC class I in P815 control cells (pZip) stained with mAh IL-A88. a-2) 
Example of flow cytometry profiles from P815-N*01301 cells expressing E5 (pZ- 
4E5) stained with mAh IL-A88. NPA, no fluorescence shift from N*01301pZip or 
N*01301pZ-4E5 cells stained with FITC conjugated secondary antibody only (a-1 
and a-2). b) Mean forward fluorescence with standard deviation calculated from 
the flow cytometry profiles of surface and total classical N*01301 MHC class I in 
P815 control cells (pcDNA and pZip) or cells expressing E5 (pc-4E5 and pZ-4E5) 
o f at least four independent experiments in duplicate.
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Figure 13 BPV-4E5 down-regulates expression o f surface and total N*01301
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3.2.7 Expression of bovine non-classical MHC class I in P815 cells expressing 
BPV-4E5
To determine the expression of non classical P815"N*50001 in E5 cells, flow 
cytometry experiments were performed as described in section 2.2.40. P815-
N* 50001 cells harbouring empty vector or expressing BPV-4E5 were incubated 
mAb IL-A88, analysed for levels of both surface and total N* 50001. The results 
showed there was no significant difference either in surface or total expression of 
N* 50001 between empty vector and E5 cells, indicated by the similarity in 
fluorescence shift between empty vector and E5 cells (figure 14a-1,2 respectively). 
To quantify the level o f surface and total non classical MHC I in E5 cells, at least 
four experiments were performed and the mean o f forward fluorescence shift was 
calculated. The results showed that expression of N* 50001 was not at all affected 
by E5 and the levels of surface or total MHC I were indistinguishable from those in 
control cells (figure 14b). There was no difference between results obtained with 
P815-N*50001-pc4E5 cells and with P815-N*50001-pZ4E5. The results show that 
BPV-4E5 is incapable of down regulating non-classical MHC I.
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Figure 14. BPV-4E5 does not down-regulate surface and total non classical 
N *50001 MHC class I. a-1) Example of flow cytometry profiles o f surface and 
total non classical N*50001 MHC class I in P815 control cells (pZip) stained with 
mAh IL-A88. a-2) Example o f flow cytometry profiles of surface and total non 
classical N*50001 MHC class I in P815 cells expressing E5 (pZ-4E5) stained with 
mAh IL-A88. NPA, no fluorescence shift from N*50001pZip or N*50001pZ-4E5 
cells stained with FITC conjugated secondary antibody only (a-1 and a-2). b) Mean 
forward fluorescence with standard deviation calculated from the flow cytometry 
profiles of surface and total non classical N*50001 MHC class I in P815 control 
cells (pcDNA and pZip) or cells expressing E5 (pc-4E5 and pZ-4E5) of at least 
four independent experiments in duplicate.
152
Chapter 3: Results
Figure 14 BPV-4E5 does not down-regulate N*50001
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3.2.8 Localization of classical MHC class I in P815 cells
In PalF-4E5 cells, E5 retains the MHC class I in the Golgi apparatus (Marchetti et
ai., 2002). We wondered whether the reduction in surface N *01301-MHC class I
.was also due to the retention o f residual complex in the Golgi. We performed two- 
colour confocal immunofluorescence in the various P815 cell lines where classical 
MHC class I were detected with mAh IL-A88 and a FITC-conjugated secondary 
antibody, and the Golgi apparatus was detected with Bodipy Ceramide-Texas Red.
The cells were examined in a Leica TCS SP2 true confocal scanner microscope.
The merge between FITC and Texas Red fluorescent signals was achieved using
. ■the Leica TCS SP2 accompanying software. The results showed that in all control 
cells, N*01301 was both associated with the Golgi membranes and clearly on the 
cell surface (figure 15a). In contrast, the cellular localisation of N*01301-MHC 
class I was markedly different in P815 cells expressing E5. Classical N*01301- 
MHC class I was totally associated with Golgi membranes and was not detectable 
on the cell surface by this technique (figure 15h). There was no difference between 
results obtained with P815-N*01301-pc4E5 cells and with P815-N*01301-pz4E5. 
These results confirm that BPV-4E5 cause a reduction of the surface expression of 
classical MHC I by retaining it in Golgi apparatus.
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Figure 15. BPV-4E5 induces retention o f N*01301 in Golgi apparatus o f P815 
cells. Two-colour confocal immunofluorescence was used to visualize Golgi 
apparatus and MHC class I. P815-N*01301 control cells (pcDNA and pZip) or 
cells expressing BPV-4 E5 (P815pc-4E5 and P815pZ-4E5) were stained with mAh 
IL-A88 and a FITC-conjugated secondary antibody, and the Golgi apparatus was 
detected with Bodipy Ceramide-Texas Red. The cells were examined in a Leica 
TCS SP2 true confocal scanner microscope. The merge between FITC and Texas 
Red fluorescent signals (orange) was achieved using the Leica TCS SP2 
accompanying software, a) The cellular localization of N*01301 in control cells, b) 
The cellular localization o f N*01301 in E5 cells. Single cells at the bottom of the 
panels are shown for greater detail. Cells in panel a-1, a-2 and cells in the lower 
panels o f b-1 and b-2 were captured at magnification x400, cells in the upper 
panels of b-1 and b2 were captured at x200.
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Figure 15 Localization ofN*01301 in P815 cells expressing BPV-4E5
P815-N*01301pZip
P815-N*01301pcDNA
157
Chapter 3: Results
P815-N*01301pc-4E5
b - 2 P815-N*01301pZ-4E5
158
Chapter 3 : Results
3.2.9 Localization of non classical MHC class I in P815 cells
To determine the cellular localization o f non-classical N*50001-MHC I, P815- 
N* 50001 cells were stained with mAh IL-A88 and a FITC-conjugated secondary 
antibody and the Golgi apparatus was detected with Bodipy Ceramide-Texas Red. 
The cells were examined in a Leica TCS SP2 true confocal scanner microscope. 
The merge between FITC and Texas Red fluorescent signals was achieved using 
the Leica TCS SP2 accompanying software. The result showed that in E5 cells, 
N *50001-MHC I was clearly on the cell surface (figure 16b) and no different from 
control cells in its localization pattern both in Golgi apparatus and on the cell 
surface (figure 16a). There was no difference between results obtained with P815- 
N*50001-pc4E5 cells and with P815- N*50001-pZ4E5. These results show that 
BPV-4E5 does not interfere with transport o f non classical MHC I to the cell 
surface.
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Figure 16. BPV-4E5 does not retain N*50001 non classical MHC I in Golgi 
apparatus of P815 cells. Two-colour confocal immunofluorescenc was used to 
visualize Golgi apparatus and MHC class I. P815-N*50001 control cells (pcDNA 
and pZip) or cells expressing BPV-4 E5 (P815pc-4E5 and P815pZ-4E5) were 
stained with mAh IL-A88 and a FITC-conjugated secondary antibody, and the 
Golgi apparatus was detected with Bodipy Ceramide-Texas Red. The cells were 
examined in a Leica TCS SP2 true confocal scanner microscope. The merge 
between FITC and Texas Red fluorescent signals (orange) was achieved using the 
Leica TCS SP2 accompanying software, a) The cellular localization of N *50001 in 
control cells, b) The cellular localization of N*50001 in E5 cells. Single cells at the 
bottom of the panels are shown for greater detail. Cells in the upper of a-1 and in 
the lower of a-2 and cells in b-1 and upper b-2 were captured at magnification 
x400, cells in the lower o f a-1 were captured at x600, and cells in upper a-2 were 
captured x500 magnification and x300 magnification in lower b-2.
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Figure 16 Localization ofN*50001 in P815 cells expressing BPV-4E5
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3.2.10 BPV-4 E5 protein does not down-regulate bovine non-classical MHC 
class I in PalF cells.
To confirm the results obtained in P815 cells in which BPV-4 E5 does not down 
regulate bovine non classical (N* 5 0001) MHC class I, primary embryonic bovine 
cells (PalF) transformed by papillomavirus oncogenes, with or without BPV-4 E5 
as described by Jaggar et al (1990) were used. These cells express either BPV-4E5, 
BPV-4E7, HPV-16E6 and activated ras (PalF-4E5) or BPV-4E7, HPV-16E5 and 
activated ras (PalF-noE5). The V*5966icDNA was excised from pcDNA6-V5-His 
and sub-cloned in pFLAG expression vector. This plasmid was transiently 
transfected into PalF-4E5 and palF-noE5 cells and N*50001-MHC class I was 
detected with monoclonal anti-FLAG antibody and a FITC-conjugated secondary 
antibody, and the Golgi apparatus was detected with Bodipy Ceramide-Texas Red. 
The cells were examined in a Leica TCS SP2 true confocal scanner microscope. 
The merge between FITC and Texas Red fluorescent signals was aehieved using 
the Leica TCS SP2 accompanying software. The result showed that in PalF-4E5 
cells, N* 50001 was clearly on the cell surface (figure 17b) and no different from 
the one in control (no E5) PalF cells in its localization pattern both in Golgi 
apparatus and on the cell surface (figure 17a). This result confirm that BPV-4E5 
does not interfere with transport o f N* 50001-MHC class I to the cell surface. To 
confirm that BPV-4E5 does retain classical MHC I in the Golgi apparatus, an 
available GFP expression vector carrying human classical MHC I (B2705) 
(Marchetti et al 2002) was transiently transfected into PalF-4E5 or noE5 PalF cells. 
The result showed that in no E5 palF cells, in addition to its localization in the 
cytoplasm, B2705 was clearly on the cell surface (figure 17c-l). In contrast, in 
PalF E5 cells, the localization o f B2705 was almost exclusively in the GA and no
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MHC could be detected on the cell membrane (figure 17c-2). It is to be noted that 
the Golgi apparatus is deformed in PalF-4E5 cells as described by (Ashrafi et al 
2002; Marchetti et al 2002). Furthermore, the morphology of Golgi apparatus was 
abnormal in E5 PalF cells. This result confirms in agreement with (Ashrafi et al 
2002) that down-regulation of MHC I by BPV-4E5 is species independent.
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Figure 17. BPV-4 E5 does not retain N *50001 MHC class I in Golgi apparatus of 
PalF cells. 50001 cDNA was cloned into pFLAG expression vector and 
transfected into PalF-4E5 and PalF-noE5 cells. N*50001-MHC class I was 
detected with monoclonal anti-FLAG antibody and a FITC-conjugated secondary 
antibody, and the Golgi apparatus was detected with Bodipy Ceramide-Texas Red. 
The cells were examined in a Leica TCS SP2 true confocal scanner microscope. 
The merge between FITC and Texas Red fluoreseent signals was achieved using 
the Leica TCS SP2 accompanying software, a) Shows the localization of N *50001 
in PalF-no E5 cells; b) Shows the localization of N*50001 in PalF-4E5 cells; c) 
shows the localization o f B2705 human classical MHC I in PalF-4E5 and PalF-noE 
cells. Cells in panels (a, b and c) were captured at x800 magnification.
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Figure 17 BPV-4E5 does not downregulate surface expression o f N*50001 in PalF cells 
a) PalF no E5-N*50001
b) PalFE5-N*50001
C-1 PalF-no E5 C-2 PalF-4E5
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3.3.1 Detection of classical and non-classical MHC I heavy chains in P815 cells
The results above show that BPV-4 E5 causes a reduction in the level of total 
N*01301-MHC class I, but not of N *50001-MHC I. To confirm this observation, 
western blot experiments were performed on protein extracts from N*01301 and 
N *50001-MHC I in P815 cells either expressing E5 or carrying empty vector. The 
membranes were incubated with mAh IL-A88, which detects all bovine MHC I 
heavy chains. The result showed that there was less N*01301 expressed in P815- 
N*01301-pc4E5 or P815-N*01301-pZE5 cells than in the control cells (Figure 
18a); on the contrary, the expression of N*50001 was unchanged in P815- 
N*50001-pc4E5 or P815-N=^50001 -pZ4E5 cells, although in control cells it was 
lower than that of N*01301. In agreement with (Ashrafi et al 2002; Marchetti et al 
2002), these results confirm that BPV-4E5 in contrast to HPV-16E5 causes a 
remarkable reduction both surface and total MHC I.
3.3.2 BPV-4 E5 protein causes degradation of bovine classical MHC I heavy 
chain but not non-classical heavy chain in P815 cells.
To investigate if  the reduction o f the total amount of MHC classes I in E5 cells is 
due to protein degradation and also to investigate whether E5 affects non-classical 
MHC class I protein stability. Control cells and E5 expressing P815 cells were 
treated with cyclohexamide to allow quantification of protein stability in E5 cells. 
Cyclohexamide is an inhibitor of protein biosynthesis as it blocks translational 
elongation, therefore allowing analysis of half-life of pre-existing proteins. Treated 
cells were harvested after 1,2, 5, 10, and 24 hours of cyclohexamide treatment and 
protein samples were extracted, elctrophoresed and transferred on nitrocellulose 
membranes as described in section 2.2.45. For detection of MHC I, membranes
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were incuhated with mouse mAh IL-A88, for detection of actin as control with 
mAh AB-1 as described in section 2.2.47. Similar experiments were performed on 
protein extracts from cells treated with DMSO, the solvent for cyclohexamide. In 
control cells, N*01301 was stable and could still be detected after 24 hours of 
treatment (figure 18b-l); in remarkable contrast, in the 4E5-expressing cells 
N*01301 was unstable and was practically undetectable after 10 hours of treatment 
(figure 18b-2). There was no difference between the stability of N* 50001 in 
control or 4E5-expressing cells; in both cases N*50001 HC was still detectable 
after 24 hours of treatment (figure 18b-3,4), comparable to that ofN *01301 in 
control cells. There was no effect of DMSO on N*50001 or N*01301 heavy chain 
stability either in control or 4E5-expressing cells (figure 18c). These results show 
that BPV-4 E5 causes degradation of classical MHC I heavy chain. The results also 
show that E5 does not disrupt expression, half-life and transport of non-classical 
N*50001-MHC class I. It has been shown in PalF cells that BPV-4E5 inhibits 
MHC I heavy chain gene transcription (Marchetti et al 2002). The effect o f E5 on 
transcription of MHC I HC could not be investigated in this system because MHC 
I is transcribed under control of immediate early (IE) promoter of cytomegalovirus.
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Figure 18. BPV-4 E5 induces degradation o f classical N*01301 MHC class I heavy 
chain but not non-classical N*50001 heavy chain. For detection of N*01301 and 
N*50001 MHC class I, the membranes were incubated with the mAb IL-A88 
specific for MHC class I heavy chain and mAb AB-1, specific for p-actin. a) 
Steady state levels of classical N*01301 heavy chain in P815 control cells (pcDNA 
and pZip) lane 1 and lane 6 respectively. There is a reduction in N*01301 heavy 
chain in E5 cells (pc-4E5 lane 2 and pZ-4E5 lane 7). There is no difference 
between levels of non-classical N*50001 heavy chain in P815 control cells 
(pcDNA lane 3 and pZip lane 8) and cells expressing E5 (pc-4E5 lane 4 and pZ- 
4E5 lane 9), but there are comparable amounts o f p-actin in all cell lines, b) Half- 
life measurement o f classical N*01301 and non-classical N*50001 heavy chain in 
cyclohexamide-treated P815 control cells and cells expressing E5 cells, panel (1) 
represents N*01301 HC in control cells; panel (2) represents N*01301 HC in B5 
cells; panel (3) represents N*50001 HC in control cells and panel (4) represents 
N*50001 HC in E5 cells. N*01301 HC in E5 cells was detected up to 
approximately 5 hours and disappeared after 10 hours o f treatment whereas 
N* 50001 HC can still be detected after 24 hours of treatment as indicated by red 
circles, c) P815 control cells and cells expressing E5 were treated with DMSO for 
different periods of time (1-24 hours), panel (1) represents N*01301 HC in control 
cells; panel (2) represents N*01301 HC in B5 cells.
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Figure 18
a- BPV-4E5 reduces expression ofN*01301 heavy chain
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b) BPV-4E5 causes degradation ofN*01301 heavy chain
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c) Protein blots from treated cells with DMSO as control
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3.4 The C-terminal domain of BPV-4 E5 is responsible for down-regulation of 
MHC class I
The C-terminal tail o f E5 has an integral role in the function of the protein. The C 
terminus truncated form of E5 (E5T), comprises only the first 32 amino acid 
residues (O'Brien et al 1999). E5T is not transforming, does not induce the typical 
morphological changes brought about by E5, does not distort the GA and does not 
down-regulate MHC I (Ashrafi et al 2000; Ashrafi et al 2002). E5 physically 
interacts with MHC class I heavy chain and this interaction is mediated by the C 
terminal tail of E5 (Marchetii et a l ,  2006) indicating that interaction between E5 
and HC is partially responsible for down-regulation of MHC I. To determine 
whether the C-terminus tail o f E5 is responsible for retention of MHC I in the 
Golgi apparatus, PalF cells expressing 4E5T or not were incubated with BODIPY 
ceramide TR for Golgi visualization. For detection of MHC I, cells were incubated 
with mAh IL-A88 and antimouse IgG FITC-conjugated secondary antibody. The 
cells were examined in a Leica TCS SP2 true confocal scanner microscope. The 
merge between FITC and Texas Red fluorescent signals was achieved using the 
Leica TCS SP2 accompanying software. The result showed that the localization of 
MHC I on the cell surface was not disrupted in cells expressing E5T (figure 19b), 
and was similar to control cells, being found both in the Golgi apparatus and on the 
cell surface (figure 19a). In agreement with (Ashrafi et al 2002; Marchetti et al 
2002), these results confirm that the C-terminal tail o f BPV-4E5 is responsible for 
down-regulation of MHC I.
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Figure 19. Surface localization o f MHC class I in control PalF cells (a), and in cells 
expressing BPV-4 E5T (h). MHC class I was detected with mAh IL-A88 and 
FITC-conjugated secondary antibody (green) and the Golgi apparatus with 
BODIPY-TR-ceramide (red) in a Leica TCS SP2 confocal scanner microscope. 
The merge between the FITC and Texas Red fluorescent signals was achieved 
using the Leica TCS SP2 accompanying software. Cells in panels (a and b) were 
captured at x 1,200 magnification.
174
Chapter 3 : Results
Figure 19 The C-terminal tail o f BPV-4E5 is essential for down-regulation of MHC I
PalF-no E5
PalF-E5T
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3.5 HPV-16 E5 protein down-regulates human MHC class I (HLA) molecules
Mouse mastocytoma P815 cell lines were extremely useful in the investigation of 
the effects o f BPV-4 E5 on bovine classical and non classical MHC class I, since 
classical and non classical MHC I can not be distinguished in bovine cells. 
Furthermore, P815 cells provided definite proof that E5 can interfere with classical 
MHC class I pathways by itself. Down-regulation of classical EILA-A and B by 
FIPV-16 E5 protein, but not o f HLA-E and HLA-C, has been reported in 
immortalized human kératinocytes (Ashrafi et al 2005). To investigate the effect of 
HPV-16E5 on the expression of HLA-A2 and HLA-E separately fi'om each other 
and from other HLA molecules, as mAh DT9 does not distinguish between HLA-C 
and HLA-E, P815 cells were transfected with pcl6E5 prior to introducing HLA-E 
or HLA-A2.
3.5.1.1 Introduction of HPV-16E5 into P815 cells
Parental P815 cells were stably transfected with 4pg of either pcDNA or pcl6E5 
by using Nucleofector (Amaxa- Germany) according to manufacturer instructions. 
Positive selection of transfectants was achieved by growing cells in medium 
containing G418 as described in section 2.2.19.
3.5.1.2 HPV-16 E5 expression in P815 cells
Like BPV-4 E5, HPV-16 E5 is expressed at low levels in cells and there is no 
dependable antibody for detection o f E5 protein. Therefore, we investigated the 
transcription of the E5 ORE in P815 cells using quantitative RT-PCR. RNA was 
isolated, purified from any residual DNA and typically 1 pg of purified RNA was 
used for each sample. We analysed two pc-16E5 representing two P815 pools for
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the presence of E5 transcripts. Probes and primers for H PV I6 E5 and mouse (3- 
actin were designed using the primer Express Software programme (refer to page 
103). In each experiment, additional reactions, with 10 fold serial dilutions of 
template DNA, were performed with each set of primers and probes on the same 
96-well plates to generate standard curves. Quantitive RT-PCR was used to 
determine the relative amount o f HPV-16 E5 and P-actin inRNA in triplicate 
experiments of each E5 transfected cell line and from cells carrying empty vectors 
by using a standard curve (figure 20a). The results show that all of the transfected 
cells (pcl6E5) express the E5 gene but at 10,000 fold less than P-actin (figure 
20b). As expected, no E5 RNA was detected in the control cells. This low level of 
E5 expression is in agreement with, Ashrafi et al, 2005, in all HPV-16 E5- 
transfected HaCaT, NIH 3T3 and bovine PalF cell lines.
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Figure 20. Taq-Man RT-PCR was used to determine the expression o f E5 mRNA in 
the transfected P815 cells, a) The expression of HPV-16 E5 RNA and actin mRNA 
was determined in P815-pcDNA cells or cells expressing HPV-16 E5 (pcl6E5), (two 
pools o f pcl6E5). b) The histograms represent the average with standard deviation of 
four independent measurements. Note that the levels of E5 RNA are four orders of 
magnitude lower than those o f P-actin RNA.
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Figure 20
a) Expression o f HPV-16 E5 RNA in transfected P815 cells
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b) Quantitative HPV-16E5 and actin RNA in transfected P815 cells
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3.5.1.3 Introduction of HLA-A2 cDNA into P815-16E5 cells
To determine the effect of HPV E5 on expression of HLA-A2, HLA-A2 cDNA 
was firstly excised from the pBLuescript II SK (+) plasmid using digestion 
enzymes and recloned in pcDNA6 plasmid as described in section 2.2.21. 
Secondly, P815 cells carrying empty vector or cells expressing 16E5 were 
transfected with HLA-A2 cDNA using Nucleofector (Amaxa- Germany) according 
to manufacturer instructions. Transfectants were selected in medium containing 
blasticidin as described in section 2.2.21.
3.5.1.4 Introduction of HLA-E cDNA into P815-16E5 cells
To determine the effect o f HPV E5 on expression of HLA-E, HLA-E cDNA was 
first amplified by PCR from the pBLuescript II SK (+) plasmid utilizing the 
primers described on page 89 of this thesis, (section 2.2.20). The PCR products 
were sub-cloned into pcDNA6 plasmid as described on page 90 (section 2.2.20). 
Secondly, P815 cells carrying empty vector or cells expressing 16E5 were 
transfected with HLA-E cDNA using Nucleofector (Amaxa- Germany) according 
to manufacturer instructions. Transfectants were selected in medium containing 
blasticidin as described in section 2.2.20. There was no need to co-transfect the 
human p2 microglobulin (pzm) gene with the HLA-A2 and HLA-E HC genes into 
P815 cells because the human class I HC associates with mouse P2m. However, it 
is not known whether human HLA-A2/E HCs exchange mouse P2m with bovine 
P2in provided by the foetal calf serum in the culture medium.
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3.5.2 Expression of HLA in cells expressing HPV-16E5
The effect o f E5 on MHC class I was investigated by FACS, immunofluorescence 
and western blots. FACS was used to determine the surface and total expression of 
HLA class I, immunofluorescence to show the cellular localization of HLA class I, 
and western blots to show the expression o f HLA class I heavy chains in P815 cells 
carrying empty vectors or cells expression HPV-16 E5.
3.5.2.1 Detection of HLA-A2 by FACS analysis
It has been shown that HPV-16 E5 causes the retention of HLA-A/B in the Golgi 
apparatus and prevents its export to the plasma membrane of immortalized HaCaT 
cells (Ashi'afi et al 2005). We extended these observations to investigate the effect 
of HPV-16E5 on HLA-A2 separately from HLA-B molecules. P815-HLA-A2 cells 
harbouring the empty vector pcDNA or expressing HPV-16E5 were incubated with 
anti-HLA class I mAh W6/32, analysed for levels of hoth surface and total HLA 
class I. The results showed that there was no fluorescence shift from parental P815 
cells stained with mAh W6/32 or from P815-HLA-A2 stained with secondary 
antibody only. In control cells, P815-HLA-A2-pcDNA, there was a considerable 
fluorescence shift representing the surface expression of HLA-A2 (figure 21a-l). 
In contrast, in P815-HLA-A2 expressing 16E5, there was a remarkable reduction 
in fluorescence shift for surface HLA (figure 2 la-2) compared with control cells. 
There was no difference in fluorescence shift for total HLA-A2 between control 
and cells expressing 16E5. To quantify the level of surface and total HLA-A2 in 
E5 cells, at least four experiments were performed and the mean o f forward 
fluorescence was calculated. The results showed that P815-HLA-A2 expressing 
HPV-16E5 had approximately 50 % lower surface HLA-A2 than control cells. In
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contrast, there was no significant difference in total HLA-A2 level between control 
and cells expressing HPV-16E5 (figure 21b). These results confirm that HPV-16E5 
reduces the level of surface HLA-A2 but does not affect its total amount.
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Figure 21. Down-regulation o f HLA-A2 on the cell surface was investigated in 
P815 cells expressing HPV-16 E5. P815-HLA-A2-pcDNA cells or P815-HLA-A2 
cells expressing HPV-16 E5 were stained with mAh W6/32 and analysed for 
expression of surface and total HLA-A2 by FACS, a) Example of flow cytometry 
profiles o f surface and total HLA-A2 in P815 control cells or cells expressing E5. 
b) The mean forward fluorescence with standard deviation calculated from the 
flow cytometry profiles o f at least four independent experiments performed on two 
cell lines.
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Figure 21 HPV-16E5 down-regulates surface expression o f HLA-A2
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3.S.2.2 Detection of HLA-E by FACS analysis
It has been reported that HPV-16E5 does not interfere with surface expression of 
HLA C/E in E5-transformed HaCaT cells by using mAb DT9. This antibody does 
not distinguish between classical HLA-C and non classical HLA-E, hence we 
investigated the specific effect of HPV-16E5 on HLA-E in P815 cells expressing 
only HLA-E. P815-HEA-E-pcDNA or P815-HLA-E-16E5 cells were incubated 
with mAb DT9 and analysed for levels of both surface and total HLA-E. The 
results showed that there was no significant difference in fluorescence shift for 
surface HLA-E in the two cell lines (figure 22a-1, 22a-2). Likewise, there was no 
difference between two cell lines in the total HLA-E. To quantify the level of 
surface and total HLA-E in E5 cells, at least four experiments were performed and 
the mean of forward fluorescence shift was calculated. The levels of surface and 
total o f HLA-E were unaffected in cells expressing HPV-16E5 and were similar to 
the levels o f surface and total HLA-E in control cells (figure 22b). These results 
confirm that HPV-16E5 does not down-regulate non-classical HLA-E.
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Figure 22. HPV-16E5 does not down-regulate non-classical MHC I on the cell 
surface in the transfected P815 cells. P815-HLA-E-pcDNA or P815-HLA-E- 
pcl6E5 were stained with mAb DT9 and analysed for expression of surface and 
total HLA-E by flow cytometry, a) Example o f flow cytometry profiles o f surface 
and total HLA-E in P815 control cells (a-1) or cells expressing E5 (a-2). b) The 
mean forward fluorescence with standard deviation calculated from the flow 
cytometry profiles o f at least four independent experiments performed on two cell 
lines.
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Figure 22 HPV-16E5 does not down-regulate surface expression o f HLA-E
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3.5.2.3 Detection of HLA-A2 by immunofluorescence
In HaCaT-16E5 cells, E5 retains the HLA-A and B in the Golgi apparatus (Ashrafi 
et al 2005). We wondered whether the reduction in surface HLA-A2 in P815 cells 
was also due to the retention of the complex in the Golgi. To investigate the 
cellular localization o f HLA-A2, we performed two-colour confocal 
immunofluorescence in two P815 cell lines. The cell pellet was resuspended in 
fixing solution for 10 min, washed twice in PBS and seeded in poly-L-lysine-pre- 
treated eight-well slide at 2x 10"^  cells/well following the immunofluorescence 
staining protocol. P815-HLA-A2-pcDNA or P815-HLA-A2-pcl6E5 cells were 
stained with mAh W6/32 and a FlTC-conjugated secondai-y antibody, and the 
Golgi apparatus was detected with Bodipy Ceramide-T R. In pcDNA cells, HLA- 
A2 was detected both on the cell surface and in the Golgi apparatus (figure 23 a) 
whereas, in cells expressing HPV-16E5, HLA-A2 was only detected in the Golgi 
apparatus (figure 23b). The result confirms that HPV-16E5 retains HLA-A2 in the 
Golgi apparatus and prevents its transport to the cell surface.
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Figure 23. HPV-16E5 induces retention of HLA-A2 in Golgi apparatus in P815 
cells. Two-colour confocal immunofluorescence. P815-HLA-A2-pcDNA cells or 
cells expressing HPV-16 E5 were stained with mAh W6/32 and a FlTC-conjugated 
secondary antibody, and the Golgi apparatus was detected with Bodipy Ceramide- 
Texas Red, The merge between FITC and Texas Red fluorescent signals (orange) 
was achieved using the Leica TCS SP2 accompanying software, a) The cellular 
localization of HLA-A2 in control cells, b) The cellular localization of HLA-A2 in 
cells expressing E5. Single cells at the bottom of panel (b) are shown for greater 
detail. Cells in panel (a) were captured at x200, and x300 magnification for cells in 
panel (b).
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Figure 23 Cellular localization o f HLA-A2 in P815 cells
P815HLA-A2 pcDNA
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3.S.2.4 Detection of HLA-E by Immunofluorescence
To investigate the cellular localization o f HLA-E, we performed two-colour 
confocal immunofluorescence in two P815 cell lines. P815/HLA-E pcDNA or 
P815/HLA-E pcl6E5 cells were incubated with anti-HLA-C/E mAb DT9 and a 
FlTC-conjugated secondary antibody, and the Golgi apparatus was detected with 
Bodipy Ceramide-T R. The result showed that there was no significant difference 
between empty vector and 16E5 P815 cells in their expression pattern o f HLA-E 
both on the cell surface and in the Golgi apparatus (figure 24a,b). These results 
confirm that HPV-16E5 does not interfere with the transport of HLA-E to the cell 
surface.
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Figure 24. HPV-16 E5 does not retain HLA-E in Golgi apparatus in P815 cells. 
Two-colour confocal immunofluorescence. P815-HLA-E-pcDNA cells or cells 
expressing HPV-16 E5 were stained with mAh DT9 and a FlTC-conjugated 
secondary antibody, and the Golgi apparatus was detected with Bodipy Ceramide- 
Texas Red. The merge between FITC and Texas Red fluorescent signals (orange) 
was achieved using the Leica TCS SP2 accompanying software, a) The cellular 
localization o f HLA-E in control cells, b) The cellular localization o f HLA-E in 
cells expressing E5. Single cells at the bottom of the panels are shown for greater 
detail. The top of panels (a) and (b) are at x200 magnification, the bottom of the 
panels (a) and (b) are at x400 magnification.
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Figure 24 Cellular localization o f HLA-E in P815 cells
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P815-HLA-Epcl6E5
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3.5.2.S Expression of HLA-A2 or HLA-E heavy chains is not inhibited by 
HPV-16E5
The FACS results above showed that there was no difference in the amount of total 
MHC I between control and cells expressing HPV-16 E5, suggesting that HPV-16 
E5 in contrast to BPV-4 E5 does not interfere with MHC I heavy chain synthesis. 
To confirm this observation, immunoblotting analysis was performed in control 
P815- HLA-A2 and P815-HLA-E and in cells expressing HPV-16E5 by using 
mAb HCIO or mAb MEM-E/02 which specifically detect HLA-A and B heavy 
chain or HLA-E heavy chain respectively as described in section 2.2.47. We 
determined that HPV-16 E5 had no influence on HLA-A2 heavy chain (figure 
25a). There was no significant difference in HLA-A2 heavy chain between control 
cells and cells expressing HPV-16 E5 as shown in lane 1 and 3 (mAbHC-10 did 
not cross react with mouse MHC 1). Likewise, there was no significant difference 
between control and E5 cells in their expression of HLA-E heavy chain (figure 
25b) lane 1 and 2. The results confirm that HPV-16 E5 does not affect the 
expression of HLA-A2 and HLA-E heavy chains.
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Figure 25. HPV-16E5 does not affect E1LA-A2 heavy chain or HLA-E heavy 
chain. Immunoblotting analysis was performed in control P815- HLA-A2 and 
P815-HLA-E and in cells expressing HPV-16E5 by using mAb HCIO or mAb 
MEM-E/02 which specifically detect HLA-A and B heavy chain or HLA-E heavy 
chain respectively, a) Detection of HLA-A2 heavy chain in control cells (lane 1) 
and in cells expressing 16E5 (lane 3), lane 2 indicates that mAh HC-10 does not 
cross react with mouse MHC I. b) Detection o f HLA-E heavy chain in control cells 
(lane 1 ) and in cells expressing 16E5 (lane 2).
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Figure 25 HPV-16E5 does not down-regulate expression o f HLA heavy chains
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3.S.2.6 Detection of mouse H2D in P815 cells expressing HPV-16E5 by FACS
It has been shown that BPV-4E5 down-regulates the surface expression of mouse 
Ha-L^ in mouse fibroblast N1H3T3 (Ashrafi et al 2002). To determine the MHC 1 
haplotype expressed in P815 cells, FACS experiment was performed by staining 
both parental P815 cells and NIH3T3 cells with either mAh anti-H2L or mAh anti- 
H2D. We found that H%-D ,^ is the most common MHC 1 haplotype expressed by 
P815 cells. To investigate whether HPV-16E5 like BPV-4E5 causes down- 
regulation of mouse MHC 1 in P815 cells, P815-pcDNA or P815-16E5 was 
incubated mAb anti-H2D, analysed for levels o f both surface H2D. The results 
showed that there was no fluorescent shift from parental P815 cells or P815- 
pcDNA cells stained with secondary antibody only. In control cells, P815-pcDNA, 
there were a considerable fluorescence shift for the surface expression of H2D 
(figure 26a). In contrast, in P815 expressing 16E5, there was a reduction in 
fluorescence shift for surface H2D compared with control cells (figure 26b). To 
quantify the level of surface H2D in E5 cells, at least four experiments were 
performed and the mean of forward fluorescence shift was calculated. The results 
showed that P815 expressing HPV-16E5 had approximately the third lower surface 
H2D than control cells (figure 26c).
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Figure 26. Down-regulation of mouse H2D MHC 1 by HPV-16 E5. P815- pcDNA 
cells or P815 cells expressing HPV-16 E5 were stained with mAb anti-H2D and 
analysed for expression of surface H2D by FACS. Example o f flow cytometry 
profiles o f surface H2D in P815 control cells (a) or cells expressing E5 (b). c) The 
mean forward fluorescence with standard deviation calculated from the flow 
cytometry profiles of at least four independent experiments performed on two cell 
lines.
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Figure 26 HPV-16E5 down-reguiates surface expression of mouse MHC I
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3.5.2.6.1 Detection of mouse H2D by immunofluorescence
In NIH3T3-4E5 cells, E5 retains the H2L in the Golgi apparatus (Ashrafi et al 
2002). We wondered whether the reduction in surface H2D in PS 15 cells was also 
due to the retention o f the complex in the Golgi. To investigate the cellular 
localization of H2D, we performed two-colour confocal immunofluorescence in 
two P815 cell lines. The cell pellet was resuspended in fixing solution for 10 min, 
washed twice in PBS and seeded in poly-L~lysine-pre-treated eight-well slide at 2x 
lO"^  cells/well following the immunofluorescence staining protocol. P815-pcDNA 
or P815-pcl6E5 cells were stained with mAh anti-H2D and a FITC-conjugated 
secondary antibody, and the Golgi apparatus was detected with Bodipy Ceramide- 
T R. In pcDNA cells, H2D was detected both on the cell surface and in the Golgi 
apparatus (figure 27a) whereas in cells expressing HPV-16E5, H2D was only 
detected in the Golgi apparatus (figure 27b). The result shows that HPV-16E5 
retains H2D in the Golgi apparatus and prevents its transport to the cell surface.
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Figure 27. HPV-16E5 induces retention of H2D in Golgi apparatus in P815 cells. 
Two-colour confocal immunofluorescence. P815-pcDNA cells or cells expressing 
HPV-16 E5 were stained with mAh anti-H2D and a FITC-conjugated secondary 
antibody, and the Golgi apparatus was detected with Bodipy Ceramide-Texas Red. 
The merge between FITC and Texas Red fluorescent signals (orange) was 
achieved using the Leica TCS SP2 accompanying software, a) The cellular 
localization o f H2D in control cells, b) The cellular localization of H2D in cells 
expressing E5. Cells at the top o f panel (a) and at the bottom of panel (b) were 
captured at x400; cells at the bottom of panel (a) and at the top o f panel (b) were 
captured at x600.
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Figure 27 Cellular localization o f mouse MHC I in P815 cells expressing E5
P815-pcDNA
P815-pcl6E5
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3.S.6.2 Expression of H2D heavy chain is not inhibited in P815 cells expressing 
HPV-16E5
To investigate whether HPV-16E5 affects expression of H2D heavy chain, 
immunoblotting analysis was performed in control P815~pcDNA and cells 
expressing HPV-16E5 by using mAb anti-mouse H2D as described in section 
2.2.47. The results showed that there was no significant difference in the 
expression of H2D heavy chain between control and cells expressing 16E5 (figure 
27c). We conclude that HPV-16E5 like BPV-4E5 in mouse fibroblasts does not 
down-regulate expression of mouse MHC I heavy chain.
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Figure 27c. HPV-16E5 does not affect H2D heavy chain, immunoblotting analysis 
was performed in control F815 and cells expressing HPV-16E5 by using mAb anti- 
H2D for detection of E12D heavy chain and mAb AB-1, specific for p-actin. 
Detection of H2D heavy chain in control cells (lane 1,2) and in cells expressing 
16E5 (lane 3,4).
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Figure 27c HPV-16E5 does not down-regulate mouse MHC I heavy chain
MHC I
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3.6 HPV-16 E5 protein down regulates human MHC class I (HLA) molecules 
in cervical intraepithélial neoplasia (CIN).
3.6.1 Introduction
Cancer of the cervix is a very common malignant disease in women worldwide. In 
many developing countries, and in terms of mortality, cervical cancer is second 
only to breast cancer. Cervical intraepithélial neoplasia (CIN) is essentially a 
precursor to invasive cervical cancer, and is a condition characterized by new 
growth (dysplasia) in the normal epithelium of the cervix. Risk of progression of 
CIN is associated with persistence o f high risk type HPV infection (Nobbenhuis et 
al 1999). While 60% of infected women with high risk HPV will develop CIN 
within 2-4 years of acquisition o f virus, invasive cervical cancer only occurs in a 
small subset o f cases. It has been estimated that the interval from the detection of 
CIN 1 to the development of cervical cancer is 13 years (van Oortmarssen et al 
1992). HPV-16 is the etiologic agent o f most cervical cancer and encodes three 
transforming oncogenes E5, E6, and E7. During viral infection, E5 is believed to 
play a role in the early stages of neoplastic transformation, with E5 mRNA and 
protein detected in low-grade CIN (Kell et al 1994; Stoler et al 1992). The 
expression pattern of the E5 protein is correlated with abnormal cervical cytology 
and can be detected at all stages o f development o f cervical carcinomas (Biswas et 
al 1997).
E5 is a highly hydrophobic protein and is found in the membrane compartment of 
cells. Reports have shown that the E5 protein of HPV-16 contributes to cell 
transformation by increasing the half life o f the EGF receptors, which in turn 
results in transcription of its downstream factors (Straight et al 1993). It has been 
shown that transcription of c-fos and c-jun is induced by the E5 protein.
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Complexes of c-fos/c-jun constitute the API transcription factor which induces 
upregulation of virus transcription, thus increasing the expression of viral 
transforming proteins and of cellular cell cycle proteins (Bouvard et al 1994; Chen 
et al 1996). Moreover, HPV-16 E5 in human kératinocytes has been shown to 
reduce gap junction communication and may render cells insensitive to normal 
growth regulation signals (Oelze et al 1995). The integration of HPV DNA into the 
human genome has been generally accepted as a characteristic of malignant lesions 
which results in the disruption of E5 expression. However, recent reports have 
identified that HPV-16 DNA is present in episomal, integrated, and 
episomal/integrated forms in early cervical cancer (Choo et al 1987; Cullen et al 
1991; Matsukura et al 1989; Pirami et al 1997), also HPV-16 DNA has been 
detected in an episomal form in one case of cervical carcinoma (Durst et al 1985). 
In addition to its role in the initial stages of cervical cancer, detection of E5 
throughout the whole epithelium in high grade CIN lesions (Chang et al 2001) 
provides indirect evidence that E5 plays an important role in the development and 
maintenance of CIN III. Infection with HPV predisposes to cervical cancer in a 
multistage tumorigenic process. The host immune response plays a role in the 
pathogenesis of HPV-associated neoplasia: increased incidence o f cervical 
neoplasia is observed among immunosuppressed patients (Ozsaran et al 1999; 
Seshadri et al 2001). The inhibition of immune response of the host against tumour 
is due to disorders o f number and function o f immune cells, altered expression of 
membrane proteins, including MHC molecules. Papillomavirus has evolved a 
mechanism to avoid immune recognition by inducing down-regulation of MHC 
class I by E5 proteins (Ashrafi et al 2002; O'Brien and Campo 2002). Thus 
persistence of lesions has been attributed, at least in part, to a disruption of
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presentation of viral peptides to cytotoxic T cells as a result of interference with 
the MHC class I pathway by E5 protein. Down regulation of HLA class I antigens 
is a well-known feature o f premalignant and malignant cervical epithelium. 
Immunologic surveillance o f HPV-associated lesions is performed by T ceils, 
which are activated when foreign (antigenic) proteins are presented to the T-cell 
receptor by HLA class I proteins. Loss of HLA class I is associated with severity of 
CIN lesions and HLA is significantly down-regulated in more aggressive lesions 
(Torres et al 1993). Occurrence of CIN is accompanied by down-regulation of 
specific HLA class I alleles (Wang et al 2001). It has been reported that up 
regulation o f selected HLA class I allele expression, induced by IFN-gamma, 
correlates with the resolution o f cervical intraepithélial lesions and high-risk HPV 
DNA clearance in vivo (Sikorski et al 2004). In vitro, HPV-16 E5 has been shown 
to induce down regulation of HLA class I in immortalized human kératinocytes 
(Ashrafi et al 2005). No correlation between E5 and HLA class I expression in 
cervical lesions has been made (Hilders et al 1994; Hilders et al 1995). The aim of 
this part o f the study is to investigate whether, as in the case o f bovine papillomas, 
expression of E5 correlates with absence of HLA class 1.
3.6.2 Expression of HLA in normal cervix
HLA-ABC antigens are expressed constitutively by most normal nucleated cells 
(Daar et al 1984), but may be lost during transformation to the neoplastic state. To 
evaluate the expression of HLA class I in the normal cervix, 10 paraffin blocks of 
normal cervix from hysterectomies and biopsies taken for reasons unrelated to 
HPV infection were obtained from Dr David Millan, NHS, Glasgow. Sections 
were deparaffinised, re-hydrated through a graded series o f alcohol and
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endogenous peroxidase was inhibited in methanol containing 1.5% hydrogen 
peroxide. After antigen retrieval, any background staining that could result by 
incubation with secondary antibody was avoided by applying normal rabbit serum. 
Sections were then incubated with mAh HCIO, which detects HLA-A, B and C 
heavy chains. Sections were incubated with biotin-labeled rabbit anti-mouse 
secondary antibody. Signal was amplified by staining sections with avidin-biotin- 
peroxidase. HLA class I staining was visualised in brown colour by applying DAB 
to sections. HLA class I staining was firstly evaluated microscopically and images 
were captured by using images analysis software (Zeiss KS300). There was strong 
HLA class I staining in basal and suprabasal layers with a clear staining pattern, 
fainter staining was detected in the upper layers (figure 28a,b). HLA staining was 
also observed in derma (stroma, lymphocytes). The specificity of HLA class I 
staining was verified by incubation o f sections without mAb HCIO (figure 28c,d).
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Figure 28. Detection of HLA class I on paraffin sections from normal cervix, a and 
b) Representative examples o f immunostaining for HLA class I by using mAb HC­
IO; c and d) Verification o f the specificity o f HLA class I staining, normal sections 
were stained with secondary antibody only. x200 magnification.
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Figure 28 Sections o f  normal cervix incubated with HCIO
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3.6.3 Expression of HPV-16E5 in CIN
To determine the expression pattern o f HPV-16 E5, immunostaining analysis was 
performed on paraffin sections representing 10 samples of CIN I using antisera 
against the N and C terminal halves of HPV-16 E5 (Hwang et al 1995). We have 
chosen CIN I to investigate the expression o f HPV-16E5 as E5 is most likely to be 
expressed in the early stages o f infection, although E5 has been shown to be 
expressed in CIN II and CIN III which are more advanced stage o f infection 
(Chang et al 2001). Sections were incubated with unlabeled swine serum, and then 
incubated with E5 antisera at ratio 1:1. Sections were incubated with biotin-labeled 
swine anti-rabbit immunoglobulin and biotinolated HRP streptavidin complex 
following immunohistochemistry protocol. Brown staining of cytoplasm indicated 
E5 expression which was detected mainly in the suprabasal (figure 29a 1,2) and 
granular layers of the epithelium (figure 29a 3,4). The staining o f keratinized 
layers is mostly background as shown by the staining of normal section with E5 
antisera (figure 29b-1). The specificity of E5 staining was verified by incubating 
CIN sections without E5 antisera (figure 29b-2,3). We conclude that the 
cytoplasmic detection of E5 in the suprabasal layer confirms that PV E5 proteins 
are expressed in the deep layers (Anderson et al 1997) where E5 is sufficient to 
play a role in avoiding immune recognition by down-regulation o f MHC I. 
Detection of E5 in the upper layers confirms its role in the productive stages of 
viral life cycle (Fehrmann et al 2003; Genther et al 2003).
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Figure 29. Expression o f HPV-16E5 in CIN I. Representative CIN I and normal 
sections were stained with E5 anti-serum, a) Panel of CIN sections show detection 
of E5 mainly in suprabasal as indicated by rectangular (a-1) and by arrows (a-2) 
while (a 3,4) show detection o f E5 mainly in granular layers as indicated by square 
(a-3) and by arrows (a-4). b) Verification E5 specificity o f staining, (1) normal 
section was stained with E5 anti-serum. (2,3) CIN sections were stained with 
secondary antibody only, (a-1,2,3 and 4 and b-1,2) x200 magnification, b-3 xlOO 
magnification.
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Figure 29 a) Detection o f HPV-16E5
P
b) Verification o f E5 staining
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3.6.4 Expression of HLA in CIN
To determine whether expression of HPV-16 E5 in CIN is associated with down ^
regulation of HLA class I, serial sections of CIN were stained either with mAb 
HC-10 for MHC I detection or with anti-E5 antisera as above. Slides were
microscopically examined by looking at E5 staining patterns in particular areas and
:matching them with the same areas in the section stained for HLA class I. Two 
staining patterns were observed: in 2 out of 10 samples, E5 and HLA class I were 
detectable in the same cells (figure 30a); in 6 out of 10 samples, no HLA class I 
was detected in cells where E5 expression was observed and vice versa E5 positive 
cells did not express HLA class I (figure 30b). Occasionally, in 2 out of 10 
samples, a mixed pattern was observed (figure 30c). Theses results suggest that 
also in CIN 16E5 is responsible for down-regulation of HLA class I.
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Figure 30. Expression o f HLA class I in different CBM I lesions. Representative 
CIN I sections were stained with mAb HCIO for HLA detection or with E5 
antiserum, a) Panel o f CIN show detection o f HLA class I and HPV-16E5 in the 
same CIN I cells; b) HLA class I was not detected in E5 positive cells; c) mixed 
staining pattern of HLA class I in the same CIN section, (a, c and lower 4 panels of 
b) x200 magnification, (upper b) xlOO magnification.
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Figure 30 Expression o f HLA class 1 in CIN sections
a) Detection o f E5 and HLA in the same cells
E5 HLA
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b) No HLA in cells expressing HPV-16E5
LI##
c) Mixed pattern o f a and b
m
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3.6.5 The proliferation state in CIN
The Ki“67 is nuclear antigen expressed in proliferating cells throughout the cell 
cycle except during the GO and early G1 phases. The Ki67 antigen is 
predominantly localized in the nucleus and has an important role in the 
maintenance and regulation o f the cell division. To evaluate the proliferation state 
of CIN cells, serial sections representing 10 samples from CIN I, as well as 10 
samples from normal cervical epithelium were either incubated with mouse 
monoclonal MIB-1 antibody which recognizes nuclei of proliferating cells or with 
anti" E5 antisera. Sections stained for Ki67 were incubated with rabbit anti-mouse 
secondary antibody whereas sections stained for E5 were incubated with swine 
anti-rabbit as described in section 2.2.9. Signal was amplified by staining section 
with avidin-biotin-peroxidase. Staining was visualised by applying DAB to 
sections. The slides were examined microscopically; the Ki67 positive nuclei and 
E5 positive cells were identified and correlated. Images from selected areas were 
captured by using images analysis software (Zeiss KS300).
In normal epithelium, only a few nuclei o f basal and suprabasal cells were stained 
with monoclonal antibody MIB-1 against the nuclear antigen Ki67. In contrast, in 
most CIN sections (8 out o f 10 samples), the intensity of MIB-1 staining was 
strong and the expression of Ki67 was detected throughout the lower third of 
epithelium with exception for few CIN sections in which the expression of Ki67 
was detected in suprabasal cells with lower number of positive cells (figure 31a). 
Most basal cells were negative both in normal cervical epithelium and in CIN I. 
The results show that in some cases the expression of Ki67 was associated with 
expression of HPV-16E5 throughout the lower third of epithelium (figure 31b). 
Although HPV-16E5 is the minor transforming protein compared with E6 and E7,
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according to in vitro data which showed that E5 contributes to the cell cycle by 
activating the positive regulators and inliibiting the negative regulator o f cell cycle, 
in our experiments, no correlation was made between expression of E6 or E7 and 
Ki67 expression. This result is in agreement with, Fehrmann et al, (2003), 
suggesting that a potential role of E5 in cell transformation is to increase cyclin A 
and B expression and subsequently overcome the differentiation-induced cell cycle 
arrest. Also, expression o f Ki67 throughout the lower third suggests that these 
lesions have the potential to progress to CIN II / CIN III to invasive cancer (Kruse 
et al 2004). Restriction o f Ki67 expression to the suprabasal layer in some CIN 
sections would suggest that the cells proliferate slowly and that these lesions are 
unlikely to progress.
223
J
_____
Chapter 3 : Results
Figure 31. Expression of Ki67 in CIN I. a) Representative CIN I sections show two 
different pattern of Ki67 expression; in the basal and suprabasal layers, and 
throughout the lower third of epithelium, b) Serial CIN I sections were stained with 
E5 anti-serum or mAb MIB-1, Ki67 was detected throughout the lower third of the 
epithelium, in some cells, Ki67 expression was accompanied by expression of 
HPV-16E5. (a and b) x200 magnification.
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Figure 31
a) Different expression patterns o f Ki67 in CIN I
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b) Co-expression o f HPV-16E5 and Ki67 in CIN 1
Ki67
I
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3.7 HPV-16 E5 protein down-regulates HLA in raft cultures
Organtypic epithelial raft cultures are tissue culture systems that allow keratinocyte 
monolayer to stratify and achieve full differentiation via culturing o f the cells on 
collagen gels at the air-liquid interface. Histologically, the raft cultures have 
similar structure and morphology to the intact epithelia. We cannot rule out that 
down-regulation of HLA class I in GIN is only due to expression o f E5 since E6 
and E7 are also expressed in these lesions and down-regulation of HLA class I is 
in part due to expression o f by E7 (Georgopoulos et al 2000). Furthermore, the 
viral load o f high-risk HPV DNA was strongly correlated with GIN II and GIN III 
when compared with women with only GIN I or normal cervix (Santos et al 2003). 
Hence we investigated the expression of HPV-16 E5 and its impact on changing 
patterns of MHG class I expression in epithelial layers using artificial epidermis 
that mimics the normal one in stratification, differentiation and the diversity of 
MHG class I patterns among epithelial layers. The immortalized human HaGaT 
cells were stably transfected with two different plasmid pcDNA or PL2 carrying 
HPY-16E5 cDNA as described (Ashrafi et al 2005). The transfected HaGaT cells 
were cultured on collagen gels for 10-14 days and the stratified cells were 
harvested and embedded on paraffin blocks. The culture of these cells was made 
by Dr Sheila Graham, IBLS, Glasgow University. To examine the effects of E5 on 
epithelial moiphology and differentiation, sections o f raft from HaGaT parental, 
pcDNA and cells expressing E5 were stained with haematoxylin and eosin. 
Gontrol cells differentiated, with nuclear staining predominantly localized to cells 
in the basal layer (figure 32a). However, the cultures were not “fully normal”, as 
occasionally invasion of the kératinocytes into the collagen was observed (figure 
32b). HaGaT cells expressing E5 showed an altered differentiation pattern, with a
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thickening of the basal layer and nuclear staining throughout all layers (figure 32c). 
Also there was abnormal distribution in the keratin; extensive kératinisation was 
localized in the lower epithelium instead o f the superficial layer (figure 32d). 
These observations confirm that E5 stimulates cellular proliferation via its effects 
on cell cycle regulators and epidermal growth factor receptors. This 
hyperkeratinization resembles the one observed in HPV-16E5 transgenic mice 
(Genther Williams et al 2005).
To determine down-regulation of HLA class 1 and expression of HPV-16 E5 in 
artificial stratified epithelium, serial raft sections from HaCaT parental, pcDNA 
and cells expressing E5 were either stained with anti-E5 antisera, HCIO for 
detection of classical HLA class I or mAh MEM-E/02, specific for HLA-E as 
described in section 2.2.9. In HaCaT control cells, both classical and non classical 
HLA class I were detected in most epithelial layers with clear staining pattern 
(figure 33a and b). In contrast, HaCaT cells expressing pcl6E5 (figure 33c), did 
not express classical HLA class I (figure 33 d), while they retained expression of 
HLA-E (figure 33e). These results confirm that HPV-16E5 down-regulates 
classical HLA class I, but does not down-regulate non classical HLA-E.
It has to be noted that the analysis of the relationship between E5 and HLA class I 
in GIN and in raff culture is preliminary and requires more experimentation.
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Figure 32. Morphology and differentiation pattern o f HaCaT cells in raft culture 
sections stained with haematoxylin and eosin. (a and b) Differentiation o f parental 
HaCaT rafts, (c and d) Alteration of the differentiation pattern o f HaCaT cells 
expressing HPV-16E5. (a and b) x200 magnification, (c and d) x400 
magnification.
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Figure 32
HPV-16E5 causes alteration in morphology and differentiation pattern o f HaCaT cells
7
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Figure 33. Expression o f HLA class I in raft culture o f HaCaT cells, a) Expression 
of classical HLA class I in parental HaCaT cells, b) Expression o f non classical 
HLA-E in parental HaCaT cells, c) Expression of HPV-16E5 in HaCaT cells, d) 
Expression o f classical HLA class I in HaCaT cells expressing HPV-16E5. e) 
Expression o f HLA-E in HaCaT cells expressing E5. (a) x400 magnification, (b,c,d 
and e) x200 magnification
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Figure 33 HPV-16E5 down-regulates classical HLA class 1 but does not affect HLA-E
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4 Discussion
4.1 Introduction
Viruses are totally dependent upon host biosynthetic machinery for replicating 
their genomes and establishing infection. These processes are associated with the 
production of antigenic proteins that make the infected cell susceptible to immune 
surveillance which ultimately results in elimination of viral infection. However, 
viruses have developed mechanisms to escape cellular immune recognition by 
encoding proteins that interfere with antigen presentation to immune cells. In 
general, recognition and subsequent elimination of virally-infected cells involves 
three major immune effector mechanisms; Ab-dependent lysis, MHC class I- 
restricted CTL-mediated lysis and NK cell-mediated lysis. These mechanisms are 
influenced by cytokines, which function as chemical messengers between cells 
(Diamond 2003). One mechanism by which viruses evade clearance by the host 
immune response is to inhibit CTL recognition by down-regulation of MHC-I 
expression on the surface of infected cells. Cells are always under surveillance by 
CTLs, which continuously examine somatic cell surfaces for MHC class I 
molecules presenting non-self peptides derived from viral antigens. MHC class I 
molecules are particularly attractive targets for immune evasion by viruses, 
because decreasing expression and/or antigen presentation by MHC class I can 
attenuate CDS T-cell-mediated recognition o f infected cells (Yang and Wilson 
1995). Both self and foreign antigens are degraded in the cytosol to peptides which 
are translocated into the endoplasmic reticulum where they are loaded onto MHC I 
molecules and are transported via the Golgi apparatus to the cell surface (Yewdell 
and Bennink 1992).
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Papillomaviruses infect cutanous and mucosal epithelium, causing benign lesions 
which persist for several months to one year before regression by cell-mediated 
immunity. However, occasionally some lesions, particularly those caused by BPV- 
4, can persist and transform to squamous cell carcinoma in the gastrointestinal tract 
of cattle. This is particularly evident in cattle grazing on bracken fern which 
contains mutagens including quercetin; these act as dietary factors for malignant 
conversion. Also, in individuals who are HPV-16 infected, CIN lesions can 
progress and develop into cervical cancer, particularly in presence of 
immunosuppressive diseases such as HIV infection in which failure of immune 
recognition is accompanied by malignant conversion (O'Brien and Campo 2003).
The ability o f papillomaviruses to persist for significant periods of time has been 
linked to the nature o f infection which indirectly subverts host immune responses 
to the infected cells by minimising the exposure of virus to immune cells. 
Papillomaviruses can potentially subvert the immune response by interference with 
antigen presentation to CTLs by down-regulation of MHC I (Ashrafi et al 2002). 
Papillomavirus E5 protein is mainly localized to Golgi apparatus and endoplasmic 
reticulum and causes impairment of the MHC I trafficking to the cell surface. 
Recently, it has been found that BPV-4 E5 protein physically interacts with the 
heavy chain o f MHC class I and irreversibly retains the MHC complex in the Golgi 
apparatus (Marchetti et al 2006). Like other oncogenic viruses, which interfere 
with several steps of MHC class I pathway, BPV-4 E5 proteins have wide effect on 
MHC class I; they inhibit MHC class I gene transcription, protein stability and 
trafficking of MHC class I molecules to cell surface. These viral strategies used to 
prevent peptide/MHC-I presentation at the surface of infected cells may be
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protective against CTL recognition and destruction. However, they leave the 
infected cells susceptible to lysis by another arm of the host's immune system, the 
NK cells, because o f the reduced opportunity to engage NK cell inhibitor receptors 
(Biassoni et al 2001). However, it has been found that the inhibitory receptors 
recognize MHC leader sequence peptide presented by the non classical MHC class 
I molecules such as HLA-E (Braud et al 1998a). These molecules are able to 
deliver negative signals to NK cells through immunoreceptor tyrosine-based 
inhibitory motifs (ITIM) in their cytoplasmic domain, which act to recruit tyrosine 
phosphatases, thereby cutting positive signal pathways (Eissmann et al 2005; 
Watzl 2003; Lanier 1998).
4.2 BPV-4E5 induces down-regulation of bovine classical MHC I but does not 
affect non classical MHC I in P815 cells
Because there is no monoclonal antibody available which exclusively recognizes 
non-classical class I molecules, to study the relationship of BPV-4 E5 with 
classical and non-classical MHC I, we separately expressed a classical, NW1301, 
and a non-classical, N*50001, allele in mouse P815 cells and subsequently 
introduced E5 in these cells. This proved to be a powerful system which has 
confirmed that E5 down-regulates classical MHC class I, while it does not interfere 
with the biosynthetic pathway o f this non-classical MHC class I.
4.2.1 BPV-4E5 and classical MHC class I
It has been shown in bovine PalF cells (Marchetti et al., 2006), that E5 down- 
regulates classical MHC class I at more than one level. However, in PalF cells, E5 
was co-expressed with E6, E7 and activated ras (Permie et ah, 1993), leaving open
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the possibility, albeit remote, that down-regulation of MHC class I was due to a 
functional interaction between the viral and cellular oncoproteins. In P815 cells, 
we have found that E5 profoundly inhibits expression of both surface and total 
classical MHC class I in the absence of other viral or cellular oncoproteins (figure 
13). It has been shown that BPV-4E5 down-regulates mouse MHC class I in 
NIH3T3 cells and bovine MHC class I in PalF cells (Ashrafi et al 2002). We have 
shown that BPV-4E5 down-regulates bovine classical N*01301 MHC class I in 
P815 cells (figure 13) and human classical B2705 MHC class I expressed in 4E5- 
PalF cells (figure 17c). Our observations demonstrated that down-regulation of 
MHC class I by BPV-4E5 is not species specific. In P815 cells, unlike PalF cells, 
the Golgi structure was not affected in cells expressing E5. It has been suggested 
that the Golgi fragmentation is due to the combined action of BPV-4E5 and other 
viral proteins and activated ras. However, it is still to be determined whether Golgi 
fragmentation is due to the combined action only in bovine cells (tissue specific) or 
can be induced in PS 15 cells by co-transfection o f P815 cells with BPV-4E5, E6, 
E7 and activated ras.
4.2.2 BPV-4E5 and non-classical MHC class I
We investigated the effect of E5 on expression of non classical MHC class I. 
N*50001 is bovine non-classical MHC class I, it differs from classical N*01301 
MHC class I; N* 5 0001 lacks an intracytoplasmic domain. We found that in 
marked contrast to its inhibitory effect on classical MHC class I, E5 does not affect 
non-classical MHC class I. Non-classical MHC class I reach the cell surface 
(figure 14) and non-classical N*50001 HC is expressed to the same levels as in 
control cells (figure 18). It has been shown that HPV-16E5 does not affect the
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localization of HLA-E on the cell surface of HaCaT cells (Ashrafi et al 2005). 
Thus, it is possible that the presence of non-classical MHC class I on the cell 
surface of E5 expressing cells would protect these from killing by NK cells which 
become activated as result of lacking classical MHC class I on the cell surface.
4.2.3 How does BPV-4E5 down-regulate N*01301?
Immunological surveillance o f viral infection is performed by T cells, which are 
activated when foreign antigenic proteins are presented to the T-cell receptors by 
class I MHC molecules. The ability o f MHC class I molecules to sample the 
intracellular environment and present antigens to CTLs poses a great thi'eat to 
viruses and other intracellular pathogens. In order to circumvent this problem, 
many viruses have evolved strategies to interfere with the MHC class I antigen 
presentation pathway. It is now clear that all individual steps in MHC class I 
pathway are targeted by viral proteins that modulate the host immune response 
(Wagner et al 2002). Redirecting MHC class I heavy chains into the cytosol for 
degradation by subversion o f Sec61 is one o f the most important steps in the MHC 
I pathway targeted by viral proteins. Sec61 is an important translocon which 
consists of complex proteins associated with the translocation of nascent 
polypeptides into the cisternal space of the endoplasmic reticulum from the cytosol 
and re-directs transport o f mis-folded proteins back into the cytosol where they are 
rapidly degraded by the proteasome (Romisch 1999). This retrograde transport 
system is commandeered by US2 and U Sl 1 proteins of HCMV which route newly 
synthesised MHC I HC to Sec61 for rapid dislocation into the cytosol and 
degradation by proteasome (Wiertz et al 1996). Also it has been reported that the 
p l2  protein of HTLV-1 binds to the HLA class I heavy chain thus preventing its
238
Chapter 4: Discussion
association with P2M, and reroutes MHC I HC into the cytosol for proteasomal 
degradation (Johnson et al 2000). It has also been shown that HIV N ef protein 
binds to MHC I heavy chain, creating a binding site for the adaptor protein AP-1 
which in turn leads to the recruitment o f MHC I into the lysosomes for degradation 
(Roeth et al 2004). Moreover, N ef protein may decrease heavy chain gene 
transcription via its activation o f c-jun (Fackler et al 1999) as a complex of c-jun/c- 
fos acts as a negative trans-acting factor that down regulates MHC I gene 
expression (Howcroft et al 1993). Papillomaviruses, like other viruses, have been 
implicated in interference with many steps of MHC class I pathway. It has been 
shown that BPV-4 E5 inhibits transcription of the MHC class I heavy chain gene 
and transport o f the complex to the cell surface (Ashrafi, 2002; Marchetti et ah, 
2006). In P815 cells, in addition to blocking MHC class I in the Golgi apparatus 
and preventing its transport to the cell surface, E5 induces the degradation of 
N*01301 HC. In control cells, the half-life of the HC is approximately 20 hours, 
whereas in the presence of E5 its half-life is dramatically reduced to less than 5 
hour's. We do not yet know how E5 causes MHC class I heavy chain degradation. 
HIV N ef protein shares similarity with E5 protein and as mentioned before N ef re­
directs HC to the lysosomes for degradation tluough the simultaneous interaction 
with HC and with the AP-1 complex. As suggested by Marchetti et ah, (2006), it is 
thus possible that E5 also interacts with both HC and AP-1 inducing lysosomal 
degradation of HC, but this remains to be elucidated.
Transcription of the bovine N*01301 HC gene cannot be analysed in P815 cells: 
E5 inhibits transcription from the homologous promoter of the HC gene (Marchetti 
et al., 2006), while in P815 cells the N *01301 HC gene is under the control of the 
CMV IE promoter.
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4.2.4 Down-regulation of MHC I is mediated by the C-terminal domain of 
BPV-4E5
Previous studies have shown that the E5 oncoprotein of BPV-4 interacts 
physically with 16k subunit c, leading to loss of gap junctional intercellular 
communication. It has been shown that both the hydrophilic C-terminal tail and the 
residue at position 17 in the hydrophobic domain are crucial for the transforming 
activity of E5 protein (O'Brien et al 1999). It is reasonable to assume that a 
profound effect on MHC class I transport is a consequence of the interaction 
between E5 and MHC I HC. We investigated whether down-regulation of MHC I 
can be attributed to E5/MHC I HC interaction and whether the C-terminal domain 
or position 17 is responsible for E5/HC interaction and down-regulation of MHC I. 
We have shown that E5 and HC proteins co-precipitate in vitro and in vivo 
(Marchetti et al., 2006) and the E5 mutant N17Y binds HC but does not inhibit 
MHC class I expression. The E5T mutant which lacks the C-terminal domain, as 
reported by Ashrafi et ah, (2002), does not inhibit the expression of MHC class I or 
its transport to the cell surface. Also, E5T does not interact with HC and the 
interaction between E5 and HC is prevented by a peptide corresponding to the C- 
terminus of E5 (Marchetti et al., 2006). Our observations have demonstrated that 
potential immune evasion through down regulation of MHC I is accompanied by 
cell transformation (Ashrafi, 2002; O'Brien, 2003), and that the C-terminus domain 
of BPV-4E5 which mediates the transforming activity of E5, is also responsible for 
E5/HC interaction and down- regulation of MHC I.
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4.3.1 HPV-16E5 causes down-regulation of MHC class I
HLA-A, B and C encode transmembrane glycoproteins which are involved in the 
process of immune recognition. Class I molecules are heterodimers consisting of a 
polymorphic heavy chain non-covalently associated with an invariant light chain 
(termed p2-microglobulin) and they function by binding intracellularly processed 
peptides, presenting them on the cell surface to cytotoxic T lymphocytes (Williams 
et al 1996). Individual subunits of glycoproteins are synthesized in the rough 
endoplasmic reticulum (RER), where they fold and may undergo modifications 
such as disulfide bond formation and glycosylation (Hurtley and Helenius 1989). 
Transport of peptides from the cytosol to the ER is mediated by a transporter 
associated with antigen processing (TAP). In the ER, the assembly of newly 
synthesized MHC class I heavy chain (HC) molecules with Pi-microglobulin (p2- 
m) and peptide is assisted by transient interactions with a number of ER-resident 
chaperones. Following peptide association, class I molecules dissociate from TAP 
and the stable MHC class I/Pi-m /peptide trimer transits from the ER via the trans 
Golgi to the cell surface for presentation to CTL.
Localization of papillomavirus E5 proteins in Golgi and other cytoplasmic 
compartments causes interference with Golgi functions (Schapiro et al 2000). 
Since processing of MHC I takes place in these compartments and its transport to 
the cell surface takes place thi’ough the Golgi, it is to be expected that translocation 
of MHC I complex to the cell surface would be disrupted in E5 cells. Previous 
studies have shown that HPV-16E5 down-regulates HLA-A and B but not HLA- 
C/E in HaCaT cells (Ashrafi et al 2005). We confirmed this observation by 
investigating the effects of E5 on expression of HLA-A2 in mouse mastocytoma 
P815 cells. We have shown that HPV-16E5 down-regulates HLA-A2 on the cell
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surface, reducing the level of surface HLA-A2 to approximately half of that in the 
control cells (21). Furthermore, we found that HLA-A2 was retained in the GA 
(figure 23). The effect of HPV-16E5 on MHC I is similar to effects o f BPV-4E5 in 
retaining MHC I within the Golgi and reducing its levels on the cell surface, but 
does not affect HLA-A2 heavy chain (figure 25). Prevention of MHC I transport to 
the cell surface is a biological characteristic shared by papillomaviruses E5. It has 
also been shown that HPV-2a E5 and HPV-83E5 can inhibit MHC I transport to 
the cell surface (Cartin and Alonso 2003; Ashrafi et al 2006). Thus, down- 
regulation of surface MHC class I seems a characteristic displayed by many 
papillomavirus E5 proteins.
4.3.2 HPV-16E5 does not down-regulate HLA-E
The cell surface expression of non classical HLA-E inhibits NK cell-mediated lysis 
by interacting with inhibitory NK receptors. There are specifically two types of 
receptors for self MHC class I molecules to inhibit NK cells, including killer cell 
immunoglobulin-like receptors (KIR) that predominantly recognize classical MHC 
class I, and the lectin-like hetrodimer CD94/NKG2 receptors that recognize HLA- 
E (Braud et al 1998a). The absence of classical MHC class I on the cell suiface of 
the virus-infected cells causes these to be susceptible to killing by NK cells unless 
HLA-E molecules are presented on the surface. It has been shown that HPV-16E5 
does not interfere with expression of HLA-E/C on the surface of HaCaT cells, but 
it could not be determined whether the localization o f MHC I on the surface was 
HLA-E or HLA-C as the mAh DT9 cross-reacts with both of them. For this reason 
we have used the powerful system o f P815 cells to introduce HLA-E cDNA into 
cells expressing 16E5. The expression o f HLA-E was analyzed using mAh DT9.
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Our observations have confirmed that HPV-16E5 does not down-regulate the 
expression of HLA-E (figure 22). We conclude that HPV-16 E5 down-regulates 
HLA-A2 by retaining it in the Golgi apparatus, but it does not affect HLA-E. 
Additionally, HPV-16E5 down-regulates the surface expression of mouse H2D 
MHC class I by one-third. HPV-16E5 induces down-regulation o f MHC class I in 
HaCaT, PalF, and NÏH3T3 cells (Ashrafi et al., 2005). Therefore, down-regulation 
of MHC class I by HPV-16E5 like BPV-4E5 is not species specific.
4.4.1 Expression of BPV-4 E5 induces cellular proliferation in papillomas
The cell cycle in mammalian cells is regulated by the coordinated activity of a 
family of cyclin-dependent kinases (CDKs). Cyclin A promotes both G l/S and 
G2/M transitions. Cyclin A is also required for DNA synthesis and once 
transported into the nucleus, it forms a complex with CDK, which is required for 
entry into mitosis (Pagano et al 1992). Previous studies have reported that BPV- 
4E5 expression in NIH3T3 cells promotes transcriptional activation of the cyclin A 
promoter and increases endogenous protein levels, thus allowing proliferation in 
the absence of mitogens (O'Brien and Campo 1998). In the present study, we have 
also shown that expression o f the proliferation marker Ki67 is associated with 
expression of E5 in differentiated kératinocytes, while in normal epithelium Ki67 
staining is found only in the proliferative basal cells. In agreement with in vitro 
studies we conclude that BPV-4 E5 causes alteration in the cell cycle and forces 
post-mitotic cells to re-enter the cycle and proliferate.
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4.4.2 Expression of HPV-16 E5 induces cellular proliferation in CINI
HPV-16 E5, along with the more transforming E6 and E7 proteins of the virus, has 
been found to be oncogenic. E5 transactivates viral genes via the activation of AP- 
1 and thereby increases viral E6/E7 gene expression (Chen et al 1996a). E5 may 
also play role in cell transformation by regulating the expression o f other cellular 
and viral genes. It has also been demonstrated that E5 proteins of HPV-11 and -16 
repress the expression o f tumoui' suppressor gene p21 and impair the control of the 
cell cycle checkpoint, and this might be one of the mechanisms by which E5 
stimulates cell proliferation (Tsao et al 1996). In our present study we investigated 
the Ki67 immunostaining as an index of cellular proliferation in CIN I and 
correlation between the Ki67 and HPV-16 E5 expression was analysed. We have 
shown that there are two staining pattern o f Ki67 in CIN I; in approximately 80% 
of CIN I samples, the K167 expression was detected throughout the lower third of 
epithelium including the basal layer with more intensity of positive nuclei (figure 
3 la-3,b), in 20% of samples, Ki67 was detected in the basal and suprabasal layers 
with lower numbers of positive cells and no staining in intermediate layers and, in 
some cases, no significant difference between normal and CIN epithelium (figure 
3 la -1,2). Our results ai'e in agreement with Kruse et al, 2004, who proposed that 
lesions in which Ki67 is expressed throughout the lower third of epithelium are 
likely to progress, while lesions in which Ki67 is restricted to basal and suprabasal 
layers are unlikely to progress. Unlike in bovine papillomas, expression o f Ki67 is 
only partially associated with E5 in some CIN cells. This may be due to the fact 
that HPV-16E5 is a minor transfonning protein while E6 and E7 are the major 
transforming proteins and progression to malignancy is due to E6 and E7, which 
disrupt the pathways of p53 and of p i 05 Rb.
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4.5 Down-regulation of MHC class I in papillomas and CIN and rafts
We have shown that BPV-4E5 and HPV-16E5 down-regulate bovine classical 
MHC class I and human classical HLA-A2 respectively by using the powerful 
system of P815 cells. We extended our observations to investigate the effect of E5 
on MHC class I in naturally infected cells on paraffin sections of papillomas and 
CIN by using immunohistochemistry.
4.5.1 BPV-4 E5 protein down-regulate MHC class I in bovine papillomas
We investigated the relationship between the expression of BPV-4 E5 and 
expression of MHC class I in naturally infected papilloma cells 
immunohistochemically by using E5 antisera and mAb IL-A88 for detection of 
MHC class I. We have found that E5 was detected exclusively in the cytoplasm of 
epidermal cells, from the basal and parabasal layers to the spinous and squamous 
layers. Cells that expressed E5 did not express MHC class I. We conclude that in 
bovine papillomas, expression of E5 is clearly not compatible with expression of 
MHC class I. Our observations are in agreement with previous studies (Anderson 
et al 1997; Burnett et al 1992) and confirm the hypothesis of the functions of E5 
protein in natural infection; expression of E5 protein in the basal layer supports its 
role in immune evasion by down regulation of MHC class I in those cells that are 
accessible to immune surveillance. Expression of E5 protein in differentiated 
layers supports its role in viral replication and packaging of the viral genome 
(Fehrmann et al 2003). In addition, expression of E5 protein in the intermediate 
layers supports its role in the maintenance of the transformed state o f papillomas.
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4.5.2 Down-regulation of MHC I is due to expression of E5 not E7
Previous studies have shown that the E7 proteins of HPV-16 and -11 are 
implicated in the down-regulation of MHC I either through inhibition of the 
transcriptional promoter o f the MHC I heavy chain (Georgopoulos et al 2000) or 
indirectly through inhibition of TAP, the transporter associated with peptide 
(Vambutas et al 2000) respectively. In our present study, we have shown that in 
cells that expressed E5 and did not express E7, or expressed it at levels below 
detection, there was little or no MHC I. On the contrary, cells that expressed BPV- 
4 E7, but not E5, still had detectable MHC I, We conclude that although 
cooperation between BPV-4 E5 and E7 is necessary to achieve full transformation, 
down-regulation o f MHC I is only induced in the presence o f E5 and E7 is not 
responsible for down-regulation o f MHC I.
4.5.3 HPV-16E5 protein down-regulates MHC class I in CIN I
It has been shown that HPV-16E5 down-regulates HLA-A/B but it does not down- 
regulate HLA-C/E in cultured HaCaT cells (Ashrafi et al 2005). We confirm that 
HPV-16E5 induces down-regulation of HLA-A2 by using the powerful system of 
P815 cells. Down-regulation of MHC class I has been observed in premalignant 
lesions and squamous carcinomas of the uterine cervix (Chil et al 2003). In our 
present study, we extended our observations to investigate the relationship between 
expression of HPV-16E5 and down-regulation of MHC class I in paraffin sections 
of CIN I. We have found that in approximately 60 % of CIN I, expression of HPV- 
16E5 is not compatible with expression o f MHC class I and in 40 % of samples, E5 
and MHC class I are co-expressed. We conclude that although some E5 cells do 
not express MHC class I, down-regulation of MHC class I in CIN I, unlike in
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bovine papillomas, needs further analysis. It has been shown that E7 proteins of 
HPV-11 and HPV-16 are in part responsible for down-regulation o f MHC class I. 
We did not investigate the relationship between expression of E7 and expression of 
MHC class I. Therefore the reduction or absence o f MHC class I expression in CIN 
I cells may be due to expression o f HPV-16E7. Absence of MHC class I was 
predominantly observed in cells of higher layers, while the cells in very deep 
layers still expressed MHC class I. We hypothesize that a reduction in MHC I is 
not required in deeper layers as E6 and E7 expression is very limited; the low 
expression o f E6 and E7 within these cells is insufficient to raise a host immune 
response. Because no host immune response is raised, there is no requirement for 
immune evasion mechanisms to be generated by the virus. In the middle and upper 
layers, E6 and E7 are expressed at much greater concentrations requiring that the 
vims block antigenic presentation via manipulation of MHC I. More investigation 
is required to validate this hypothesis.
4.5.4 HPV-16E5 protein down-regulates MHC class I in raft culture
Because we did not investigate expression of HPV-16E7 in CIN, we cannot state 
that down-regulation o f MHC class I in CIN I is only due to expression of HPV- 
16E5. In the present study, we firstly investigated the impact o f E5 on the 
morphology and differentiation o f HaCaT cells in raft sections. It has been shown 
that expression of HPV-16 in raft cultures o f primary kératinocytes induces 
alteration in the differentiation pattern of these cells (McCance et al 1988). 
Moreover, raft cultures o f cell lines derived from cervical intraepithélial neoplasia 
exhibited abnormal differentiation patterns similar to those of cervical 
intraepithélial neoplasia in vivo (Rader et al 1990). It has been shown that
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expression of HPV-31 E5 in rafts of human foreskin kératinocytes induces an 
altered differentiation pattern, with a thickening of the basal layer and nuclear 
staining throughout all layers (Fehrmann et al 2003). It has been shown that 
expression o f HPV-11 DNA in organotypic raft culture induces thickness in the 
epithelium and extensive kératinisation (Fang et al 2006). We have found that 
expression of HPV-16 E5 induces hyperkeratinization and a highly proliferative 
morphology o f HaCaT rafts compared with control rafts. We investigated 
expression o f HLA-A2 and HLA-E in HaCaT rafts expressing HPV-16 E5. As 
expected, given that all cells express E5, no cells express classical HLA-A (figure 
33d), but they do express HLA-E (figure 33e). These observations confirm that 
HPV-16E5 down-regulates classical MHC class I but does not down-regulate 
HLA-E even during stratification and abnormal differentiation.
4.6 Future work
Future work should be focused on the effects o f BPV-4E5 on MHC class I. It has 
been shown that HIV N ef protein binds to MHC I heavy chain, creating a binding 
site for AP-1 which in turn leads to the recruitment of MHC I into the lysosomes 
for degradation (Roeth et al 2004). The mechanisms by which BPV-4E5 causes 
degradation of MHC class I heavy chain should be investigated. It has been found 
that BPV-4E5 still interacts with MHC heavy chain lacking the C terminal tail of 
HC, suggesting that there are other domains in HC that are essential for the 
physical interaction with E5. It should be determined which amino acids in the HC 
are essential for interaction with E5.
It has been shown that expression o f BPV-4E5 increases the pH o f the Golgi, 
which is thought to be a result o f its binding to 16k subunit c (Schapiro et al 2000).
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The aikalization of the Golgi interferes with processing and transporting of 
proteins including the MHC complex. It has been shown that BPV-4E5 physically 
interacts via its C terminal domain with MHC class I heavy chain and this 
interaction is associated with the down-regulation o f MHC complex. This suggests 
that BPV-4E5 reduces the presentation of MHC class I on the cell surface both by 
interacting with 16K subunit c and by binding to MHC heavy chain. It should be 
determined whether the physical interactions o f BPV-4E5 with the MHC heavy 
chain and with 16K subunit c can take place concurrently.
We have shown that expression of HPV-16E5 down-regulates expression of HLA 
class I in some CIN I cells. However, other CIN cells that express E5 still have 
detectable HLA class I. Unlike bovine papilloma cells in which expression of 
BPV-4E5 is not compatible with expression of MHC class I, down-regulation of 
HLA class I by HPV-16E5 in CIN I is still not clear and more investigations of 
CIN I and CIN II sections are required to elucidate the relationship between 
expression of E5 and HLA class I.
It has been suggested that lack of surface expression of classical MHC class I in 
infected epithelial cells of bovine papillomas and CIN expressing BPV-4E5 and 
HPV-16E5 respectively would allow evasion of destruction by cytotoxic T 
lymphocyte and therefore establishment of viral infection. The presence o f non 
classical MHC class I would inhibit destruction of these cells by NK cells. It is 
important to clarify this point by applying CTL and NK killing assays on E5- 
expressing cells.
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